Treatment methods for female infertility

JP7583504B2Active Publication Date: 2024-11-14MYOVANT SCIENCES GMBH
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2023003187
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-09-30
Filing Date
2023-01-12
Publication Date
2024-11-14
Estimated Expiration
2037-09-29

AI Technical Summary

Benefits of technology

【0011】 本開示は、不妊の問題を抱える女性を助けるための方法、使用法及び組成物に関するものである。別の態様では、本開示は、内因性LHのレベルを上昇させる必要のある女性の内因性LHのレベルを上昇させることに関するものである。いくつかの態様では、本開示は、現在の黄体期補助方法の代替策を提供することによって、ARTプロセスでの安全性と有効性を向上させる黄体期補助に関するものである。その女性は、ARTを受けていても受けていなくてもよい。これらの改良型の方法と使用法の考え得る利点の1つは、ARTを受けている女性において、OHSSのリスクを有意に低減できる点である。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007583504000024
    Figure 0007583504000024
  • Figure 0007583504000025
    Figure 0007583504000025
  • Figure 0007583504000026
    Figure 0007583504000026
Patent Text Reader

Abstract

To provide treatment methods for female infertility [Solution] Further, according to the present disclosure, there are methods for promoting egg maturation in assisted reproductive technologies, such as in vitro fertilization (IVF) or embryo transfer (ET) processes. Methods also exist for reducing ovarian hyperstimulation syndrome (OHSS) rates, achieving equivalent or improved pregnancy rates, shortening time to pregnancy, and preventing premature ovulation. These methods comprise administering a therapeutically effective amount of the active pharmaceutical ingredient 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 62 / 402,018, filed September 30, 2016, and U.S. Provisional Patent Application No. 62 / 402,150, filed September 30, 2016, the entireties of which are incorporated by reference herein.

[0002] Sequence Listing Reference The sequence listing accompanying this application is provided in text format in lieu of a paper copy and is incorporated herein by reference. The name of the text file containing the sequence listing is MYOV_017_01WOSeqList_ST25_txt. This text file is approximately 4KB, was created on September 13, 2017, and has been submitted electronically via EFS-Web.

[0003] The present disclosure is in the field of assisted reproductive technologies (ART), and more specifically to methods and uses of ART in women at risk for OHSS, and methods and uses of promoting egg maturation, supporting the luteal phase, and preventing premature ovulation. [Background technology]

[0004] Approximately 1.5 million assisted reproduction cycles are performed worldwide each year. Furthermore, approximately 25% of women who suffer from infertility have problems with ovulation, including the inability to produce fully mature eggs (also called oocytes) or to ovulate. Fertility specialists assist reproduction by using a group of drugs that temporarily correct the ovulation problem and increase the woman's chances of conceiving. Many assisted reproduction cycles include one or more of the following steps as part of the ultimate goal of pregnancy: (1) follicle maturation (controlling the release of eggs in the ovaries), (2) prevention of premature ovulation, (3) triggering egg maturation at the appropriate time, (4) egg retrieval and fertilization, and (5) transfer of the fertilized eggs followed by a biochemical pregnancy test. However, other important ART regimens include oocyte banking or oocyte donation, menstrual cycle regulation to allow ovulation to occur after triggering (3), followed by intrauterine insemination (IUI) or intercourse at the prescribed time. Embryo transfer with luteal phase support (ET) may also be used in women with premature ovarian failure (e.g., women who are unable to mature oocytes or ovulate despite ART) or as part of a surrogacy procedure, where the luteal phase support may be administered prior to, concurrently with, or after ET, or at one or more times prior to, concurrently with, or after ET.

[0005] Traditionally, ART protocols have used drugs such as follicle-stimulating hormone (FSH) and human menopausal gonadotropin (hMG) in the initial stimulation phase, which are preceded by a gonadotropin-releasing hormone (GnRH) agonist (GnRH receptor agonist) or supplemented with a GnRH antagonist (GnRH receptor antagonist) to prevent (inhibit) ovulation and prevent the release of immature oocytes by the luteinizing hormone (LH) surge. Inhibiting ovulation allows eggs to be retrieved directly from the ovaries (instead of the fallopian tubes) once they have matured, and prevents high-order multiple pregnancies that may result from exposure of eggs to sperm in the fallopian tubes if intercourse occurs. At the same time, this stimulation process with FSH and GnRH antagonist or GnRH agonist is called controlled ovarian stimulation (COS). (1) To facilitate final maturation and release of oocytes from the ovaries in preparation for intercourse or IUI, or (2) to facilitate oocyte transfer into the uterus after final maturation and oocyte retrieval in ART regimens that include a transfer step (e.g., in vitro fertilization (IVF)). Once the oocytes have developed to the point where they can mature, an oocyte maturation agent, or so-called "trigger" agent, is used, e.g. human chorionic gonadotropin hormone (hCG or HCG), a GnRH agonist, or both. Induction of final oocyte maturation is a routine procedure as part of COS to allow the oocytes to fully develop, resulting in a good yield of oocytes for harvest and an optimal chance of conception. This trigger therefore essentially replaces the LH surge, whose action involves ovulation after the final maturation of the oocyte in the natural menstrual cycle. In IVF cycles, triggering final oocyte maturation with a GnRH agonist instead of hCG reduces the risk of ovarian hyperstimulation syndrome (OHSS), but also reduces the live birth rate. In ART cycles with oocyte donation, the use of a GnRH agonist instead of hCG reduces the risk of OHSS and there is no evidence of a difference in live birth rate. IVF cycles triggered by GnRH agonists and hCG have comparable oocyte yields and embryo quality.

[0006] After administration of the triggering agent, other drugs (e.g. hCG, estradiol and progestins) are used to support the uterus (endometrium) in preparation for implantation (so-called luteal phase support). Luteal phase support is essential because after COS with gonadotropins, there is a problem with the inhibition of LH secretion via negative feedback at the level of the hypothalamic-pituitary-gonadal axis by supraphysiological steroid hormone concentrations. Without luteal phase support, due to low LH levels, progesterone levels would fall, decreasing the chances of implantation and thus of a successful pregnancy.

[0007] Human chorionic gonadotropin (hCG) has been used as a trigger due to its structural similarity to LH and its ability to activate the LH receptor, acting as a triggering agent resulting in a significant amount of mature oocytes. Due to hCG's long half-life (24-36 hours) and its ability to activate the LH receptor for 7-10 days, and in some cases up to 16 days, hCG also provides luteal phase support by increasing progesterone. Thus, hCG can be used in either trigger (oocyte maturation) therapy and / or luteal phase support. Furthermore, therapies that include hCG as a triggering agent are known to produce a significant amount of mature oocytes. However, the use of hCG in either therapy is associated with the highest risk of OHSS. This may raise safety concerns and increase the need for fractionated freezing protocols (i.e., cryopreserving embryos followed by transfer of frozen-thawed embryos during the next menstrual cycle) in women at high risk of OHSS, which may mitigate OHSS but delay ET and pregnancy. As discussed in more detail below, in OHSS, the ovaries may enlarge and fluid may accumulate in the abdominal cavity (ascites), and patients may experience abdominal bloating, abdominal pain, nausea, and diarrhea. Severe forms of OHSS may result in hemoconcentration, thrombosis, elevated white blood cell count, oliguria, renal failure, pleural effusion, respiratory distress (including acute respiratory distress syndrome), and death.

[0008] Ovarian hyperstimulation syndrome (OHSS) is a major complication (side effect) of ART. It is believed to be caused by supraphysiological agonism of LH receptors in the ovaries, which occurs in ovaries containing many mature follicles, due to oocyte maturation triggered by human chorionic gonadotropin (acting directly on ovarian LH receptors) and, to a lesser extent, GnRH receptor agonists (triggering an endogenous LH surge in excess of that observed in normal cycles). The main feature of clinically significant OHSS is the development of vascular hyperpermeability, which allows fluid to shift. The use of hCG leads to hyperluteinization of the ovaries, releasing large amounts of estrogen, progesterone and local cytokines. Endogenous hCG can have sustained effects in vivo, which are related to the activation of LH receptors. This is likely due to prolonged overactivation. Under the action of hCG, vascular endothelial growth factor (VEGF) is produced by the follicle, which can increase vascular hyperpermeability leading to OHSS. Severe OHSS has been reported to occur in up to 2% of the general assisted reproduction population and up to 20% of patients at high risk for developing OHSS, such as those with polycystic ovary syndrome (PCOS).

[0009] The use of GnRH agonists as triggering agents has been associated with reduced rates of OHSS, but the use of GnRH agonists as triggering agents also reduces pregnancy rates, especially in the absence of exogenous luteal phase support. Protocols using GnRH agonist triggering require the administration of agents for luteal phase support. These triggers produce LH surges that are rapid (e.g., peak amplitudes sufficient to trigger final maturation but short wavelengths) and short in duration (<20 hours or occasionally 24–36 hours). Furthermore, because the half-life of LH (approximately 60 minutes) is shorter than that of hCG, circulating levels of progesterone and estradiol after GnRH agonist triggering are significantly lower throughout the luteal phase than those obtained after hCG triggering. GnRH agonist triggering without exogenous luteal phase support can result in premature luteal regression and implantation failure. In addition, the risk of OHSS is not completely eliminated by using GnRH agonist as a trigger agent, and frozen embryo transfer in the next menstrual cycle is still considered safer to reduce the risk of OHSS. Furthermore, women are required to undergo ART to shorten the time to pregnancy without increasing the risk of OHSS. At present, it is difficult to provide the option of fresh embryo transfer while reducing the risk of OHSS and achieving the desired luteal phase support, mature oocyte yield, pregnancy rate and live birth rate.

[0010] With the need to improve both safety and efficacy, it would be desirable to have novel triggering agents for ART and additional agents that can be administered for luteal phase support. Summary of the Invention [Means for solving the problem]

[0011] The present disclosure relates to methods, uses and compositions for helping women with infertility problems. In another aspect, the present disclosure relates to increasing the level of endogenous LH in women who need to increase the level of endogenous LH. In some aspects, the present disclosure relates to luteal phase support that improves the safety and efficacy of ART processes by providing an alternative to current luteal phase support methods. The women may or may not be undergoing ART. One possible advantage of these improved methods and uses is that they can significantly reduce the risk of OHSS in women undergoing ART.

[0012] One aspect of the disclosure relates to a method of increasing endogenous LH levels in a female in need thereof, comprising administering to the female an initial dose of about 0.00003 mg to about 0.030 mg of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide (referred to herein as Compound 1), or a corresponding amount of a pharma- ceutically acceptable salt thereof, wherein the female is receiving ART and is at risk for OHSS, and wherein after administration of the initial dose, the female's blood level of endogenous LH is increased above the female's blood level of endogenous LH prior to administration of the initial dose.

[0013] Another aspect of the disclosure is a method of increasing endogenous LH levels in a woman undergoing ART in need of such an increase, comprising administering to the woman an initial dose of about 0.00003 mg to about 0.030 mg of Compound 1, or a corresponding pharma- ceutical acceptable salt thereof. wherein the woman is receiving ART and, at least 36 hours after administration of the first dose, the level of endogenous LH in the woman's blood is increased above the level of endogenous LH in the woman's blood before administration of the first dose.

[0014] One aspect of the present disclosure relates to a method of increasing endogenous LH levels in a woman in need thereof and undergoing ART, comprising administering to the woman an initial dose of about 0.00003 mg to about 0.030 mg of Compound 1, or a corresponding amount of a pharmaceutically acceptable salt thereof, wherein the woman is undergoing ART and experiences a peak blood endogenous LH level at least about 12 hours after administration of the initial dose.

[0015] Another aspect of the disclosure is a method for increasing endogenous LH levels in a woman receiving ART and at risk for OHSS, comprising administering to the woman 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a pharma- ceutical acceptable salt thereof, the method comprising administering to the woman 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a pharma- ceutical acceptable salt thereof. The present invention relates to a method for treating a rheumatoid arthritis, comprising administering an initial dose of about 0.00003 mg to about 0.030 mg of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-N ω-methyl-L-arginyl-L-tryptophanamide or a corresponding amount of a pharma- ceutical acceptable salt thereof.

[0016] One aspect of the disclosure is a method for increasing endogenous LH levels in a woman receiving ART, comprising administering to the woman 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a pharma- ceutical acceptable salt thereof, the method comprising administering to the woman 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a pharma- ceutical acceptable salt thereof. The present invention relates to a method for treating a patient suffering from atopic dermatitis, comprising administering an initial dose of about 0.00003 mg to about 0.030 mg of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-N ω-methyl-L-arginyl-L-tryptophanamide or a corresponding amount of a pharma- ceutical acceptable salt thereof.

[0017] In certain embodiments of any of the above or below, peak blood endogenous LH levels occur from about 12 hours to about 48 hours after administration of the first dose.

[0018] Another aspect of the present disclosure relates to a method of increasing endogenous LH levels in a female undergoing ART and in need of luteal phase support, comprising administering to the female an initial dose of about 0.00003 mg to about 0.030 mg of Compound 1, or a corresponding amount of a pharma- ceutical acceptable salt thereof, after the female has been administered a trigger dose of an oocyte maturation agent as part of her ART regimen.

[0019] In certain embodiments of any of the above or below, the level of endogenous LH in the woman's blood is increased from about 12 hours to about 96 hours after administration of the first dose compared to the level of endogenous LH in the woman's blood prior to administration of the first dose.

[0020] In certain embodiments of any of the above or below, the woman's blood endogenous LH level is elevated for at least 36 hours after administration of the first dose above the woman's blood endogenous LH level prior to administration of the first dose, in some embodiments, the blood endogenous LH level is elevated for about 36 hours to about 16 days or for about 36 hours to about 12 days.

[0021] In any of the above or below specific embodiments, administering the first dose promotes oocyte maturation.In some embodiments, oocyte maturation occurs without administering exogenous hCG or exogenous LH.In other embodiments, oocyte maturation occurs after administering GnRH agonist or exogenous hCG.In some embodiments, the yield of mature oocytes is at least 50%.

[0022] In certain embodiments of any of the above or below, the female does not exhibit one or more symptoms selected from the group consisting of ascites, pleural effusion, and reduced renal perfusion after administration of the first dose, in some embodiments, the size of the ovaries may not increase to more than 5 cm in diameter after administration of the first dose.

[0023] In certain embodiments of any of the above or below, the woman does not exhibit one or more symptoms of OHSS after administration of the first dose. In some embodiments, the woman does not experience a worsening of one or more symptoms of OHSS after administration of the first dose.

[0024] In certain embodiments of any of the above or below, the first dose is administered once at least three follicles measuring at least 14 mm are visible by ultrasound, or once at least three follicles measuring at least 18 mm are visible by ultrasound.

[0025] In certain embodiments of any of the above or below, the first dose is administered once the serum estradiol concentration is at least 0.49 nmol / L.

[0026] In certain embodiments of any of the above or below, the methods or uses disclosed herein further comprise administering FSH about 5 to about 12 days prior to administering the first dose.

[0027] In certain embodiments of any of the above or below, the disclosed methods or uses further comprise administering a GnRH antagonist about 2 to about 10 days prior to administering the first dose. In some embodiments, the GnRH antagonist is selected from the group consisting of relugolix, elagolix, cetrorelix, ganirelix, abarelix, Nal-Blu, antide, azaline B, degarelix, D63153 (ozarelix), OBE2109, and teverelix. In some embodiments, the disclosed methods or uses further comprise administering a GnRH agonist about 14 to about 28 days prior to administering the first dose. In certain embodiments of any of the above or below, the GnRH agonist is selected from the group consisting of leuprorelin acetate, gonadorelin, buserelin, triptorelin, goserelin, nafarelin, histrelin, deslorelin, meterelin and recirelin.

[0028] In certain embodiments of any of the above or below, the first dose is administered before oocyte collection, after oocyte collection, before or after ovulation, In some embodiments, the first dose is administered after administration of a GnRH agonist as an oocyte maturation agent.

[0029] In certain embodiments of any of the above or below, the disclosed methods or uses further comprise administering a second dose of about 0.00003 mg to about 0.030 mg of Compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. This dose is administered within about 8 to about 60 hours after administration of the first dose.

[0030] In certain embodiments of any of the above or below, the disclosed methods or uses further comprise administering a third dose of about 0.00003 mg to about 0.030 mg of Compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the third dose is administered within about 8 to about 60 hours of administration of the second dose.

[0031] In certain embodiments of any of the above or below, the disclosed methods and uses further comprise administering 1-5 additional doses of Compound 1, about 0.00003 mg to about 0.030 mg, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the administration of the 1-5 additional doses is within about 8 to about 60 hours of administration of the previous dose. In some embodiments, one or more of the first dose, the second dose, the third dose, or the 1-5 additional doses facilitates luteal phase support. In some embodiments, one or more of the first dose, the second dose, the third dose, or the 1-5 additional doses are administered by injection. In certain such embodiments, the injection is intramuscular or subcutaneous. In certain embodiments of any of the above or below, the first dose, the second dose, the third dose, or the 1-5 additional doses are about 0.0003 mg to about 0.03 mg.

[0032] In certain embodiments of any of the above or below, the disclosed methods or uses further comprise administering one or more doses of a progestogen. In certain embodiments of any of the above or below, the disclosed methods or uses do not comprise administering one or more doses of a progestogen.

[0033] In certain embodiments of any of the above or below, the method or use of the disclosure further comprises harvesting of oocytes.

[0034] In certain embodiments of any of the above or below, the woman's pituitary gland is desensitized to GnRH prior to administration of the first dose.

[0035] In certain embodiments of any of the above or below, the disclosed methods or uses further comprise the transfer of an embryo. In some embodiments, the transfer occurs within about 2 to about 10 days of administration of the first dose. In some embodiments, the transfer occurs within about 1 to about 7 days of oocyte collection. In some embodiments, the embryo is not frozen. In some embodiments, the embryo is transferred in the same menstrual cycle as the oocyte collection.

[0036] In certain embodiments of any of the above or below, the disclosed method or use induces ovulation.

[0037] In certain embodiments of any of the above or below, the female becomes pregnant by intercourse or IUI after administration of at least the first dose. In some embodiments, the female becomes pregnant and / or gives birth after administration of at least the first dose.

[0038] In any of the above or below specific embodiments, the woman is undergoing COS.In some embodiments, the woman is one or more of PCOS, serum anti-Mullerian hormone (AMH) is more than 15 pmol / L, total antral follicle count (AFC) by ultrasound is more than 23, serum estradiol E2 is more than 3000 pg / mL, or has previously experienced one or more OHSS episodes.In some embodiments, the woman is one or more of anovulation or late childbirth, or suffers from secondary ovarian insufficiency, oligomenorrhea, amenorrhea, endometriosis or PCOS.

[0039] In certain embodiments of any of the above or below, the ART therapy is selected from the group consisting of oocyte donation, oocyte banking, intracytoplasmic sperm injection (ICSI), IVF, embryo transfer (ET) process, ovulation induction and IUI.

[0040] One aspect of the present disclosure relates to a method of inducing terminal maturation and early luteinization of ovarian follicles in a female in need thereof, the female being undergoing ART and having undergone pituitary desensitization and having undergone pretreatment with follicle-stimulating hormone as part of the ART, the method comprising administering to the female an initial dose of about 0.00003 mg to about 0.030 mg of Compound 1, or a corresponding amount of a pharmaceutical acceptable salt thereof, wherein after administration of the initial dose, the female's blood level of endogenous LH is increased above the female's blood level of endogenous LH prior to administration of the initial dose.

[0041] Another aspect of the present disclosure relates to a method of inducing ovulation in a female in need thereof, wherein the female has anovulatory infertility, and wherein the infertility is not due to premature ovarian failure, the method comprising administering to the female an initial dose of about 0.00003 mg to about 0.030 mg of Compound 1, or a corresponding amount of a pharma- ceutical acceptable salt thereof, wherein after administration of the initial dose, the female's blood level of endogenous LH is increased above the female's blood level of endogenous LH prior to administration of the initial dose.

[0042] Another aspect of the disclosure is a method for inducing terminal maturation of ovarian follicles and early luteinization in a woman undergoing ART, who has undergone pituitary desensitization and who has been pretreated with follicle-stimulating hormone as part of her ART, comprising administering to the woman 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide, or a pharma- ceutical acceptable salt thereof, for use in a method for inducing terminal maturation of ovarian follicles and early luteinization in a woman undergoing ART, who has undergone pituitary desensitization and who has been pretreated with follicle-stimulating hormone as part of her ART, said method comprising administering to the woman 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide, or a pharma- ceutical acceptable salt thereof. The present invention relates to a method for treating a rheumatoid arthritis, comprising administering an initial dose of about 0.00003 mg to about 0.030 mg of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a corresponding amount of a pharma- ceutical acceptable salt thereof.

[0043] One aspect of the disclosure is a method for inducing ovulation in a woman suffering from anovulatory infertility, comprising administering to the woman 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a pharma- ceutical acceptable salt thereof, for use in such a method. The present invention relates to a method for treating a rheumatoid arthritis, comprising administering an initial dose of 0.00003 mg to about 0.030 mg of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-N ω-methyl-L-arginyl-L-tryptophanamide or a corresponding amount of a pharma- ceutical acceptable salt thereof.

[0044] In certain embodiments of any of the above or below, the female is at risk of OHSS.

[0045] In certain embodiments of any of the above or below, the female has anovulatory infertility not due to premature ovarian failure.

[0046] In certain embodiments of any of the above or below, the methods and uses disclosed herein comprise administering to the female an initial dose of about 0.001 mg to about 0.003 mg, about 0.001 mg to about 0.030 mg, or about 0.0003 mg to about 0.003 mg of Compound 1, or a corresponding amount of a pharma- ceutical acceptable salt thereof.

[0047] One aspect of the present disclosure relates to the use of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for increasing endogenous LH levels in women receiving ART and at risk for OHSS.

[0048] Another aspect of the present disclosure relates to the use of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for increasing endogenous LH levels in women undergoing ART.

[0049] One aspect of the present disclosure relates to the use of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for inducing terminal maturation of ovarian follicles and early luteinization in women undergoing ART, who have undergone pituitary desensitization, and who have been pretreated with follicle-stimulating hormone as part of their ART.

[0050] Another aspect of the present disclosure relates to the use of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for inducing ovulation in a woman with anovulatory infertility, wherein said infertility is not due to premature ovarian failure.

[0051] Further embodiments of the present disclosure are described below, some of which are illustrated, but not all of the embodiments of the present disclosure.

[0052] Each embodiment disclosed herein may be used individually or in combination with any other embodiment disclosed herein.

[0053] All publications, patents and published patent applications mentioned in this application are specifically incorporated herein by reference. [Brief description of the drawings]

[0054] [Figure 1] FIG. 1 shows a schematic illustrating the ART protocol, which is not intended to be limiting. [Diagram 2] 1 shows plots showing mean plasma concentrations of Compound 1 monoacetate (API-MA) by treatment group up to 72 hours when administered to healthy European males as described in Example 5. [Diagram 3] FIG. 1 is a plot showing the mean (±standard deviation [SD]) plasma-time profile of Compound 1 monoacetate (API-MA) concentrations following a 2-hour subcutaneous (SC) administration of 0.5 mg / day and 1.0 mg / day of API-MA for 14 days in healthy European males as described in Example 6. [Figure 4] FIG. 1 is a plot showing mean plasma concentration-time curves up to 12 hours on Day 1 by dose group in European men with prostate cancer using SC depot injection as described in Example 7. [Diagram 5] FIG. 1 is a plot showing mean plasma concentration-time curves from day 2 of month 1 to month 3 by dose group in European men with prostate cancer using SC depot injection as described in Example 7. [Figure 6] 1 is a plot showing mean (SD) serum LH concentrations following a single SC bolus dose of API-MA in European men with prostate cancer, as described in Example 7. [Figure 7] 1 is a plot showing the mean (SD) of serum FSH concentrations following a single SC bolus dose of API-MA as described in Example 7. [Figure 8] 1 is a plot showing the mean serum concentration-time profile of LH as described in Example 7. [Figure 9] 1 is a plot showing the mean serum concentration-time profile of FSH, as described in Example 7. [Figure 10] 1 is a plot showing the mean serum concentrations of LH following administration of API-MA by SC bolus (day 1) and continuous SC infusion (days 2-14) as described in Example 8. [Figure 11] 1 is a plot showing the mean serum concentrations of FSH following administration of API-MA by SC bolus (day 1) and continuous SC infusion (days 2-14), as described in Example 8. [Figure 12] 1 is a plot showing LH by subject (N=3) for the API-MA 0.5 mg / day group as described in Example 8. [Figure 13] 1 is a plot showing FSH by subject (N=3) for the API-MA 0.5 mg / day group as described in Example 8. [Figure 14] 1 shows the study design detailed in Example 11, Part 1. [Figure 15]Figure 15A shows the changes in LH, FSH, estradiol and progesterone over 48 hours after administration of 9.6 nmol / kg kisspeptin-54 (KP54) to healthy women aged 18-35 years, as described in Example 11. Figure 15B shows the changes in LH, FSH, estradiol and progesterone over 48 hours after administration of 0.003 nmol / kg compound 1 to healthy women aged 18-35 years, as described in Example 11. Figure 15C shows the changes in LH, FSH, estradiol and progesterone over 48 hours after administration of 0.03 nmol / kg compound 1 to healthy women aged 18-35 years, as described in Example 11. [Figure 16] FIG 16A shows the change in LH over 48 hours after administration of 9.6 nmol / kg kisspeptin-54 (KP54) to healthy women aged 18-35 years, as described in Example 11. FIG 16B shows the change in LH over 48 hours after administration of 0.003 nmol / kg compound 1 to healthy women aged 18-35 years, as described in Example 11. FIG 16C shows the change in LH over 48 hours after administration of 0.03 nmol / kg compound 1 to healthy women aged 18-35 years, as described in Example 11. [Figure 17] As described in Example 11, the mean change in LH over 48 hours in all subjects after administration of 9.6 nmol / kg kisspeptin-54 (KP54), 0.003 nmol / kg compound 1, and 0.03 nmol / kg compound 1 to healthy women aged 18-35 years is shown. [Figure 18] As described in Example 11, following administration of 0.003 nmol / kg of Compound 1 to healthy females aged 18-35 years, the mean change in LH over 48 hours in all subjects is shown. [Figure 19] As described in Example 11, following administration of 0.03 nmol / kg of Compound 1 to healthy women aged 18-35 years, the mean change in LH over 48 hours in all subjects is shown. [Figure 20]Figure 20A shows the change in FSH over 48 hours after administration of 9.6 nmol / kg kisspeptin-54 (KP54), 0.003 nmol / kg compound 1, and 0.03 nmol / kg compound 1 to healthy women aged 18-35 years, as described in Example 11. Figure 20B shows the change in estradiol over 48 hours after administration of 9.6 nmol / kg kisspeptin-54 (KP54), 0.003 nmol / kg compound 1, and 0.03 nmol / kg compound 1 to healthy women aged 18-35 years, as described in Example 11. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0055] Assisted reproductive technologies (ART) are complex, with each assisted reproductive cycle consisting of several carefully orchestrated steps. Improper performance of any of these steps may result in failure to achieve fertilization or pregnancy. In addition, the success of ART protocols varies greatly from woman to woman, adding to the complexity. Typical phases of ART include an initial COS phase to promote and stimulate controlled follicular growth and development, followed by the use of so-called "trigger" agents to promote / induce final maturation of the oocyte. In some ART regimens, mature oocytes may then be removed from the follicles and fertilized in vitro or by ICSI, and the embryo(s) may be transferred to the uterus, or, instead of removing the eggs from the follicles, they may be ovulated and fertilized into the mature oocytes by sexual intercourse or IUI. A schematic of a representative ART regimen is shown in Figure 1. ART procedures are invasive, expensive, and may have negative side effects, so it is important to prevent or mitigate the possibility of fertilization failure or pregnancy failure.

[0056] For example, as shown diagrammatically in FIG. 1, the implementation of the long GnRH agonist method to suppress the LH surge is started in the menstrual cycle prior to the menstrual cycle in which the trigger agent is administered. In the ART treatment protocol, the administration of the GnRH agonist may be combined with FSH or FSH / hMG treatment to stimulate the ovarian follicles, or the FSH or FSH / hMG treatment may be started without the long GnRH agonist method. Alternatively, instead of the GnRH agonist, a GnRH antagonist may be used to suppress the LH surge, which is used in combination with the FSH or FSH / hMG treatment. In this case, the GnRH antagonist is administered in the same menstrual cycle in which the FSH or FSH / hMG combined treatment is started and after the FSH or FSH / hMG combined treatment is started. Following this treatment, a trigger may be administered, typically a GnRH agonist, hCG, or Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, as detailed in this disclosure. Human chorionic gonadotropin (hCG) has LH-like activity that acts on the LH receptor to induce ovulation. Typically, oocyte collection or ovulation occurs 30-62 hours after administration of the trigger. The human female subject undergoing ART may then undergo IUI or have intercourse to become pregnant. After the trigger, through ET, IUI, or intercourse, the human female subject may or may not receive luteal phase support, including but not limited to administration of low dose hCG, progestogen, estradiol, or Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing.

[0057] Disclosed herein are compounds of Compound 1, its metabolites, or pharma- ceuticals containing any of the foregoing. The present invention relates to a method and method of use of ART, comprising administering a pharma- ceutically acceptable salt of Compound 1 to a patient having a fertility of 100 or more. As used herein, Compound 1 is 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)-hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide. Compound 2 is a metabolite of Compound 1. Compound 1, its metabolites, or a pharma- ceutically acceptable salt of either of the foregoing, can mimic the natural physiology by inducing the release of endogenous LH during assisted reproduction, thereby potentially increasing the chances of successful egg (oocyte) maturation and, in some cases, ovulation at the appropriate time in the cycle, without the potentially severe side effects associated with current options for hormone stimulation treatment (such as hCG). Previous studies with compound 1 have been conducted in men or animals (e.g., rats, dogs, and monkeys) to evaluate the pharmacokinetic properties or efficacy of compound 1 in the treatment of prostate cancer. The bioavailability of compound 1 is significantly different in rats (66.3%) and dogs (92.4%). Compound 1 exhibited nonlinear pharmacokinetics after a single subcutaneous (SC) dose in rats due to increased subcutaneous first-pass metabolism. Compound 1 exhibited nonlinear subdose-proportional pharmacokinetics and decreased AUC after SC administration in rats at dose ranges of 1 mg / kg and 10 mg / kg. In contrast to linear pharmacokinetics after IV administration, nonlinear subdose-proportional pharmacokinetics was observed after SC administration, and absorption of compound 1 was limited at the highest dose level, indicating increased SC metabolism with increasing dose. Coadministration of a protease inhibitor subcutaneously restored systemic absorption of compound 1, suggesting the involvement of SC proteases in first-pass metabolism. The highest human dose administered to men by SC bolus was only about 0.008 mg / kg, and exposure was dose proportional up to this dose. SC infusion was also proportional up to about 0.1 mg / kg. Depot formulations had sub-proportional exposures over the range of about 0.1 mg / kg to 0.4 mg / kg. This disclosure describes the use of Compound 1, its metabolites, or pharma- ceutically acceptable salts of any of the foregoing in women to supplement ART.The doses of Compound 1 used in the present invention are significantly lower than those tested in rats and men, with the maximum doses being 30 μg or 0.25 μg / kg, compared to 1 mg / kg and 10 mg / kg in rats and 8 μg / kg and 0.1 mg / kg to 0.4 mg / kg in men.

[0058] Compound 1, its metabolites, or any of the pharma- tically acceptable salts thereof can promote the maturation, release (ovulation), and collection of fresh mature oocytes (or eggs (used interchangeably herein)) from the ovaries, resulting in overall pregnancy rates comparable to or superior to those of hCG triggering, as well as significantly reducing the risk of serious side effects such as OHSS, compared to hCG and GnRH agonists. In addition, compared to currently available triggering agents (especially hCG-based triggering agents), Compound 1, its metabolites, or any of the pharma-tically acceptable salts thereof can provide the advantage of significantly reducing the OHSS rate in all patients, including those with high AMH levels or those with FSH and LH receptor mutation susceptibility. Furthermore, Compound 1, its metabolites, or any of the pharma-tically acceptable salts thereof can provide luteal phase support by activating the LH surge to its natural peak, for a long period of time (more than 20 hours, mimicking the natural LH surge for 48 hours), with a low risk of OHSS. This advantage of compound 1, its metabolites, or a pharma- ceutically acceptable salt of either of the foregoing may eliminate the need for additional luteal phase support (such as daily IM progesterone injections or additional hCG supplementation), simplifying ART protocols and even allowing for the transfer of "fresh" embryos in the same menstrual cycle, potentially shortening the time to pregnancy.

[0059] Compared to currently available triggering agents, Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, may provide the advantage of shortening the time to pregnancy. Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing may be used in fresh embryo transfer. The mechanism of action of compound 1, its metabolites, or any of its pharma- ceutically acceptable salts may result in less adverse effects on the endometrium compared to current therapies. Thus, the endometrium may be ready for implantation (high endometrial receptivity) immediately after egg (oocyte) collection. This may allow implantation in the same menstrual cycle as the trigger and oocyte collection. Compared to hCG-based trigger agents (including dual triggers with GnRH agonists), compound 1, its metabolites, or any of its pharma-ceutically acceptable salts may reduce the number of IVF cycles by reducing the need for fractional freezing protocols, shortening the time to pregnancy while maintaining acceptable pregnancy rates, reducing costs, and reducing side effects such as macrosomia (large for gestational age), placenta accreta, and pre-eclampsia, all of which are accompanied by a significant reduction in OHSS rates. Compound 1, its metabolites, or a pharma- ceutically acceptable salt of either of the foregoing can provide advantageous safety and efficacy attributes over current therapies that require resolution.

[0060] The present disclosure also relates to methods and uses comprising administering Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing, to elevate endogenous LH levels in a human female subject undergoing ART (such as IVF, ICSI, oocyte donation, oocyte banking, menstrual cycle regulation, ovulation induction and / or ET processes that allow the human female subject to become pregnant by intercourse or IUI). Elevating endogenous LH levels can assist in both oocyte maturation and luteal phase support.

[0061] The present disclosure further relates to methods and uses comprising administering Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, to inhibit ovulation and premature release of oocytes during the early COS phase. These methods and uses may be applied to ART protocols using either gonadotropin releasing hormone (GnRH) agonists or GnRH antagonists during the early COS phase.

[0062] Provided herein is the use of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, in the manufacture of a medicament for treatment according to any of the methods described herein. Also provided is Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, for use in any of the methods described herein.

[0063] Compounds of the Disclosure As used herein, compound 1 is 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)-hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide. Its molecular formula is C 58 H 80 N 16 O 14 and has a molecular weight of 1225.35. Compound 1 is in a free form and is represented by the sequence Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (SEQ ID NO: 1) and the following structural formula: [ka]

[0064] In some embodiments, the compound of the disclosure is a metabolite of compound 1. In certain such embodiments, the metabolite is compound 2, which is represented by the following structural formula: [ka]

[0065] In some embodiments, pharma- ceutically acceptable salts of Compound 1 and / or its metabolites are used. "Physiologically acceptable," "pharmacologically acceptable," or "pharmacologically acceptable" compounds and compositions may include substances that are not biologically or otherwise harmful. For example, the substances can be administered to an individual without exerting any substantial undesirable biological effects or interacting in a detrimental manner with any of the components of the composition that are included in the composition. In certain embodiments, the pharma- ceutically acceptable salts of Compound 1 and / or its metabolites are pharma- ceutically acceptable acid addition salts. Such salts include, but are not limited to, salts with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, etc.) and salts with organic acids (e.g., formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc.). In certain embodiments, the pharma- ceutically acceptable salt of Compound 1 and / or its metabolites is a pharma- ceutically acceptable base addition salt, including, but not limited to, inorganic bases (e.g., alkali and alkaline earth metals such as sodium, potassium, calcium, magnesium, ammonia, etc.) or organic bases (e.g., trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N,N'-dibenzylethylenediamine, etc.).

[0066] As used herein, the form of Compound 1 is 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)-hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl. -L-tryptophanamide monoacetate. In this monoacetate salt, the molecular formula is C 58 H 80 N 16 O 14It is C2H4O2 and has a molecular weight of 1285.41. Its structural formula is: [ka]

[0067] Throughout this disclosure, the amount of Compound 1 or its metabolites refers to the amount of Compound 1 in free form present in the formulation. The term "corresponding amount" as used herein refers to the amount of pharma- ceutically acceptable salt of Compound 1 or its metabolites required to obtain the amount of Compound 1 in free form or its metabolites shown in the formulation. The method of calculating the "corresponding amount" of a salt of a compound (such as the corresponding amount of a pharma- ceutically acceptable salt of Compound 1) will be clear to one of skill in the art, taking into account the molecular weight difference between the free form of the compound and the salt form. For example, 10.0 mg of the compound free form will correspond to 10.5 mg of the monoacetate salt.

[0068] Compound 1, or a pharma- ceutically acceptable salt thereof, and pharmaceutical compositions comprising Compound 1, or a pharma- ceutically acceptable salt thereof, may be made by the methods described in U.S. Pat. Nos. 7,960,348 and 8,404,643, the disclosures of which are incorporated herein by reference.

[0069] Compound 1 is described as a kisspeptin analog. Kisspeptin, a hypothalamic neuropeptide encoded by the KISS1 gene, is a central regulator of GnRH secretion, a recently discovered hormone that is essential for normal puberty. Kisspeptin is a peptide ligand agonist of the human G protein-coupled receptor 54 (GPR54) / KISS1 receptor (KISS1R), previously known as OT7T175 / GPR54. Mutations or knockouts of the KISS1R gene result in failure to initiate puberty. Kisspeptin plays a key role in regulating the amount and pulsatility of gonadotropin-releasing hormone (GnRH) secretion in the hypothalamus. Kisspeptin administration induces the release of GnRH and gonadotropins in mammals, including humans, most likely through a direct effect of the peptide on GnRH neurons. GnRH is a key component of the hypothalamic-pituitary-gonadal axis, controlling reproductive functions, including spermatogenesis, follicular maturation and ovulation, and steroidogenesis. Thus, kisspeptin is a crucial regulator of the hypothalamic-pituitary-gonadal axis through the control of GnRH neurons. There are two mechanisms of GnRH secretion. One is the pulsatile GnRH secretion that primarily regulates spermatogenesis, follicle formation, and steroidogenesis, which is a feedback (negatively) regulated by steroid hormones. The other mechanism is the GnRH surge, which leads to the LH surge observed only in women, which induces the final maturation of oocytes and, ultimately, ovulation. Hypothalamic kisspeptin neurons can regulate both mechanisms of GnRH secretion. Pharmacologically, in several species, including humans, acute exposure to kisspeptin can stimulate GnRH-gonadotropin secretion, while Chronic exposure to kisspeptin (at higher doses) can suppress GnRH secretion and the hypothalamic-pituitary-gonadal axis through potential inhibitory mechanisms, including desensitization of GnRH receptors and / or depletion of GnRH reserve. Chronic administration of kisspeptin analogues suppresses intrinsic GnRH pulses and downstream pituitary-gonadal function, likely due to the responsiveness of GnRH neurons to endogenous kisspeptin stimulation and attenuated stimulation of GnRH neurons resulting in the continuous release of low levels of GnRH.

[0070] Kisspeptin-54 has a half-life of 32 minutes and stimulates the release of endogenous GnRH, which stimulates the release of gonadotropins and subsequently the sex hormones. Kisspeptin administration to healthy male and female human volunteers has been shown to significantly increase plasma LH, FSH and testosterone concentrations, and subcutaneous administration of kisspeptin to human female volunteers increased plasma LH during all phases of the menstrual cycle. When the triggering agent was typically administered, the effect of kisspeptin was greatest during the preovulatory phase and least during the follicular phase of the menstrual cycle. Kisspeptin has also been experimentally tested as a trigger in ART protocols including GnRH antagonist and FSH in both IVF populations of women and IVF populations at high risk for OHSS. Kisspeptin has only been used as a trigger in ART cycles using GnRH antagonist protocols. Thus, kisspeptin ART protocols may increase luteal phase defects, which typically occur in GnRH antagonist protocols in the absence of hCG as a trigger. Kisspeptin has been shown to stimulate endogenous levels of LH, but the duration of the LH surge is significantly shorter than that observed with hCG or GnRH agonist triggers, necessitating additional exogenous luteal phase support. With kisspeptin-54, the LH surge converges by 36 hours. In some women, an insufficient LH surge was observed, which reduced oocyte yields. Furthermore, increasing the dose of kisspeptin reduced pregnancy rates, and the ideal dose is not yet known. Additional studies reported in Example 11 (Figures 15A and 16A) show that in female subjects administered kisspeptin-54 during the follicular phase (when triggering agents have the least effect on LH levels), LH increased and peaked approximately 4-6 hours after administration of the kisspeptin trigger, with the LH surge lasting less than 14 hours. Studies with kisspeptin-54 have shown that, despite its drawbacks, fresh embryo transfer (implantation during the same menstrual cycle) is possible in women at high risk for OHSS.

[0071] Compound 1 or its pharma- ceutically acceptable salt has a half-life of up to 4 hours. As shown in Example 11 (Figs. 16B, 17 and 18), after administration of a dose of 0.003 nmol / kg of compound 1 (about 0.00022 mg) during the follicular phase (when the triggering agent has the least effect on LH levels) in women, serum LH levels were estimated to peak 14-36 hours after administration, and the LH surge lasted for at least about 48 hours (the duration of the natural LH surge). Thus, administration of compound 1 or its pharma-ceutically acceptable salt may not only trigger the final maturation of oocytes, but also provide luteal replenishment, thus increasing the chances of successful implantation. Surprisingly, the curve of the LH surge observed with compound 1 resembled that of the natural LH surge, and was broader and potentially longer lasting than the LH surge induced by GnRH agonist triggering. It was also surprising that follicular LH levels in women were affected so greatly by Compound 1. The effect was greater than that from kisspeptin-54, indicating that Compound 1 should also produce a rapid rise in LH levels during the preovulatory phase, potentially exceeding in both amplitude and duration the results observed with kisspeptin-54 during the preovulatory phase. As used herein, the preovulatory phase may refer to the period 15-16 days before the expected start of a woman's next menstrual period.

[0072] The nature of the LH surge observed with compound 1 (more closely mimicking the natural surge) ), Compound 1 or its metabolites may be ideal agents for inclusion in ART protocols. Triggered administration of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of either of the foregoing may limit the need for luteal phase support. It may also allow the option of fresh embryo transfer, significantly shortening the time to pregnancy and reducing the costs associated with multiple rounds of ART.

[0073] Another advantage of compound 1, its metabolites or any of the pharmacologic acceptable salts over current therapies is that its action depends on the endogenous release of the female GnRH pool.This allows for more physiological gonadotropin stimulation and prevents the overstimulation that limits current fertility treatments.Compound 1 or its metabolites stimulate the endogenous release of LH into the female circulation, thus greatly reducing the probability of potentially life-threatening OHSS.

[0074] Treatment Methods and Uses of Compounds of the Disclosure The present disclosure provides methods and uses for increasing endogenous LH levels in a woman in need thereof, comprising administering to the woman an initial dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing. In some embodiments, the woman is undergoing ART and is at risk for OHSS. In certain such embodiments, after administration of the initial dose, the woman's blood endogenous LH level is elevated above the woman's blood endogenous LH level prior to administration of the initial dose.

[0075] Throughout this disclosure, the dose or amount of compound 1, its metabolites, or any of the pharma- ceutically acceptable salts thereof used in any of the methods or uses disclosed herein (e.g., about 0.00003 mg to about 0.030 mg, about 0.0003 to about 0.003 mg, about 0.001 mg to about 0.003 mg, or about 0.001 mg to about 0.03 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof) may be any of the doses or amounts disclosed below. In addition, the formulation or pharmaceutical composition comprising compound 1, its metabolites, or any of the pharma- ceutically acceptable salts thereof, used in any of the methods and uses disclosed herein, may be any of the formulations or pharmaceutical compositions disclosed below. The doses and amounts of the formulation or pharmaceutical composition comprising compound 1, its metabolites, or any of the pharma- ceutically acceptable salts thereof disclosed herein and compound 1, its metabolites, or any of the pharma- ceutical acceptable salts thereof may be administered by any of the administration methods disclosed herein.

[0076] In the present invention, the endogenous LH level in the blood of a woman before the first dose may be calculated as the average of five LH values ​​immediately prior to the designated start date of the LH surge (i.e., five days before administration of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing). The rise is the rise above the endogenous LH level in the blood of the woman before the first dose. The end of the rise is when the LH level returns to the endogenous LH level in the blood of the woman before the first dose. As used herein, the LH peak is the highest LH value, the LH amplitude is the difference between the peak LH value and the endogenous LH level in the blood of the woman before the first dose, and the LH surge fold rise is the peak LH value divided by the endogenous LH level in the blood of the woman before the first dose. In a COS setting, a woman's endogenous LH levels in the blood before the first dose range from 2-10 IU / L, and the peak of the LH surge ranges from 20-120 IU / L (amplitude = peak - endogenous LH level in the woman's blood before the first dose). The fold increase is typically 2-60 fold. Most women can expect an LH fold increase of 2-11 fold (when done in a COS setting or preovulatory).

[0077] As will be appreciated by those skilled in the art, the success of an ART regimen depends on both the timing and dosage of the various agents administered throughout the treatment regimen and at different times during a woman's menstrual cycle. As described herein, the various regimens rely on judicious administration of agents including FSH or FSH / hMG to induce oocyte maturation, and additional agents (e.g., GnRH agonists or GnRH antagonists) at specific doses at predetermined times in the menstrual cycle to allow multiple oocytes to mature within a similar time period so that the final mature oocytes can be harvested after administration of a trigger agent and before premature ovulation, for example, for use in oocyte banking, oocyte donation, IVF, ICSI, etc., or after ovulation, the oocytes can be fertilized by IUI or intercourse within a predetermined time from the expected date of ovulation. Critical to all of these aspects of ART is the control of LH levels. For example, sufficient LH must be present to obtain a high enough oocyte yield (e.g., sufficient oocyte yield) for successful oocyte collection, i.e., to stimulate ("trigger") the final maturation of multiple oocytes within a given time period in sufficient quantities to be available for ICSI or IVF. In addition, LH levels must be elevated sufficiently to maintain progesterone production from the corpus luteum to help support the endometrium (also known as luteal supplementation), particularly if ET is envisaged in the same menstrual cycle, thereby increasing the chances of successful embryo implantation and leading to a successful pregnancy and live birth. Similarly, luteal supplementation and a receptive endometrium are also important for the same reasons when ovulation is followed by IUI or intercourse. Compound 1, its metabolites, or any of the pharma- ceutical acceptable salts thereof, may be safely used in the various ART regimens described herein to raise a woman's endogenous LH levels in the appropriate amounts and at the appropriate times, based on controlling the timing and dosage of administration of Compound 1, its metabolites, or any of the pharma-ceutical acceptable salts thereof. As described herein, Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing is used to increase endogenous LH levels in the blood.Because the source of LH is the woman's own adenohypophysis, instead of exogenous LH or drugs that agonize the LH receptor, the risk of stimulating (e.g., overstimulating) supraphysiological amounts of LH (which can lead to OHSS or other complications) is greatly reduced, while allowing for high oocyte yields during oocyte retrieval and aiding in successful implantation during ET.

[0078] The disclosure includes methods and uses comprising administration of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, in assisted reproductive technologies, such as IVF, ICSI, oocyte donation, oocyte banking, menstrual cycle regulation, ovulation induction and / or ET processes to enable a human female subject to become pregnant by intercourse or intrauterine insemination (IUI).

[0079] As used herein, "in vitro fertilization" (IVF) may refer to a method that includes collecting eggs, fertilizing the eggs with sperm in vivo, and inserting the eggs into the uterine cavity once cleavage has progressed to a certain extent. It may include the processes of ovulation induction, egg collection, IVF and culture, and embryo transfer. In IVF, induction of final maturation may allow the eggs (oocytes) to be collected when they are fully mature. Furthermore, in IVF, COS may be performed before induction of final maturation.

[0080] "Embryon transfer" may refer to the process of transferring an embryo into the uterine cavity in the IVF process. One to several embryos inserted into the uterine cavity may be transferred to the uterus, which may result in pregnancy. The term may also include frozen embryo transfer and intrafallopian tube gamete transfer (GIFT) without IVF. "Embryon transfer process" may refer to the entire period of inserting an embryo or gamete into the uterine cavity, the series of processes of transferring the embryo or gamete into the uterus, pregnancy, and administration of drugs before and after embryo transfer to achieve pregnancy.

[0081] "Intracytoplasmic sperm injection" (ICSI) can refer to a laboratory procedure in which a single sperm is drawn into a tiny glass needle and placed directly into each egg. In traditional IVF, the egg and sperm In this method, the sperm are mixed together in a petri dish and allowed to fertilize the egg "naturally". However, to have a chance of doing this, a large number of normal, highly motile sperm are required. For many couples, the number of suitable sperm available may be very limited, or there may be other factors that prevent fertilization, so traditional IVF is not an option, and ICSI is the option. ICSI refers to a laboratory procedure in which a single sperm is aspirated into a fine glass needle and placed directly into each egg. This is done in a laboratory by a trained embryologist using specialized equipment. Very few sperm are required, and the ability of the sperm to penetrate the egg is not important, as it is assisted by the ICSI technique. ICSI does not guarantee that fertilization will occur. Even if the sperm enter the egg, the normal cellular events of fertilization must occur.

[0082] In some embodiments of the methods and uses described herein, the ART is oocyte donation. In some embodiments of the methods and uses described herein, the ART is oocyte banking. In some embodiments of the methods and uses described herein, the ART is ICSI. In some embodiments of the methods and uses described herein, the ART is IVF. In some embodiments of the methods and uses described herein, the ART is an ET process. In some embodiments of the methods and uses described herein, the ART is ovulation induction. In some embodiments of the methods and uses described herein, the ART is IUI. In some embodiments of the methods and uses described herein, the ART is menstrual cycle regulation to allow a human female subject to become pregnant through sexual intercourse.

[0083] The human female subject of the methods and uses described herein may include a woman attempting to conceive. The human female subject of the methods and uses described herein may include a woman attempting to ovulate. The human female subject of the methods and uses described herein may include a woman attempting to donate or store oocytes (e.g., egg donors). The human female subject of the methods and uses described herein may include a woman attempting to become a surrogate mother. The human female subject of the methods and uses described herein may include a woman undergoing COS. The human female subject of the methods and uses described herein may also include a woman at risk of OHSS. The human female subject of the methods and uses described herein may also include a woman who is infertile, anovulatory, late-term childbearing (i.e., over 35 years of age), or secondary to ovarian insufficiency, oligomenorrhea, amenorrhea, endometriosis, or polycystic ovarian syndrome (PCOS), or any combination thereof. The human female subject of the methods and uses described herein may include a woman who has anovulatory infertility not due to premature ovarian failure. The human female subject of the methods and uses described herein may include a woman with anovulatory infertility due to premature ovarian failure (e.g., the woman is unable to undergo final maturation or ovulation of oocytes with a COS regimen). The human female subject of the methods and uses described herein may include a woman with anovulatory infertility due to secondary ovarian failure. Human female subject(s) and woman(s) are used interchangeably herein.

[0084] Women at risk for OHSS may include, but are not limited to, women with PCOS, serum AMH >15 pmol / L, total AFC by ultrasound >23, serum estradiol (E2) >3000 pg / mL, or women who have previously experienced one or more OHSS episodes. In some embodiments, women at risk for OHSS have AMH >30 pmol / L, and in some embodiments, >40 pmol / L. In some embodiments, women at risk for OHSS have serum estradiol E2 >3500 pg / mL. In other embodiments, serum E2 >4000 pg / mL or >5000 pg / mL. In yet other embodiments, Women at risk of OHSS have serum estradiol E2 above 6000 pg / mL. Women at risk of OHSS may include, but are not limited to, women under 30 years old, women with low (lean) body mass or low BMI, women with rapidly increasing E2 levels, women with many ovarian follicles, and combinations of the above.

[0085] Controlled ovarian stimulation (COS) and controlled ovarian hyperstimulation (COH) are used interchangeably herein and may refer to medical treatments to induce multiple follicular development to obtain multiple oocytes by follicular aspiration. COS may include three basic components: 1. combination treatment with exogenous gonadotropins to stimulate multiple follicular development, 2. combination treatment with either gonadotropin-releasing hormone (GnRH) agonists or GnRH antagonists to suppress pituitary function and prevent premature ovulation, and 3. triggering final maturation of oocytes prior to oocyte collection.

[0086] The use of Compound 1, its metabolites or pharma- ceutically acceptable salts of any of the foregoing as triggering agents in ART or luteal phase support may shorten the time to pregnancy, especially compared to hCG-based triggering agents, as this should reduce the need for split-freeze protocols that require more IVF cycles. "Triggering," as used herein, may mean inducing progression from meiotic prophase 1 to a second division arrest at meiotic metaphase 2 (maintained until fertilization) by an LH surge. This final maturation induction initiates the mechanisms that ultimately lead to ovulation, thereby allowing the oocyte to ovulate in the absence of initial artificial oocyte collection. As used herein, the "luteal phase" is the period from ovulation until either pregnancy is established or the onset of the menstrual cycle two weeks later. The luteal phase is characterized by the formation of the corpus luteum, which depends on the stimulation of the LH receptor by either LH or hCG to secrete the steroid hormones estrogen and progesterone. After implantation, the developing blastocyst secretes hCG to maintain the function of the corpus luteum. Interventions in ART (such as administration of GnRH agonists) can reduce LH levels, resulting in insufficient production of progesterone, luteal phase defect, and possible miscarriage. "Luteal phase support" helps resolve luteal phase defect by increasing LH levels and / or stimulating the LH receptor, thus maintaining luteal function and / or increasing progesterone, facilitating embryo implantation.

[0087] The present disclosure also includes methods and uses comprising administering Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts thereof to reduce OHSS rates. In certain such embodiments, administration of Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts thereof results in a substantial pregnancy rate or increased pregnancy rate, a shorter time to pregnancy, and suppression of premature ovulation. "Suppression of premature ovulation" may refer to suppression of premature release (ovulation) of follicles / oocytes (i.e., earlier than the timing of oocyte maturation and egg collection in IVF or other ART regimens) due to the natural LH surge that induces ovulation. Natural ovulation must be avoided in these situations, since exogenous collection of eggs may be difficult once natural ovulation occurs, making IVF or other fertilization techniques impossible.

[0088] As mentioned above, OHSS is a syndrome characterized by ovarian enlargement and the rapid shift of fluid outside the blood vessels. Symptoms may include, but are not limited to, abdominal distension, abdominal discomfort, hydrothorax, decreased renal perfusion, localized ovarian edema, ovarian diameter >5cm or >8cm, free fluid in the abdomen, hematocrit >45%, white blood cell count >15x109 / L, ALT or AST >2xULN, total protein >80g / L, creatinine >110mol / L, or in more severe cases, ascites and / or pleural effusion, and sequelae due to increased blood permeability. Complications of OHSS may include, but are not limited to, hemoconcentration, hypovolemia, and electrolyte imbalance. Mild OHSS is classified as grade 1 ( Grade 1 symptoms may be classified as grade 2 (grade 1 symptoms plus nausea, vomiting and / or diarrhea, and ovarian enlargement of 5-12 cm). Mild OHSS may be classified as grade 3 (features of mild OHSS plus ultrasound evidence of ascites, decreased renal perfusion and decreased renal function). Severe OHSS may be classified as Grade 4 (features of moderate OHSS plus clinical evidence of ascites and / or hydrothorax, dyspnea or shortness of breath, severe abdominal pain, severe nausea and vomiting, blood clots in the legs, decreased urine output, and abdominal tightness or enlargement) and Grade 5 (all of the above plus changes in blood volume, increased blood viscosity due to hemoconcentration, clotting abnormalities, and rapid weight gain (e.g., 33-44 pounds (15-20 kilograms) in 5-10 days)). In severe cases, OHSS may result in death. OHSS may result from increased blood permeability, usually due to the action of exogenous hCG. The methods and uses described herein, comprising administering Compound 1, its metabolites, or a pharma- ceutical acceptable salt of any of the foregoing, may be used to treat or prevent OHSS or to treat or prevent one or more symptoms of OHSS. As used herein, "treating" a condition (such as a given disease or disorder) or "treatment" of a condition may include treating one or more symptoms of the condition and / or preventing the onset of the condition. Treatment may include ameliorating one or more symptoms (e.g., pain) or preventing one or more symptoms (such as reducing or preventing the abdominal bloating and discomfort associated with OHSS).

[0089] In some embodiments of the methods and uses described herein, a woman may not exhibit one or more symptoms of OHSS after administration of an initial dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing.

[0090] In some embodiments of the methods and uses described herein, one or more symptoms of OHSS can be treated after administration of an initial dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing.

[0091] In some embodiments of the methods and uses described herein, after administration of an initial dose of Compound 1, a metabolite thereof, or a pharma- ceutical acceptable salt of any of the foregoing, a woman may experience no worsening of one or more symptoms of OHSS.

[0092] In some embodiments of the methods and uses described herein, one or more symptoms of OHSS can be ameliorated after administration of an initial dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing.

[0093] In some embodiments of the methods and uses described herein, after administration of an initial dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, the woman may not exhibit one or more symptoms selected from the group consisting of ascites, pleural effusion, and reduced renal perfusion.

[0094] In some embodiments of the methods and uses described herein, following administration of an initial dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, one or more symptoms selected from the group consisting of ascites, pleural effusion, and reduced renal perfusion can be treated.

[0095] In some embodiments of the methods and uses described herein, after administration of an initial dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, the size of the ovaries may not increase to more than 5 cm in diameter. In some embodiments of the methods and uses described herein, after administration of an initial dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, the size of the ovaries may not increase to more than 5 cm in diameter. After administration of a pharma- ceutically acceptable salt of the formula (I), the ovaries may not increase in size to more than 8 cm in diameter.

[0096] With hCG, ovaries undergo hyperluteinization, releasing large amounts of estrogen, progesterone, and local cytokines. Under the action of hCG, VEGF (vascular endothelial growth factor) is produced from the follicle, which may promote vascular hyperpermeability leading to OHSS. In the methods and uses described herein, compound 1, its metabolites, or any of the pharmaceutically acceptable salts thereof can be used to inhibit or reduce VEGF, thereby reducing blood permeability associated with OHSS. Compound 1, its metabolites, or any of the pharmaceutically acceptable salts thereof can have the ability to induce ovulation in COS without increasing the levels of hCG or VEGF. Compound 1, its metabolites, or any of the pharmaceutically acceptable salts thereof can also have the ability to provide luteal phase support without increasing the levels of VEGF.

[0097] GnRH agonists, when used as triggering agents, are associated with a reduced risk of OHSS, but GnRH agonists also significantly reduce pregnancy rates. Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts thereof, when used as triggering agents, can improve pregnancy rates compared to GnRH agonist triggering. In some embodiments, Compound 1, its metabolites, or any of the pharma-ceutically acceptable salts thereof, when used as triggering agents, can improve pregnancy rates compared to hCG triggering. In some embodiments, Compound 1, its metabolites, or any of the pharma-ceutically acceptable salts thereof, when used as triggering agents, can achieve a biochemical pregnancy rate of over 40%. Biochemical pregnancy may refer to serum hCG over 10mIU / mL 11 days after embryo transfer. In some embodiments, Compound 1, its metabolites, or any of the pharma-ceutically acceptable salts thereof, when used as triggering agents, can achieve a clinical pregnancy rate of over 40%. Clinical pregnancy may refer to an intrauterine gestational sac with heartbeat seen on ultrasound at 6 weeks of pregnancy. In some embodiments, using compound 1, its metabolites, or any of the pharma- ceutically acceptable salts as a triggering agent can achieve a birth rate of over 40%. Compound 1, its metabolites, or any of the pharma-ceutically acceptable salts as a triggering agent can induce ovulation without excessive VEGF production in ovarian follicles, without persistently increasing hCG, without excessive stimulation of LH receptors, and without excessive amounts of estrogen, progesterone, or local cytokines, which may alleviate the risk of OHSS. Oocyte maturation and ovulation induction by compound 1, its metabolites, or any of the pharma-ceutically acceptable salts as a triggering agent can ultimately result in pregnancy rates that are comparable to or even higher than those seen with currently available triggering agents. Compound 1, its metabolites, or any of the pharma-ceutically acceptable salts as a triggering agent can also alleviate symptoms of polycystic ovary syndrome (PCOS) by stimulating the normalization of ovulation in patients with ovarian insufficiency.

[0098] In some embodiments, the use of compound 1, its metabolites, or any of the pharma- ceutically acceptable salts for luteal phase support during ART may significantly reduce the risk of OHSS compared to conventional therapy (i.e., hCG luteal phase support). Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts may provide luteal phase support without excessive VEGF production in the follicle and without excessive amounts of estrogen, progesterone, or local cytokines, which may mitigate the risk of OHSS. The use of compound 1, its metabolites, or any of the pharma- ceutically acceptable salts for luteal phase support may ultimately result in pregnancy rates comparable to or even exceeding those seen with currently available luteal phase support agents. In some embodiments, the use of compound 1, its metabolites, or any of the pharma- ceutically acceptable salts for luteal phase support may result in biochemical pregnancy rates of over 40%. In some embodiments, the use of compound 1, its metabolites, or any of the pharma- ceutically acceptable salts for luteal phase support may result in biochemical pregnancy rates of over 40%. Using Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing for luteal phase support can result in a clinical pregnancy rate of greater than 40%.

[0099] The present disclosure provides methods and uses for increasing pregnancy rates after ovulation induction by compound 1, its metabolites, or any of the pharma- ceutically acceptable salts, instead of hCG or GnRH agonist triggering agents. In some embodiments, compound 1, its metabolites, or any of the pharma- ceutically acceptable salts, is administered to a human female subject as a triggering agent, followed by a COS phase. In some embodiments, compound 1, its metabolites, or any of the pharma- ceutically acceptable salts, can effectively promote follicular maturation and induce ovulation without (i) increasing the total blood concentration level of VEGF, or (ii) increasing the total level of VEGF for less than 24 hours after administration. In some embodiments, compound 1, its metabolites, or any of the pharma- ceutically acceptable salts, is used for luteal phase support to increase pregnancy rates.

[0100] The present disclosure also provides methods and uses for increasing pregnancy rates after ovulation is induced by a triggering agent, comprising administering Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts thereof, for luteal phase support. In some embodiments, administration of Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts thereof occurs after or substantially simultaneously with the trigger. In certain such embodiments, Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts thereof can provide luteal phase support by (i) not increasing total blood levels of VEGF, or (ii) increasing total levels of VEGF for less than 24 hours after administration.

[0101] A progestogen (such as progesterone) may or may not be administered as part of the methods and uses described herein. In some embodiments, progesterone is not administered with the methods and uses described herein. Indeed, one possible advantage of administering multiple doses of compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, is that progestogens may not be required for luteal phase support. This would greatly simplify ART protocols, as many people require daily administration of progestogens (such as progesterone), often by injection. After egg collection, administration of progestogens (such as progesterone) may be required for three or more months. Eliminating or reducing the need for progestogens (such as progesterone) through administration of compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing would reduce the burden imposed by ART and simplify the protocol.

[0102] The present disclosure further provides a method and use for reducing the likelihood of developing OHSS after inducing ovulation with compound 1, its metabolites, or any of the pharma- tically acceptable salts, instead of a triggering regimen that includes hCG. In some embodiments, the method or use of the present disclosure is followed by a phase of COS, and the method or use of the present disclosure involves administering compound 1, its metabolites, or any of the pharma-tically acceptable salts, which can effectively stimulate follicular maturation and induce ovulation, to a human female subject as a triggering agent. In some embodiments, the use of compound 1, its metabolites, or any of the pharma-tically acceptable salts as a triggering agent results in (i) no increase in the total blood concentration level of VEGF, or (ii) an increase in the total level of VEGF less than 24 hours after administration.

[0103] The present disclosure further provides for reducing the likelihood of OHSS occurring after inducing ovulation by using Compound 1, its metabolites, or any of the foregoing pharma- ceutical acceptable salts for luteal phase support. In certain such embodiments, administration of Compound 1, its metabolites, or any of the foregoing pharma- ceutical acceptable salts is administered after a trigger or In some embodiments, the use of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing for luteal phase support results in (i) no increase in total blood concentration levels of VEGF, or (ii) an increase in total levels of VEGF of less than 24 hours after administration.

[0104] The present disclosure provides a method of increasing endogenous LH levels in a woman undergoing ART and in need of increasing endogenous LH levels using Compound 1, its metabolites, or any of the aforementioned pharmaceutical acceptable salts, wherein the endogenous LH levels in the woman's blood are increased at least about 36 hours after the first dose is administered, compared to the endogenous LH levels in the woman's blood before the first dose is administered. In some embodiments, the endogenous LH levels in the woman's blood are increased at least about 24 hours after the first dose is administered, compared to the endogenous LH levels in the woman's blood before the first dose is administered. In some embodiments, the endogenous LH levels in the woman's blood are increased at least about 40 hours after the first dose is administered, compared to the endogenous LH levels in the woman's blood before the first dose is administered. In some embodiments, at least about 44 hours after administration of the first dose of Compound 1, its metabolites, or any of the pharmaceutically acceptable salts, the endogenous LH level in the blood of the woman is increased above the endogenous LH level in the blood of the woman before administration of the first dose. In some embodiments, at least about 48 hours after administration of the first dose of Compound 1, its metabolites, or any of the pharmaceutically acceptable salts, the endogenous LH level in the blood of the woman is increased above the endogenous LH level in the blood of the woman before administration of the first dose. In some embodiments, at least about 52 hours after administration of the first dose of Compound 1, its metabolites, or any of the pharmaceutically acceptable salts, the endogenous LH level in the blood of the woman is increased above the endogenous LH level in the blood of the woman before administration of the first dose.

[0105] The present disclosure also provides a method of increasing endogenous LH levels in a woman undergoing ART in need of increasing endogenous LH levels using Compound 1, its metabolites, or any of the aforementioned pharmaceutically acceptable salts, wherein the peak endogenous LH blood level occurs at least about 12 hours after administration of the first dose. In some embodiments, after administration of the first dose of Compound 1, its metabolites, or any of the aforementioned pharmaceutically acceptable salts, the peak endogenous LH blood level occurs about 12 hours to about 48 hours after administration of the first dose. In some embodiments, after administration of the first dose of Compound 1, its metabolites, or any of the aforementioned pharmaceutically acceptable salts, the peak endogenous LH blood level occurs about 12 hours to about 36 hours after administration of the first dose. In some embodiments, after administration of the first dose of Compound 1, its metabolites, or any of the aforementioned pharmaceutically acceptable salts, the peak endogenous LH blood level occurs about 12 hours to about 24 hours after administration of the first dose. In some embodiments, after administration of the first dose of Compound 1, its metabolites, or any of the pharmaceutically acceptable salts, the highest blood endogenous LH level occurs about 12 hours to about 18 hours after administration of the first dose. In some embodiments, after administration of the first dose of Compound 1, its metabolites, or any of the pharmaceutically acceptable salts, the highest blood endogenous LH level occurs about 14 hours after administration of the first dose. In some embodiments, after administration of the first dose of Compound 1, its metabolites, or any of the pharmaceutically acceptable salts, the highest blood endogenous LH level occurs about 16 hours after administration of the first dose. In some embodiments, after administration of the first dose of Compound 1, its metabolites, or any of the pharmaceutically acceptable salts, the highest blood endogenous LH level occurs about 18 hours after administration of the first dose. In some embodiments, after administration of the first dose of Compound 1, its metabolites, or any of the pharmaceutically acceptable salts, the highest blood endogenous LH level occurs about 20 hours after administration of the first dose. In some embodiments, after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, the peak blood endogenous LH level occurs about 22 hours after administration of the first dose. In some embodiments, after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, the peak blood endogenous LH level occurs about 22 hours after administration of the first dose. After administration of any pharma- ceutically acceptable salt, the peak blood endogenous LH level is about 24 hours after administration of the first dose. In some embodiments, after administration of the first dose of Compound 1, its metabolites, or any pharma- ceutically acceptable salt thereof, the peak blood endogenous LH level is about 28 hours after administration of the first dose. In some embodiments, after administration of the first dose of Compound 1, its metabolites, or any pharma- ceutically acceptable salt thereof, the peak blood endogenous LH level is about 32 hours after administration of the first dose. In some embodiments, after administration of the first dose of Compound 1, its metabolites, or any pharma- ceutically acceptable salt thereof, the peak blood endogenous LH level is about 36 hours after administration of the first dose.

[0106] The present disclosure provides a method and use for increasing endogenous LH levels in a woman undergoing ART and in need of luteal phase support, comprising administering to the woman an initial dose of Compound 1, its metabolites, or any of the pharmaceutically acceptable salts thereof after the woman has received a trigger dose of an oocyte maturation agent as part of her ART regimen. In an ART regimen, an oocyte maturation agent or triggering agent may be used prior to oocyte collection (e.g., IVF, ICSI), or prior to ovulation, e.g., as part of the treatment of PCOS, to promote final maturation of oocytes, and if preovulatory, IUI or intercourse may be timed after ovulation to maximize the chance of fertilization. The oocyte maturation agent may include, for example, Compound 1, its metabolites, or any of the pharmaceutically acceptable salts thereof, hCG, recombinant luteinizing hormone (rLH), or GnRH agonist. In some embodiments, the GnRH agonist is selected from the group consisting of leuprorelin acetate, gonadorelin, buserelin, triptorelin, goserelin, nafarelin, histrelin, deslorelin, meterelin, recirelin, or a pharma- ceutically acceptable salt of any of the above. In some embodiments, a woman in need of luteal phase support may be administered one or more doses of compound 1, its metabolites, or any of the above pharma- ceutically acceptable salts either before oocyte collection, after oocyte collection, or both before and after oocyte collection. Similarly, in an ART regimen that does not incorporate oocyte collection, a woman in need of luteal phase support may be administered one or more doses of compound 1, its metabolites, or any of the above pharma- ceutically acceptable salts either before ovulation, after ovulation, or both before and after ovulation.

[0107] In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated about 12 hours to about 96 hours after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated about 12 hours to about 84 hours after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated about 12 hours to about 72 hours after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated about 12 hours to about 60 hours after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, from higher than the level of endogenous LH in the woman's blood before the first dose was administered. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated about 12 hours to about 48 hours after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ... In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated about 14 hours to about 84 hours after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before the first dose is administered. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated about 14 hours to about 72 hours after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before the first dose is administered. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated about 14 hours to about 60 hours after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before the first dose is administered. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated about 14 hours to about 48 hours after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated about 24 hours to about 84 hours after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated about 24 hours to about 72 hours after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is increased about 24 hours to about 60 hours after administration of a first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of either of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose.In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is increased about 24 hours to about 48 hours after administration of a first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of either of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose.

[0108] In some embodiments of the methods and uses described herein, the endogenous LH level in the woman's blood is elevated for at least about 36 hours after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the endogenous LH level in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the endogenous LH level in the woman's blood is elevated for at least about 48 hours after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the endogenous LH level in the woman's blood before administration of the first dose. One possible advantage of the methods and uses described herein is the convenience of elevating LH levels for more than 36 hours compared to current triggers. If ovulation is reliably achieved about 48 hours after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, the methods and uses described herein may be beneficial in adjusting ART appointment schedules compared to the current standard of care. Currently, if the trigger is administered around 8pm, egg retrieval occurs 36 hours later (8am). As shown in the present disclosure, if egg retrieval can be reliably performed at about 48 hours, the trigger can be administered to the patient and egg retrieval can occur during normal clinic hours. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for at least about 48 hours after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 36 hours to about 16 days after administration of the first dose of Compound 1, its metabolites, or a pharma-ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the endogenous LH levels in the blood of a woman are increased after administration of an initial dose of Compound 1, a metabolite thereof, or a pharma- ceutical acceptable salt of either of the foregoing. After administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, the level of endogenous LH in the woman's blood is elevated for about 36 hours to about 12 days above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, the level of endogenous LH in the woman's blood is elevated for about 36 hours to about 11 days above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, the level of endogenous LH in the woman's blood is elevated for about 36 hours to about 10 days above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 36 hours to about 9 days after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 36 hours to about 8 days after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 36 hours to about 7 days after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 36 hours to about 6 days after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 36 hours to about 5 days after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose.In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 36 hours to about 4 days after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 36 hours to about 3 days after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 36 hours to about 2 days after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose.

[0109] In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 48 hours to about 16 days after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 48 hours to about 12 days after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 48 hours to about 11 days after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is increased for about 48 hours to about 10 days after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of either of the foregoing, above the level of endogenous LH in the woman's blood prior to administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 48 hours to about 9 days after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 48 hours to about 8 days after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 48 hours to about 7 days after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 48 hours to about 6 days after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 48 hours to about 5 days after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 48 hours to about 4 days after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is increased for about 48 hours to about 3 days after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of either of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose.

[0110] In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 24 hours to about 16 days after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 24 hours to about 12 days after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 24 hours to about 11 days after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 24 hours to about 10 days after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 24 hours to about 9 days after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 24 hours to about 8 days after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is increased for about 24 hours to about 7 days after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of either of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose.In some embodiments of the methods and uses described herein, the female's blood endogenous LH levels are maintained for about 24 hours to about 6 days after administration of an initial dose of Compound 1, a metabolite thereof, or a pharma- ceutical acceptable salt of either of the foregoing. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 24 hours to about 5 days after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 24 hours to about 4 days after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is elevated for about 24 hours to about 3 days after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, the level of endogenous LH in the woman's blood is increased for about 24 hours to about 2 days after administration of the first dose of Compound 1, a metabolite thereof, or a pharma- ceutical acceptable salt of either of the foregoing, above the level of endogenous LH in the woman's blood before administration of the first dose.

[0111] Compound 1, its metabolites, or any of the pharmaceutically acceptable salts thereof may be used to induce the maturation of oocytes or eggs, which may then be removed and fertilized by IVF or ICSI before being transferred to the uterus (ET). Alternatively, oocytes or eggs may be released from the ovaries (induction of ovulation) and then fertilized by sexual intercourse or IUI. For successful and proper collection of oocytes, the maturation of oocytes and induction of those oocytes at the appropriate time must first occur. The COS phase can help prevent premature ovulation, and Compound 1, its metabolites, or any of the pharmaceutically acceptable salts thereof may be used as a triggering agent to promote the maturation of oocytes, allowing for egg collection, in vitro fertilization, and embryo transfer, or to induce the release (ovulation) of oocytes, allowing for fertilization by sexual intercourse or IUI. Thus, administration of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of either of the foregoing can result in pregnancy rates that are similar to or higher than current pregnancy rates, shorten the time to pregnancy, and reduce the risk of developing OHSS.

[0112] The present disclosure provides methods and uses comprising administering Compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof, to stimulate oocyte maturation or trigger ovulation in assisted reproductive technology (ART). The methods and uses described herein allow Compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof to be used in ART to stimulate oocyte maturation or trigger ovulation without the administration of a separate triggering agent (such as hCG, exogenous LH, and / or GnRH agonist). In some embodiments of the methods and uses described herein, an initial dose of Compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof stimulates oocyte maturation. In some embodiments of the methods and uses described herein, oocyte maturation occurs without the administration of exogenous hCG or exogenous LH. In certain such embodiments, the yield of mature oocytes is at least 50%. In certain such embodiments, the yield of mature oocytes is at least 75%. Oocyte yield may refer to the percentage of mature (metaphase II, M2) oocytes taken from a number of 14 mm follicles at the last ultrasound scan prior to administration of the trigger. Oocytes may be independently classified as M2 by the presence of a first polar body and round ooplasm. In some embodiments, administration of a trigger comprising Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing results in a greater amount of mature oocytes than does an hCG trigger.

[0113] As used herein, a "mature" oocyte is an oocyte that has reached metaphase 2 of meiosis (M2). Oocytes are classified as M2 by the presence of the first polar body and rounded ooplasm. In response to the LH surge in the midcycle, the oocyte resumes meiotic maturation. This final maturation of the oocyte can be medically induced by either hCG or GnRH agonists. hCG binds to the LH receptor, and GnRH agonists stimulate the release of endogenous gonadotropin stores from the pituitary gland. Resumption of meiosis (so-called nuclear maturation) occurs 14-18 hours after the onset of the LH surge, the first meiotic division is completed within 35 hours, and the oocyte reaches metaphase of the second meiotic division (M2). Meanwhile, in response to the LH surge, the cumulus cells expand almost completely by 20 hours, followed by detachment of the mature cumulus cell-oocyte complex from the follicle wall before ovulation. Although nuclear maturation and cumulus cell expansion are closely related, it is unclear whether different LH levels are required to regulate these two processes.

[0114] According to the present disclosure, in some embodiments, administration of compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing promotes oocyte maturation and induces (trigger) ovulation in a human female subject (i) without increasing VEGF levels, or (ii) with an increase in VEGF levels for less than 24 hours.

[0115] The present disclosure provides a method and use for inducing ovulation using compound 1, its metabolites, or any of the pharmaceutically acceptable salts. In certain such embodiments, the method or use of the present disclosure may include administering to a human female subject an amount of FSH or the like in conjunction with a GnRH agonist or GnRH antagonist to promote the early COS phase of ART. In some embodiments, after the early COS phase, compound 1, its metabolites, or any of the pharmaceutically acceptable salts may be administered as a triggering agent to effectively promote oocyte maturation and induce ovulation. In some embodiments, administering compound 1, its metabolites, or any of the pharmaceutically acceptable salts as a triggering agent effectively promotes oocyte maturation and induces ovulation by (i) not increasing the total blood concentration level of VEGF, or (ii) increasing the total level of VEGF for less than 24 hours. In some embodiments, a GnRH antagonist or GnRH agonist may be administered in an amount and for a period sufficient to act to suppress ovulation in a controlled manner during the COS phase, and the GnRH antagonist or GnRH agonist is administered in combination with FSH or an FSH analog. In some embodiments, the GnRH antagonist is relugolix.

[0116] The present disclosure also provides a method and use comprising administering Compound 1, its metabolites, or any of the pharmaceutically acceptable salts thereof, to induce ovulation in an anovulatory human female subject suffering from secondary ovarian insufficiency. The secondary ovarian insufficiency originates from the hypothalamus and adenohypophysis, where the hypothalamus and adenohypophysis are unable to hormonally stimulate the ovaries, thereby failing to stimulate ovarian function. In some embodiments, the method or use of the present disclosure comprises (1) pretreating the subject with human gonadotropin, and (2) administering to the subject Compound 1, its metabolites, or any of the pharmaceutically acceptable salts thereof.

[0117] The present disclosure also provides methods and uses comprising administering Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, for luteal phase support in an anovulatory human female subject suffering from premature ovarian failure. Premature ovarian failure is follicular depletion or failure accompanied by cessation of menstruation before age 40. "Premature ovarian failure" is the preferred term over premature ovarian failure, as recommended by the National Institutes of Health, since in many cases, ovarian function is intermittent or unpredictable. Premature ovarian failure can be distinguished from natural menopause and can also be described as a decline in ovarian reserve, since only 5-10% of women with premature ovarian failure experience natural conception and childbirth. In some embodiments, the methods and uses of the present disclosure may further include the ET process.

[0118] The present disclosure provides a method for inducing terminal follicular maturation and early luteinization in women undergoing ART. The present invention provides methods and uses comprising administering Compound 1, a metabolite thereof, or a pharma- tically acceptable salt of any of the foregoing, to a woman undergoing ART, the woman having undergone pituitary desensitization and prior treatment with follicle-stimulating hormone. In certain such embodiments, after administration of a first dose of Compound 1, a metabolite thereof, or a pharma-tically acceptable salt of any of the foregoing, the woman's blood endogenous LH level is elevated above the woman's blood endogenous LH level prior to administration of the first dose. In some embodiments of the methods and uses described herein, in which administration of Compound 1, a metabolite thereof, or a pharma-tically acceptable salt of any of the foregoing is for inducing terminal maturation of follicles and early luteinization in a woman undergoing ART, the woman having undergone pituitary desensitization and prior treatment with follicle-stimulating hormone, the woman is at risk for OHSS. In some embodiments of the methods and uses described herein, in which administration of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing is for inducing terminal maturation and early luteinization of follicular follicles in a woman undergoing ART, and the woman has undergone pituitary desensitization and been pretreated with follicle-stimulating hormone, the woman's blood endogenous LH level is increased at least about 36 hours after administration compared to the woman's blood endogenous LH level before the first dose was administered. In some embodiments of the methods and uses described herein, in which administration of Compound 1, its metabolites, or a pharma-tically acceptable salt of any of the foregoing is for inducing terminal maturation and early luteinization of follicular follicles in a woman undergoing ART, and the woman has undergone pituitary desensitization and been pretreated with follicle-stimulating hormone, the woman's blood endogenous LH level is increased at least about 12 hours after administration of the first dose of Compound 1, its metabolites, or a pharma-tically acceptable salt of any of the foregoing.In some embodiments of the methods and uses described herein, where administration of Compound 1, its metabolites, or a pharma- ceutical acceptable salt of any of the foregoing, is for inducing terminal maturation of follicular follicles and early luteinization in a woman undergoing ART, where the woman has undergone pituitary desensitization and has been pre-treated with follicle-stimulating hormone, peak circulating endogenous LH levels occur about 12 hours to about 48 hours after administration of the first dose of Compound 1, its metabolites, or a pharma-ceutical acceptable salt of any of the foregoing. In some embodiments of the methods and uses described herein, wherein administration of Compound 1, its metabolites, or a pharma- ceutical acceptable salt of any of the foregoing, is for inducing terminal maturation of follicular follicles and early luteinization in a woman undergoing ART, wherein the woman has undergone pituitary desensitization and has been pre-treated with follicle-stimulating hormone, the woman's blood endogenous LH level is elevated about 12 hours to about 96 hours after administration of a first dose of Compound 1, its metabolites, or a pharma-ceutical acceptable salt of any of the foregoing, above the woman's blood endogenous LH level prior to administration of the first dose. In some embodiments of the methods and uses described herein, wherein administration of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing is for inducing terminal maturation of follicular follicles and early luteinization in a woman undergoing ART, wherein the woman has undergone pituitary desensitization and has been pre-treated with follicle-stimulating hormone, the woman's blood endogenous LH level is elevated for at least about 36 hours after administration above the woman's blood endogenous LH level prior to administration of the first dose.In some embodiments of the methods and uses described herein, wherein administration of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing, is for inducing terminal maturation of follicular follicles and early luteinization in a female undergoing ART, said female having undergone pituitary desensitization and prior treatment with follicle-stimulating hormone, the level of endogenous LH in the female's blood is elevated for at least about 24 hours after administration of a first dose of Compound 1, its metabolites, or a pharma-tically acceptable salt of any of the foregoing, above the level of endogenous LH in the female's blood prior to administration of the first dose. In some embodiments of the methods and uses described herein, wherein administration of Compound 1, its metabolites, or a pharma-tically acceptable salt of any of the foregoing, is for inducing terminal maturation of follicular follicles and early luteinization in a female undergoing ART, said female having undergone pituitary desensitization and prior treatment with follicle-stimulating hormone ... In some embodiments of the methods and uses described herein, where the administration of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing is for inducing terminal maturation of follicular follicles and early luteinization in a woman undergoing ART, and where the woman has undergone pituitary desensitization and has been pretreated with follicle-stimulating hormone, blood endogenous LH levels are elevated for about 36 hours to about 16 days after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing. In some embodiments of the methods and uses described herein, where the administration of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing is for inducing terminal maturation of follicular follicles and early luteinization in a woman undergoing ART, and where the woman has undergone pituitary desensitization and has been pretreated with follicle-stimulating hormone, blood endogenous LH levels are elevated for about 36 hours to about 12 days after administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing. In some embodiments of the methods and uses described herein, in which administration of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing is for inducing terminal maturation and early luteinization of follicular follicles in a woman undergoing ART, and in which the woman has undergone pituitary desensitization and has been pretreated with follicle-stimulating hormone, blood endogenous LH levels are elevated for about 24 hours to about 16 days after administration of a first dose of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing. In some embodiments of the methods and uses described herein, in which administration of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing is for inducing terminal maturation and early luteinization of follicular follicles in a woman undergoing ART, and in which the woman has undergone pituitary desensitization and has been pretreated with follicle-stimulating hormone, blood endogenous LH levels are elevated for about 24 hours to about 12 days after administration of a first dose of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing.

[0119] The present disclosure provides methods and uses comprising administering Compound 1, its metabolites, or any of the pharma- ceutical acceptable salts, to induce ovulation in a woman with anovulatory infertility, where the infertility is not due to premature ovarian failure. In certain such embodiments, after administration of a first dose of Compound 1, its metabolites, or any of the pharma-ceutical acceptable salts, the woman's blood endogenous LH level is elevated above the woman's blood endogenous LH level before administration of the first dose.

[0120] In some embodiments of the methods and uses described herein, in which Compound 1, its metabolites, or any of the pharmaceutically acceptable salts are administered to induce ovulation in a woman with anovulatory infertility, and the infertility is not due to premature ovarian failure, the woman is at risk of OHSS. In some embodiments of the methods and uses described herein, in which Compound 1, its metabolites, or any of the pharmaceutically acceptable salts are administered to induce ovulation in a woman with anovulatory infertility, and the infertility is not due to premature ovarian failure, the endogenous LH level in the woman's blood is increased at least about 36 hours after the first dose of Compound 1, its metabolites, or any of the pharmaceutically acceptable salts is administered above the endogenous LH level in the woman's blood before the first dose is administered. In some embodiments of the methods and uses described herein, in which the administration of Compound 1, its metabolites, or any of the pharma- tically acceptable salts is for inducing ovulation in a woman with anovulatory infertility, and the infertility is not due to premature ovarian failure, the woman's blood endogenous LH level is increased at least about 24 hours after the administration of the first dose of Compound 1, its metabolites, or any of the pharma-tically acceptable salts above the endogenous LH level in the woman's blood before the administration of the first dose. In some embodiments of the methods and uses described herein, in which the administration of Compound 1, its metabolites, or any of the pharma-tically acceptable salts is for inducing ovulation in a woman with anovulatory infertility, and the infertility is not due to premature ovarian failure, the peak blood endogenous LH level is achieved at least about 12 hours after the administration of the first dose of Compound 1, its metabolites, or any of the pharma-tically acceptable salts. In some embodiments of the method of use, in which administration of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing is for inducing ovulation in a woman with anovulatory infertility, and in which the infertility is not due to premature ovarian failure, the peak blood endogenous LH level occurs about 12 hours to about 48 hours after administration of the first dose of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing. In some embodiments of the methods and uses described herein, in which administration of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing is for inducing ovulation in a woman with anovulatory infertility, and in which the infertility is not due to premature ovarian failure, the woman's blood endogenous LH level increases about 12 hours to about 96 hours after administration of the first dose of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing from the level of endogenous LH in the woman's blood prior to administration of the first dose. In some embodiments of the methods and uses described herein, in which administration of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing is for inducing ovulation in a woman with anovulatory infertility, and in which the infertility is not due to premature ovarian failure, the woman's blood endogenous LH level is elevated for at least about 36 hours after administration of a first dose of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing, above the endogenous LH level in the woman's blood before administration of the first dose. In some embodiments of the methods and uses described herein, in which administration of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing is for inducing ovulation in a woman with anovulatory infertility, and in which the infertility is not due to premature ovarian failure, the blood endogenous LH level is elevated for at least about 36 hours to about 16 days after administration of a first dose of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing.In some embodiments of the methods and uses described herein, in which administration of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing is for inducing ovulation in a woman with anovulatory infertility, and the infertility is not due to premature ovarian failure, the blood endogenous LH level is elevated for at least about 36 hours to about 12 days after the first dose of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing. In some embodiments of the methods and uses described herein, in which administration of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing is for inducing ovulation in a woman with anovulatory infertility, and the infertility is not due to premature ovarian failure, the blood endogenous LH level of the woman is elevated for at least about 24 hours after administration of the first dose of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing above the blood endogenous LH level of the woman prior to administration of the first dose. In some embodiments of the methods and uses described herein, in which administration of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing is for inducing ovulation in a woman with anovulatory infertility, and in which the infertility is not due to premature ovarian failure, endogenous LH levels in the blood are elevated for at least about 24 hours to about 16 days after the first dose of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing. In some embodiments of the methods and uses described herein, in which administration of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing is for inducing ovulation in a woman with anovulatory infertility, and in which the infertility is not due to premature ovarian failure, endogenous LH levels in the blood are elevated for at least about 24 hours to about 12 days after the first dose of Compound 1, its metabolites, or a pharma- tically acceptable salt of any of the foregoing.

[0121] The larger the size of the follicle at the time of triggering, the higher the yield of mature oocytes. The present disclosure provides for administering a dose of Compound 1, its metabolites, or any pharma- ceutically acceptable salt thereof, the first dose being administered when at least three follicles of at least about 14 mm are visible by ultrasound. In some embodiments of the methods and uses described herein, the first dose of Compound 1, its metabolites, or any pharma-ceutically acceptable salt thereof is administered when at least three follicles of at least about 18 mm are visible by ultrasound.

[0122] The disclosure also provides for administering a dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, with the initial dose being administered after ovulation. In some embodiments of the methods and uses described herein, the initial dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing is administered prior to ovulation.

[0123] In some embodiments, the methods and uses described herein include harvesting oocytes. The disclosure provides for administering a dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, the first dose being administered after harvesting oocytes. In some embodiments of the methods and uses described herein, the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing is administered prior to harvesting oocytes.

[0124] In some embodiments of the methods and uses described herein, the female's pituitary gland is desensitized to GnRH prior to administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing. In certain embodiments of the methods and uses described herein, the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing is administered when the serum estradiol concentration is at least about 0.49 nmol / L. In certain embodiments of the methods and uses described herein, the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing is administered when the serum estradiol concentration is at least about 0.91 nmol / L.

[0125] In some embodiments of the methods and uses described herein, an embryo is transferred after administration of an initial dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing. In certain such embodiments, transfer occurs within about 2 to about 10 days (such as about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, or about 10 days) from administration of the initial dose. In some embodiments of the methods and uses described herein, embryo transfer occurs within about 1 to about 7 days (such as about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days) from collection of oocytes. In certain embodiments of the methods and uses described herein, the embryo is fresh (i.e., the embryo has not been frozen). In certain such embodiments, the embryo is transferred in the same menstrual cycle as collection of the oocytes. Due to the mechanism of action of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, there may be less adverse effects on the endometrium compared to current therapies. Thus, the endometrium can be in a state of implantation (high endometrial receptivity) immediately after egg collection. Compound 1, its metabolites, or any of the pharmaceutically acceptable salts thereof, can reduce the need for split-freeze protocols by not using hCG-based triggers or GnRH agonist triggers (including dual triggers with GnRH agonists), thereby reducing the number of IVF cycles, shortening the time to pregnancy while maintaining acceptable pregnancy rates, reducing costs, and reducing side effects (such as macrosomia (large for gestational age)), the risk of placenta accreta, and the risk of preeclampsia) with a significant reduction in OHSS rates. Compound 1, its metabolites, or any of the pharmaceutically acceptable salts thereof can provide significant safety and efficacy attributes compared to current therapies that require splitting.

[0126] Because the uses and methods of the present disclosure allow for the use of fresh embryos, the present disclosure also provides for shortening the time to pregnancy after induction of ovulation with Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, instead of hCG or GnRH agonist triggering agents. In some embodiments, Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, is administered to a human female subject as a triggering agent, followed by a phase of COS. In certain such embodiments, Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, is administered to a human female subject as a triggering agent, followed by a phase of COS. A pharma- ceutically acceptable salt of any of the above can effectively promote follicular maturation and induce ovulation without (i) increasing the total blood concentration level of VEGF, or (ii) increasing the total blood level of VEGF for less than 24 hours after administration.

[0127] The present disclosure also provides methods and uses for shortening the time to pregnancy after ovulation is induced by a triggering agent, comprising administering Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts thereof, for luteal phase support. In some embodiments, administration of Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts thereof is after or substantially simultaneous with the trigger. In certain such embodiments, Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts thereof can provide luteal phase support by (i) not increasing total blood levels of VEGF, or (ii) increasing total levels of VEGF for less than 24 hours after administration.

[0128] The present disclosure provides methods and uses that include administering a dose of Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts thereof, to induce ovulation. In certain such embodiments, after administering at least an initial dose of Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts thereof, the human female subject becomes pregnant by intercourse or IUI. By administering Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts thereof to trigger the release of oocytes without harvesting them, ovulation can be predicted, with the time from administration to ovulation ranging from 30 to 62 hours after administration, or 36 to 48 hours after administration. This allows intercourse or IUI to be conveniently scheduled around ovulation, maximizing the chance of conception. Administration of Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts thereof can also help women who have difficulty ovulating to ovulate and become pregnant by intercourse or IUI. In some embodiments, triggering oocyte release with Compound 1, its metabolites, or any of the foregoing pharma- ceutically acceptable salts, can be reserved for women who require IUI and for whom LH monitoring proves difficult or unreliable. In some embodiments, triggering oocyte release with Compound 1, its metabolites, or any of the foregoing pharma-ceutically acceptable salts, can be utilized when LH monitoring has not shown an LH surge by cycle day 18 (cycle day 1 being the first day of the last menstrual period) and follicles are greater than 20 mm in size.

[0129] In some embodiments of the methods and uses described herein, after administration of at least an initial dose of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, the human female subject becomes pregnant or gives birth. In some embodiments, the human female subject gives birth by Caesarean section. In some embodiments, the human female subject gives birth vaginally.

[0130] In some embodiments of the methods and uses described herein, the dosage, use, administration or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.00003 mg to about 0.030 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.001 mg to about 0.030 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration or use amount of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.001 mg to about 0.003 mg. In some embodiments of the methods and uses described herein, the dosage, use amount, administration amount, or administration or use amount (e.g., initial administration amount) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is from about 0.00003 mg to about 0.0003 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.00003 mg to about 0.003 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.00003 mg to about 0.00006 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.00003 mg to about 0.00009 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.00003 mg to about 0.00015 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.00003 mg to about 0.0006 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.00003 mg to about 0.0009 mg. In some embodiments of the methods and uses described herein, the dosage, use amount, administration amount, or use amount (e.g., an initial dose) of Compound 1, or a corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.00003 mg to about 0.0015 mg. In some embodiments of the methods and uses described herein, the dosage, use amount, administration amount, or use amount (e.g., an initial dose) of Compound 1, or a corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.00003 mg to about 0.006 mg.In some embodiments of the methods and uses described herein, the dosage, use amount, administration amount, or use dose (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.00003 mg to about 0.009 mg. In some embodiments of the methods and uses described herein, the dosage, use amount, administration amount, or use dose of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.00003 mg to about 0.015 mg.

[0131] In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.0003 mg to about 0.030 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.0003 mg to about 0.0006 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.0003 mg to about 0.0009 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., an initial dose) of Compound 1, or a corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.0003 mg to about 0.0015 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., an initial dose) of Compound 1, or a corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.0003 mg to about 0.006 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., an initial dose) of Compound 1, or a corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.0003 mg to about 0.009 mg. In some embodiments of the methods and uses described herein, the dosage, use amount, administered dose, or administered or administered amount (e.g., an initial dose) of Compound 1, or the corresponding administered or administered amount of a pharma- ceutically acceptable salt thereof, is from about 0.0003 mg to about 0.015 mg.

[0132] In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.003 mg to about 0.030 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.003 mg to about 0.006 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.003 mg to about 0.009 mg. In some embodiments of the methods and uses described herein, the dosage, use amount, administered dose, or administered or administered amount (e.g., an initial dose) of Compound 1, or the corresponding administered or administered amount of a pharma- ceutically acceptable salt thereof, is from about 0.003 mg to about 0.015 mg.

[0133] In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.0003 mg to about 0.003 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.0006 mg to about 0.003 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.0009 mg to about 0.003 mg. In some embodiments of the methods and uses described herein, the dosage, use amount, administered dose, or administered or administered amount (e.g., an initial dose) of Compound 1, or the corresponding administered or administered amount of a pharma- ceutically acceptable salt thereof, is from about 0.0015 mg to about 0.003 mg.

[0134] In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.00006 mg to about 0.030 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.00009 mg to about 0.030 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.00015 mg to about 0.030 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.0006 mg to about 0.030 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.0009 mg to about 0.030 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration amount, or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.0015 mg to about 0.030 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.006 mg to about 0.030 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.009 mg to about 0.030 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration or use amount (e.g., initial dose) of Compound 1, or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof, is about 0.015 mg to about 0.030 mg.

[0135] In some embodiments of the methods and uses described herein, the dosage, use, administration or use amount of Compound 1 (e.g., an initial dose) or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof is about 0.00003 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration or use amount of Compound 1 (e.g., an initial dose) or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof is about 0.030 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration or use amount of Compound 1 (e.g., an initial dose) or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof is about 0.0003 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration or use amount of Compound 1 (e.g., an initial dose) or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof is about 0.003 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration or use amount of Compound 1 (e.g., an initial dose) or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof is about 0.00005 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration or use amount of Compound 1 (e.g., an initial dose) or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof is about 0.0005 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration or use amount of Compound 1 (e.g., an initial dose) or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof is about 0.005 mg. In some embodiments of the methods and uses described herein, the dosage, use, administration or use amount of Compound 1 (e.g., an initial dose) or the corresponding dosage or use amount of a pharma- ceutical acceptable salt thereof is about 0.010 mg. In some embodiments of the methods and uses described herein, the dosage, use amount, administered dose or dosage amount (e.g., an initial dose) of Compound 1, or the corresponding dosage or dosage amount of a pharma- ceutically acceptable salt thereof, is about 0.0001 mg.In some embodiments of the methods and uses described herein, the dosage, use amount, administered dose or use amount of Compound 1, or the corresponding administered dose or use amount of a pharma- ceutically acceptable salt thereof, is about 0.001 mg.

[0136] Thus, the dose of Compound 1, or the corresponding amount of a pharma- ceutically acceptable salt, may be expressed, for example, in nmol / kg or μg / kg (e.g., as shown in Example 11). For example, approximately 0.003 nmol / kg translates to 0.0037 μg / kg of the free form of Compound 1, and 0.03 nmol / kg translates to 0.037 μg / kg of the free form of Compound 1. For a 60 kg woman, a dose of 0.003 nmol / kg would be approximately 0.22 μg or 0.00022 mg, and a dose of 0.03 nmol / kg would be approximately 2.2 μg or 0.0022 mg.

[0137] In some embodiments of the methods and uses described herein, the dosage, use, administration or use of a metabolite of Compound 1 (e.g., Compound 2), or its pharmacopoeial effects are The corresponding dosage or use amount of an acceptable salt is about 0.00002 mg to about 0.020 mg. In some embodiments of the methods and uses described herein, the dosage, use amount, administration dose or use amount of a metabolite of Compound 1 (e.g., Compound 2), or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof is about 0.001 mg to about 5 mg. In some embodiments of the methods and uses described herein, the dosage, use amount, administration dose or use amount of a metabolite of Compound 1 (e.g., Compound 2), or the corresponding dosage or use amount of a pharma- ceutically acceptable salt thereof is about 0.00002 mg to about 0.002 mg. In some embodiments of the methods and uses described herein, the dosage, use amount, administration dose or use amount of a metabolite of Compound 1 (e.g., Compound 2), or the corresponding dosage or use amount of a pharma- ceutical acceptable salt thereof is about 0.0002 mg to about 0.002 mg. In some embodiments of the methods and uses described herein, the dosage, use amount, administration amount, or use dose of a metabolite of Compound 1 (e.g., Compound 2), or a corresponding dosage or use dose of a pharma- ceutically acceptable salt thereof, is about 0.00002 mg to about 5 mg. In some embodiments of the methods and uses described herein, the dosage, use amount, administration amount, or use dose of a metabolite of Compound 1 (e.g., Compound 2), or a corresponding dosage or use dose of a pharma-ceutically acceptable salt thereof, is about 0.0002 mg to about 0.020 mg.

[0138] Combination therapy As briefly described above, compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof may be administered in combination with other drugs used in ART. Such drugs may include drugs used in the COS phase (e.g., FSH, hMG, GnRH agonists or GnRH antagonists, and combinations thereof), triggering agents (GnRH agonists, hCG, and combinations thereof), and hCG, estradiol, progestogens (such as progesterone), and combinations thereof for luteal phase support prior to embryo transfer, IUI, or intercourse. Compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof may be administered in combination with each other. In some embodiments, multiple sequential doses of compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof may be administered in the methods and uses described herein. The therapeutically effective amount of the combined drugs may vary depending on the method of administration, the selected drug, and the condition of the female human subject. As used herein, a "therapeutically effective amount" may refer to an amount of a compound sufficient to produce a particular effect (eg, triggering final maturation of oocytes, supporting the endometrium, etc.).

[0139] The co-administration of these agents is typically over a period of time (usually minutes, hours, days or weeks, depending on the combination selected). In certain embodiments, the agents are administered sequentially, i.e., each agent is administered at a different time, and the administration of the agents or at least two of the agents is substantially simultaneous. Substantially simultaneous administration may be achieved, for example, by administering to a human female subject a single injection having a fixed ratio of each agent, or by administering multiple single injections for each agent. Sequential or substantially simultaneous administration of each agent may be achieved by any suitable route, including, but not limited to, oral, intravenous, subcutaneous, intramuscular, and direct absorption through mucosal tissue. The agents may be administered by the same or different routes. Alternatively, for example, all therapeutic agents may be administered by intravenous injection. When injected, compound 1, its metabolites, or pharma- ceutically acceptable salts of any of the above may be combined with other agents used in ART to reduce the number of injections administered to the patient.

[0140] Compound 1, its metabolites, or pharma- ceutically acceptable salts of any of the foregoing may be used in combination with many of the therapeutic agents involved in ART. These include therapeutic agents used in the COS phase of the ART process (e.g., therapeutic agents used to stimulate oocyte development and growth, such as erythropoietin, which is a stimulant for the growth and development of oocytes, and erythropoietin, which is a stimulant for the growth and development of oocytes). These include, but are not limited to, follicle growth agents (such as FSH, hMG, etc.) used to control ovarian stimulation and prevent premature ovulation, and GnRH agonists or GnRH antagonists, or any combination thereof, used to control ovarian stimulation and prevent premature ovulation.

[0141] In some embodiments of the methods and uses described herein, FSH is administered prior to administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing. In some embodiments of the methods and uses described herein, FSH is administered about 5 to about 12 days prior to administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing. In certain such embodiments, administration of FSH is about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12 days prior to administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing.

[0142] In some embodiments of the methods and uses described herein, the GnRH antagonist is administered prior to administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing. In some embodiments of the methods and uses described herein, the GnRH antagonist is administered about 2 to about 10 days (such as about 3 to about 5 days before administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing) prior to administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing. In certain such embodiments, administration of the GnRH antagonist is about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, or about 10 days prior to administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing.

[0143] In some embodiments of the methods and uses described herein, the GnRH agonist is administered prior to administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing. In some embodiments of the methods and uses described herein, the GnRH agonist is administered about 14 to about 28 days prior to administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, such as about 14 to about 17 days prior to administration of the first dose of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing. In certain such embodiments, administration of the GnRH agonist is about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, about 21 days, about 22 days, about 23 days, about 24 days, about 25 days, about 26 days, about 27 days or about 28 days prior to administration of the first dose of compound 1, its metabolite, or a pharma- ceutically acceptable salt of any of the foregoing.

[0144] With regard to the above-mentioned GnRH agonists that may be used in combination with compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing during the COS phase of ART to prevent premature ovulation, these agents include GnRH (gonadotropin releasing hormone) superactive agonists (such as leuprorelin acetate, gonadorelin, buserelin, triptorelin, goserelin, nafarelin, histrelin, deslorelin, meterelin, resilelin, or a pharma- ceutically acceptable salt of any of the foregoing), or GnRH antagonists (such as cetrorelix, ganirelix, abarelix, Nal-Blu, antide, azaline B, degarelix, D63153 (ozarelix), OBE2109, teverelix, elagolix, relugolix, or a pharma- ceutically acceptable salt of any of the foregoing). In some embodiments in the COS phase to prevent premature ovulation, the GnRH agonist is leuprorelin acetate.

[0145] In some embodiments in the COS phase for preventing premature ovulation, the GnRH antagonist may be relugolix or a pharma- ceutically acceptable salt thereof. Golix is ​​N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea and is represented by the formula: [ka]

[0146] Relugolix is ​​orally active and antagonizes GnRH via the GnRH receptor present in the anterior pituitary basophil cells (secretory cells), inhibiting the GnRH-stimulated secretion of LH and FSH from those cells. In some embodiments of the methods and uses described herein, the dose of relugolix, or the corresponding amount of a pharmacologic acceptable salt thereof, is about 20 mg to about 120 mg (e.g., 80 mg). In some embodiments of the methods and uses described herein, the dose of relugolix, or the corresponding amount of a pharmacologic acceptable salt thereof, is less than about 20 mg, less than about 40 mg, less than about 80 mg, or less than about 120 mg.

[0147] Relugolix or a pharma- ceutical acceptable salt thereof is an orally available GnRH antagonist that may be useful in the COS phase of ART when used with FSH or FSH / hMG to prevent premature ovulation by suppressing the natural LH surge, thereby making compound 1, its metabolites, or a pharma- ceutical acceptable salt of any of the foregoing available as a trigger to promote oocyte maturation in preparation for subsequent egg retrieval, fertilization (in vitro fertilization), ET, ICSI, oocyte donation, oocyte banking, intercourse or IUI, or ovulation induction.

[0148] Relugolix, when used in combination with Compound 1 (as a triggering agent), its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, may result in lower OHSS rates, higher pregnancy rates, and shorter time to pregnancy than when a GnRH agonist is administered instead of Relugolix. Additionally, in some embodiments, an injectable formulation containing Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing may be used with oral FSH and an oral GnRH antagonist (such as Relugolix), which may allow ART cycles to be primarily oral, as opposed to current protocols that include multiple injections.

[0149] Compound 1, its metabolites or any pharma- ceutically acceptable salts thereof may be used in conjunction with other triggering agents for oocyte maturation (i.e., oocyte maturation agents). In some embodiments of the methods and uses described herein, an initial dose of Compound 1, its metabolites or any pharma- ceutically acceptable salts thereof may be administered after administration of a GnRH agonist as an oocyte maturation agent. In some embodiments of the methods and uses described herein, an initial dose of Compound 1, its metabolites or any pharma- ceutically acceptable salts thereof may be administered simultaneously with ... Compound 1, its metabolites or any pharma- ceutically acceptable salt thereof may be administered prior to administration of a GnRH agonist as an oocyte maturation agent. In some embodiments, the GnRH agonist is selected from the group consisting of leuprorelin acetate, gonadorelin, buserelin, triptorelin, goserelin, nafarelin, histrelin, deslorelin, meterelin, recirelin or any pharma- ceutically acceptable salt thereof. In some embodiments, oocyte maturation occurs after administration of the GnRH agonist. In certain such embodiments, the yield of mature oocytes is at least 50%. In certain such embodiments, the yield of mature oocytes is at least 75%. As mentioned above, the yield of oocytes may refer to the percentage of mature oocytes taken from the number of 14mm follicles at the last ultrasound scan before trigger administration. The present disclosure provides that compound 1, its metabolites or any of the pharma- ceutically acceptable salts thereof can be administered in combination with a GnRH agonist as an oocyte maturation agent to prevent one or more symptoms of OHSS from worsening in a human female subject.The present disclosure also provides that compound 1, its metabolites or any of the pharma-ceutically acceptable salts thereof can be administered in combination with a GnRH agonist as an oocyte maturation agent to treat one or more symptoms of OHSS.

[0150] Compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof may be used with hCG as an oocyte maturation agent. In some embodiments, hCG is administered simultaneously with administration of Compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof. In some embodiments, hCG is administered prior to administration of Compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof. In some embodiments, hCG is administered after administration of Compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof. In some embodiments, hCG is administered within 24 hours of administration of Compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof. In some embodiments, hCG is administered within 48 hours of administration of Compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof. Ovulation will occur 38-40 hours after a single hCG injection, and transvaginal collection of oocytes typically occurs 34-36 hours after hCG injection, just prior to the time when the follicle is expected to rupture. In certain embodiments, oocyte maturation occurs after administration of exogenous hCG. In certain such embodiments, the yield of mature oocytes is at least 50%. In certain such embodiments, the yield of mature oocytes is at least 75%. As mentioned above, the yield of oocytes may refer to the percentage of mature oocytes taken from the number of 14mm follicles at the last ultrasound scan before the trigger administration. The present disclosure provides that administration of Compound 1, its metabolites, or any of the pharma- tically acceptable salts thereof in combination with hCG as an oocyte maturation agent can prevent the exacerbation of one or more symptoms of OHSS in a human female subject. The present disclosure also provides that administration of Compound 1, its metabolites, or any of the pharma- tically acceptable salts thereof in combination with hCG as an oocyte maturation agent can treat one or more symptoms of OHSS. In some embodiments, the hCG used in ART can be recombinant or urinary derived.

[0151] In some embodiments of the methods and uses described herein, recombinant luteinizing hormone (rLH) may be used to mature oocytes. In certain such embodiments, rLH is administered simultaneously with Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing. In some embodiments, rLH is administered after Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing. In some embodiments, rLH is administered before Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing.

[0152] The present disclosure provides for the use of Compound 1, its metabolites, or any of the above pharma- ceutically acceptable salts, together with a GnRH agonist and hCG in combination as an oocyte maturation agent. In some embodiments, Compound 1, its metabolites, or any of the above pharma- ceutically acceptable salts, In some embodiments, compound 1, its metabolite or any of the pharmaceutically acceptable salts are administered simultaneously with GnRH agonist and hCG. In some embodiments, compound 1, its metabolite or any of the pharmaceutically acceptable salts are administered before GnRH agonist and hCG. In some embodiments, compound 1, its metabolite or any of the pharmaceutically acceptable salts are administered after GnRH agonist and hCG.

[0153] In some embodiments of the methods and uses described herein, compound 1 or a pharma- ceutically acceptable salt thereof is used in combination with a metabolite of compound 1 (such as compound 2 or a pharma- ceutically acceptable salt thereof) as an oocyte maturation agent. In certain embodiments of the methods and uses described herein, multiple doses of compound 1 or a pharma- ceutically acceptable salt thereof are used for oocyte maturation, e.g., two doses. In certain embodiments of the methods and uses described herein, multiple doses of a metabolite of compound 1 (such as compound 2 or a pharma- ceutically acceptable salt thereof) are used for oocyte maturation, e.g., two doses.

[0154] In addition, Compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof may be used in the ET process by intercourse or IUI, or in ovulation induction (e.g., luteal phase support with estradiol, progestogens (e.g., progesterone), low dose hCG, or a combination thereof) in combination with facilitators for implantation or pregnancy. In some embodiments of the methods and uses described herein, a combination of estradiol and progestogens (e.g., progesterone) are administered for luteal phase support. In some embodiments of the methods and uses described herein, a progestogen (e.g., progesterone) is administered in combination with Compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof for luteal phase support. In some embodiments of the methods and uses described herein, estradiol is administered in combination with Compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof for luteal phase support. In some embodiments of the methods and uses described herein, estradiol and a progestogen (such as progesterone) are administered in combination with Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing for luteal phase support. In some embodiments of the methods and uses described herein, one or more doses of a progestogen (such as progesterone) are administered for luteal phase support. In certain embodiments, the progestogen (such as progesterone) may be administered from the time of oocyte collection up to 12 weeks after collection. In some embodiments, the progestogen (such as progesterone) may be administered at the time of oocyte collection. In some embodiments, the progestogen (such as progesterone) may be administered from the time of oocyte collection up to 1 week after collection. In some embodiments, the progestogen (such as progesterone) may be administered from the time of oocyte collection up to 2 weeks after collection. In some embodiments, the progestogen (such as progesterone) may be administered from the time of oocyte collection up to 3 weeks after collection. In some embodiments, a progestogen (such as progesterone) may be administered from the time of oocyte collection up to four weeks after collection.In some embodiments, a progestogen (such as progesterone) may be administered from the time of oocyte collection up to 5 weeks after collection. In some embodiments, a progestogen (such as progesterone) may be administered from the time of oocyte collection up to 6 weeks after collection. In some embodiments, a progestogen (such as progesterone) may be administered from the time of oocyte collection up to 7 weeks after collection. In some embodiments, a progestogen (such as progesterone) may be administered from the time of oocyte collection up to 8 weeks after collection. In some embodiments, a progestogen (such as progesterone) may be administered from the time of oocyte collection up to 9 weeks after collection. In some embodiments, a progestogen (such as progesterone) may be administered from the time of oocyte collection up to 10 weeks after collection. In some embodiments, a progestogen (such as progesterone) may be administered from the time of oocyte collection up to 11 weeks after collection.

[0155] In some embodiments of the methods and uses described herein, a progestogen (such as progesterone) is administered after administration of Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing (trigger) for luteal replacement. In some embodiments of the methods and uses described herein, estradiol is administered after administration of Compound 1, its metabolites, or a pharma-ceutically acceptable salt of any of the foregoing (trigger) for luteal replacement. In some embodiments of the methods and uses described herein, a progestogen (such as progesterone) and estradiol are administered after administration of Compound 1, its metabolites, or a pharma-ceutically acceptable salt of any of the foregoing (trigger) for luteal replacement.

[0156] For luteal phase support, some embodiments provide for the use of natural preparations of progesterone (P4), including dydrogesterone, medrogesterone, and progesterone itself, in the methods and uses described herein. In some embodiments of the methods and uses described herein, P4 may be administered orally, intramuscularly (IM), or vaginally. IM progestogens (such as progesterone) may be prepared in sesame, coconut, or peanut oil, and the dosage is 50 mg once daily. There are several vaginal formulations of progestogens (such as progesterone), including gels, suppositories, and inserts. Prometrium® may be used as a vaginal preparation, with a recommended dose of 200 mg inserted into the vagina three times daily. Vaginal gel Crinone® 8% (Columbia Laboratories Inc.; Livingston, New York) (Jersey) may be applied once daily and contains 90 mg of a progestogen (such as progesterone). 100 milligrams of Endometrin® (Ferring Pharmaceuticals Inc.; Suffern, New York) may be administered vaginally two or three times daily.

[0157] In certain embodiments of the methods and uses described herein, low dose hCG is administered for luteal phase support. In some embodiments of the methods and uses described herein, low dose hCG is administered after compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof (trigger) for luteal phase support. In certain embodiments of the methods and uses described herein, low dose hCG is administered in combination with a progestogen (such as progesterone) after compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof (trigger) for luteal phase support. In certain embodiments of the methods and uses described herein, low dose hCG is administered in combination with estradiol after compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof (trigger) for luteal phase support. In certain embodiments of the methods and uses described herein, low dose hCG is administered in combination with a progestogen (such as progesterone) and estradiol after compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof (trigger) for luteal phase support.

[0158] In some embodiments of the methods and uses described herein, low dose hCG is administered in combination with Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing for luteal phase support. In certain embodiments of the methods and uses described herein, low dose hCG is administered in combination with Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, and a progestogen (such as progesterone) for luteal phase support. In certain embodiments of the methods and uses described herein, low dose hCG is administered in combination with Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, and estradiol for luteal phase support. In certain embodiments of the methods and uses described herein, low dose hCG is administered in combination with Compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing, and a progestogen (such as progesterone) and estradiol for luteal phase support.

[0159] In some embodiments, the female is administered an hCG trigger, followed by administration of Compound 1, a metabolite thereof, or a pharma- tically acceptable salt of any of the foregoing, for luteal supplementation. In some embodiments, the female is administered a GnRH agonist trigger, followed by administration of Compound 1, a metabolite thereof, or a pharma- tically acceptable salt of any of the foregoing, for luteal supplementation. In some embodiments, the female is administered both an hCG trigger and a GnRH agonist trigger, followed by administration of Compound 1, a metabolite thereof, or a pharma- tically acceptable salt of any of the foregoing, for luteal supplementation. In some embodiments, the female is administered Compound 1, a metabolite thereof, or a pharma- tically acceptable salt of any of the foregoing (the trigger), followed by administration of Compound 1, a metabolite thereof, or a pharma- tically acceptable salt of any of the foregoing, for luteal supplementation. In some embodiments, the female is administered a GnRH agonist trigger and Compound 1, a metabolite thereof, or a pharma- tically acceptable salt of any of the foregoing (the trigger), followed by administration of Compound 1, a metabolite thereof, or a pharma- tically acceptable salt of any of the foregoing, for luteal supplementation. In some embodiments, a female is administered both an hCG trigger and Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing (the trigger), followed by administration of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing for luteal supplementation. In some embodiments, a female is administered both an hCG trigger and a GnRH agonist trigger and Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing (the trigger), followed by administration of Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing for luteal supplementation.

[0160] In some embodiments of the methods and uses described herein, compound 1 or a pharma- ceutically acceptable salt thereof is used in combination with a metabolite of compound 1 (such as compound 2 or a pharma- ceutically acceptable salt thereof) for luteal phase support. In certain embodiments of the methods and uses described herein, multiple doses of compound 1 or a pharma- ceutically acceptable salt thereof are used for luteal phase support, e.g., two doses. In certain embodiments of the methods and uses described herein, multiple doses of a metabolite of compound 1 (such as compound 2 or a pharma- ceutically acceptable salt thereof) are used for luteal phase support, e.g., two doses.

[0161] The advantage of compound 1 or its pharmaceutically acceptable salt is that it may be used not only as a trigger for ovulation, but also re-administered one or more times to provide additional LH for luteal phase support. This may reduce the need for progesterone injections and supplementation. Current ART protocols typically use GnRH agonist trigger followed by low dose hCG for luteal phase support, which increases the risk of OHSS. By administering one or more doses of compound 1 or its pharmaceutically acceptable salt, it can reduce the OHSS risk present in current ART protocols and act as a trigger for oocyte maturation and / or as luteal phase support. Multiple doses of compound 1 or its pharmaceutically acceptable salt can prevent the increase of serum VEGF, thereby reducing blood permeability, thereby reducing the risk of OHSS.

[0162] In some embodiments, compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof are administered in combination with a protease inhibitor. In certain such embodiments, the co-administration of compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof with a protease inhibitor is for luteal phase support. In certain such embodiments, the administered formulation comprises both compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof, and a protease inhibitor. In some embodiments, the formulation comprising both compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof, and a protease inhibitor is immediate release, sustained or extended release, or delayed release. In certain such embodiments, the formulation may exhibit an immediate release profile. In some embodiments, the co-administration of compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof with a protease inhibitor is for luteal phase support. In certain such embodiments, the formulation comprises both compound 1, its metabolites, or any pharma- ceutically acceptable salts thereof, and a protease inhibitor. A formulation containing both a pharma- ceutically acceptable salt of Compound 1, its metabolites, or any of the foregoing, and a protease inhibitor may exhibit a sustained or extended release profile. In some embodiments, a formulation containing both Compound 1, its metabolites, or any of the foregoing, and a protease inhibitor may exhibit a delayed release profile. In some embodiments, a formulation containing Compound 1, its metabolites, or any of the foregoing, and a protease inhibitor is administered separately from a formulation containing a protease inhibitor. Possible protease inhibitors that may be used in the methods and uses of the present disclosure include, but are not limited to, 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF), EDTA, bestatin, E-64, leupeptin (such as leupeptin hemisulfate monohydrate), aprotinin, (2S,3S)-3-carboxyoxirane-2-carbonyl]-L-leucine(4-guanidinobutyl)amide hemihydrate, and salts of any of the foregoing.

[0163] Formulation, Dosage and Administration The present disclosure provides a formulation or pharmaceutical composition comprising Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts, and a pharma- ceutically acceptable excipient or carrier, for use in the methods and uses disclosed herein. In ART, Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts may be administered as a formulation or pharmaceutical composition comprising one or more pharma- ceutically acceptable carriers or excipients. The dosage of Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts may vary according to the weight, age, and medical condition of the human female subject. The therapeutically effective amount of Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts used in the present invention may vary according to the method of administration, the drug selected, and the condition of the female human subject.

[0164] In contrast to many peptide drugs that must be stored and reconstituted at -20°C, Compound 1 or a pharma- ceutically acceptable salt thereof is stable at 4°C and may be stored at 4°C.

[0165] The formulations of the present disclosure may be formulated to provide various release rates (immediate release, sustained or extended release, or delayed release). In some embodiments, the formulations of the present disclosure may exhibit an immediate release profile. In some embodiments, the formulations of the present disclosure may exhibit a sustained or extended release profile. In some embodiments, the formulations of the present disclosure may exhibit a delayed release profile.

[0166] The carrier or excipient of the formulation of the present disclosure may be a blend of excipients and may be in an amount that optimizes the effectiveness of the formulation of the present disclosure. Excipients include, for example, various organic or inorganic excipients or carrier materials.

[0167] Formulations containing Compound 1, its metabolites, or pharma- ceutically acceptable salts of any of the foregoing may be administered by injection, for example, intravenously (IV), intramuscularly (IM), or subcutaneously (SC). In some embodiments, the injection is IM. In other embodiments, the injection is SC. In some embodiments, the SC injection is a bolus. In some embodiments, the SC injection is an infusion. An injection typically involves delivering a discrete amount of a liquid composition with a hypodermic needle and syringe or other injection device known in the art. Examples of injections may also include infusions and intravenous devices. An injection may be immediate or over a period of time.

[0168] Injection formulations containing Compound 1, its metabolites, or any of the pharma- ceutically acceptable salts thereof may be water- or oil-based as a vehicle or carrier. Examples of vehicles or carriers include, but are not limited to, water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil, olive oil, vegetable oil, cottonseed oil, corn oil, and the like. In some embodiments, the vehicle or carrier is water for injection. Alternatively, the injection formulation may be water-based. The injection formulation may take the form of an emulsion, suspension or solution. The injection formulation may have other components such as dispersing agents, dissolving agents, suspending agents, stabilizers, surfactants, solubilizers, surfactants, buffers, isotonicity agents, pH adjusters and soothing agents. Suitable dispersing agents include, but are not limited to, Tween 80 (Atlas Powder Company USA), HCO 60 (Nikko Chemicals Co., Ltd.), polyethylene glycol, carboxymethylcellulose, sodium alginate, hydroxypropylmethylcellulose, dextrose and dextrin. In some embodiments, the dispersing agent is dextrose. Suitable stabilizers include, but are not limited to, ascorbic acid and sodium pyrosulfite. Suitable surfactants include, but are not limited to, polysorbate 80 and macrogol. Suitable solubilizing agents include, but are not limited to, glycerin and ethanol. Suitable buffering agents include, but are not limited to, phosphate or an alkali metal salt thereof, citric acid or an alkali metal salt thereof, acetate and carbonate. Suitable tonicity agents include, but are not limited to, sodium chloride, glycerin, potassium chloride, mannitol, sorbitol, glycerol and glucose. In some embodiments, the tonicity agent is mannitol. Suitable pH adjusting agents include, but are not limited to, hydrochloric acid, acetic acid and sodium hydroxide. In some embodiments, the pH adjusting agent is acetic acid. Suitable preservatives include, but are not limited to, ethyl p-oxybenzoate, benzoic acid, methylparaben, propylparaben and benzyl alcohol. Suitable solubilizing agents include, but are not limited to, concentrated glycerin and meglumine. Suitable solubilizing agents include, but are not limited to, propylene glycol and saccharose. Suitable soothing agents include, but are not limited to, glucose and benzyl alcohol.Examples of dissolution aids include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, etc. Examples of suspending agents include surfactants such as stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionate, lecithin, benzalkonium chloride, benzethonium chloride, glycerin monostearate, etc., and hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, etc. Examples of other excipients that may be used include, for example, lactose, sucrose, starch, corn starch, crystalline cellulose, silicic anhydride, light silicic anhydride, etc.

[0169] Other additives such as preservatives, antioxidants, and colorants may also be used. Possible preservatives include, but are not limited to, paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid, etc. Possible antioxidants include, but are not limited to, sulfites, ascorbic acid, etc. Possible colorants include, but are not limited to, ferric oxide.

[0170] In some embodiments, an injectable formulation of the present disclosure comprises Compound 1, a metabolite thereof, or a pharma- ceutically acceptable salt of any of the foregoing, mannitol, acetic acid, and water for injection. In certain such embodiments, the formulation further comprises glucose and / or dextrose.

[0171] In some embodiments, the injectable formulation of the present disclosure may be adjusted to a pH of 2 to 12, preferably 2.5 to 8.0, by adding a pH adjusting agent.

[0172] The dosage for the injectable formulation is ART (IVF, ICSI, oocyte donation, oocyte transfer) In some embodiments, the injectable formulation of the present disclosure may be administered in an amount effective to promote oocyte maturation during a period of time such as during a trigger phase, prior to harvesting of oocytes from the ovaries, during IVF, ICSI, oocyte donation, oocyte banking, menstrual cycle regulation to enable a human female subject to become pregnant by intercourse or IUI, and during transfer of a fertilized embryo to the uterus. In some embodiments, the injectable formulation of the present disclosure may be administered in a single dose. In some embodiments, the injectable formulation of the present disclosure may be administered in a split dose. In some embodiments, two doses of the injectable formulation of the present disclosure may be administered. In some embodiments, the second injectable dose is administered within about 8 to about 60 hours of administration of the first dose. In some embodiments, three doses of the injectable formulation of the present disclosure may be administered. In some embodiments, the third injection dose is administered within about 8 to about 60 hours after administration of the second dose. In some embodiments, the third injection dose is administered followed by 1 to 5 additional injection doses. In some embodiments where the third injection dose is administered followed by 1 to 5 additional injection doses, the administration of the 1 to 5 additional doses is within about 8 to about 60 hours after administration of the previous dose.

[0173] Compound 1, its metabolites or any pharma- ceutically acceptable salts thereof may be administered in a depot preparation. Injectable depot forms may be made by forming microencapsulated matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters), poly(anhydrides) and (poly)glycols (such as PEG). Depending on the ratio of drug to polymer and the nature of the specific polymer used, the rate of drug release may be controlled. Injectable depot preparations may also be prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.

[0174] The injectable formulations of the present disclosure may be sterilized, for example, by filtration through a bacterial-retaining filter immediately prior to use, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other injectable sterile medium.

[0175] Compound 1, its metabolites or any of the pharma- ceutically acceptable salts thereof may be administered in intranasal formulations.The formulation may be in liquid form so that it can be sprayed into the nostrils, but semi-solid formulations such as intranasal creams may also be possible.Liquid intranasal formulations may be in the form of solutions, suspensions or emulsions, and may be aqueous or non-aqueous.Intranasal formulations may be prepared according to methods known in the art using the components listed above for injection dosage forms.

[0176] The intranasal dosage of compound 1, its metabolites, or a pharma- ceutically acceptable salt of any of the foregoing may be an amount effective to promote oocyte maturation in ART (such as IVF, ICSI, oocyte donation, oocyte banking, menstrual cycle regulation or ovulation induction and / or ET processes to enable a human female subject to become pregnant by intercourse or IUI). In some embodiments, the intranasal formulation of the present disclosure may be administered in a single dose. In some embodiments, intranasal administration may be performed when release and collection of mature oocytes is desired (such as during the trigger phase, prior to collection of oocytes from the ovaries, IVF, ICSI, oocyte donation, oocyte banking, menstrual cycle regulation to enable a human female subject to become pregnant by intercourse or IUI, and during transfer of a fertilized embryo to the uterus). In some embodiments, the intranasal formulation of the present disclosure may be administered in a single dose. In some embodiments, the intranasal formulation of the present disclosure may be administered in a split dose. In some embodiments, the intranasal formulation of the present disclosure may be administered in two doses. In some embodiments, the second intranasal dose is administered within about 8 to about 60 hours after administration of the first dose. In some embodiments, three doses of the intranasal formulation of the present disclosure may be administered. In some embodiments, the second intranasal dose is administered within about 8 to about 60 hours after administration of the second dose. In some embodiments, the third intranasal dose is administered followed by one to five additional intranasal doses. In some embodiments, the third intranasal dose is administered followed by one to five additional intranasal doses. In some embodiments, the third intranasal dose is administered followed by one to five additional intranasal doses, the administration of the one to five additional doses is within about 8 to about 60 hours of administration of the previous dose.

[0177] In addition, conventional additives such as preservatives, antioxidants, colorants, sweeteners, adsorbents, wetting agents, etc., may be suitably used in suitable amounts in any dosage form, if necessary. Possible preservatives include, for example, p-hydroxybenzoates, paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid, ethyl p-oxybenzoate, benzoic acid, methylparaben, propylparaben, etc. Possible antioxidants include, for example, sulfites, ascorbic acid, α-tocopherol, etc.

[0178] Dosage forms containing Compound 1 and pharma- ceutically acceptable salts thereof are disclosed, for example, in U.S. Patent Application Publication Nos. 2012 / 0302508, 2013 / 0210742, 2011 / 0312898, and 2011 / 0212890, the disclosures of which are incorporated herein by reference. These publications also disclose various indications and end uses for Compound 1.

[0179] In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.00003 mg to about 0.030 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.001 mg to about 0.030 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.001 mg to about 0.003 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.00003 mg to about 0.0003 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.00003 mg to about 0.003 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.00003 mg to about 0.00006 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.00003 mg to about 0.00009 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.00003 mg to about 0.00015 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.00003 mg to about 0.0006 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.00003 mg to about 0.0009 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.00003 mg to about 0.0015 mg of Compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.00003 mg to about 0.006 mg of Compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof.In some embodiments, the formulation or pharmaceutical composition of the disclosure comprises from about 0.00003 mg to about 0.009 mg of Compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the disclosure comprises from about 0.00003 mg to about 0.015 mg of Compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof.

[0180] In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.0003 mg to about 0.030 mg of Compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.0003 mg to about 0.0006 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.0003 mg to about 0.0009 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.0003 mg to about 0.0015 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.0003 mg to about 0.006 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.0003 mg to about 0.009 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, a formulation or pharmaceutical composition of the disclosure comprises from about 0.0003 mg to about 0.015 mg of Compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof.

[0181] In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.003 mg to about 0.030 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.003 mg to about 0.006 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.003 mg to about 0.009 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.003 mg to about 0.015 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof.

[0182] In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.0003 mg to about 0.003 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.0006 mg to about 0.003 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.0009 mg to about 0.003 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.0015 mg to about 0.003 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof.

[0183] In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.00006 mg to about 0.030 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.00009 mg to about 0.030 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.00015 mg to about 0.030 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.0006 mg to about 0.030 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.0009 mg to about 0.030 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.0015 mg to about 0.030 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.006 mg to about 0.030 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.009 mg to about 0.030 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.015 mg to about 0.030 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof.

[0184] In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.00003 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.030 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.0003 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.003 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.00005 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.0005 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.005 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the disclosure comprises about 0.010 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the disclosure comprises about 0.0001 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the disclosure comprises about 0.001 mg of compound 1, or a corresponding amount of a pharma- ceutically acceptable salt thereof.

[0185] In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.00002 mg to about 0.020 mg of a metabolite of Compound 1 (e.g., Compound 2), or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.001 mg to about 5 mg of a metabolite of Compound 1 (e.g., Compound 2), or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.00002 mg to about 0.002 mg of a metabolite of Compound 1 (e.g., Compound 2), or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the formulation or pharmaceutical composition of the present disclosure comprises about 0.0002 mg to about 0.002 mg of a metabolite of Compound 1 (e.g., Compound 2), or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, a formulation or pharmaceutical composition of the disclosure comprises from about 0.00002 mg to about 5 mg of a metabolite of Compound 1 (e.g., Compound 2), or a corresponding amount of a pharma- ceutically acceptable salt thereof. In some embodiments, a formulation or pharmaceutical composition of the disclosure comprises from about 0.0002 mg to about 0.020 mg of a metabolite of Compound 1 (e.g., Compound 2), or a corresponding amount of a pharma- ceutically acceptable salt thereof.

[0186] In some embodiments, the formulation or pharmaceutical composition of the present disclosure may be administered in a single dose. In some embodiments, the formulation or pharmaceutical composition of the present disclosure may be administered in split doses. In some embodiments, the formulation or pharmaceutical composition of the present disclosure provides luteal phase support in the first dose. In some embodiments, the formulation or pharmaceutical composition of the present disclosure triggers oocyte maturation in the first dose. In some embodiments, the formulation or pharmaceutical composition of the present disclosure may be administered in two doses. The formulation or pharmaceutical composition of the present disclosure may improve oocyte viability and pregnancy rates in some women with a second dose. Additionally, a second dose may be required to provide a sufficient LH surge to obtain mature oocytes and may be administered in both oocyte donation and oocyte banking, as well as IVF / ICSI cycles. In some embodiments, a second dose may be required for luteal phase support. In certain such embodiments, a second dose may be required in ART protocols involving fresh embryo transfer of embryos. In some embodiments, the second dose is administered within about 8 to about 60 hours of administration of the first dose. In certain such embodiments, the second dose is administered within about 8 to about 12 hours after administration of the first dose. In some embodiments, the second dose is administered within about 8 to about 16 hours after administration of the first dose. In some embodiments, the second dose is administered within about 8 to about 24 hours after administration of the first dose. In some embodiments, the second dose is administered within about 8 to about 24 hours after administration of the first dose. The second dose is administered within about 8 to about 32 hours. In some embodiments, the second dose is administered within about 8 to about 40 hours after administration of the first dose. In some embodiments, the second dose is administered within about 8 to about 48 hours after administration of the first dose. In some embodiments, the second dose is administered within about 8 to about 54 hours after administration of the first dose. In some embodiments, the second dose is administered within about 12 to about 16 hours after administration of the first dose. In some embodiments, the second dose is administered within about 12 to about 24 hours after administration of the first dose. In some embodiments, the second dose is administered within about 12 to about 32 hours after administration of the first dose. In some embodiments, the second dose is administered within about 12 to about 40 hours after administration of the first dose. In some embodiments, the second dose is administered within about 12 to about 48 hours after administration of the first dose. In some embodiments, the second dose is administered within about 12 to about 54 hours after administration of the first dose. In some embodiments, the second dose is administered within about 24 to about 36 hours after administration of the first dose. In some embodiments, the second dose is administered within about 24 to about 48 hours after administration of the first dose. In some embodiments, the second dose is administered within about 24 to about 60 hours after administration of the first dose. In some embodiments, the second dose is administered within about 36 to about 48 hours after administration of the first dose. In some embodiments, the second dose is administered within about 36 to about 60 hours after administration of the first dose. In some embodiments, the second dose is administered within about 48 to about 60 hours after administration of the first dose.

[0187] In some embodiments, the formulation or pharmaceutical composition of the present disclosure may be administered in three doses. In some embodiments, the formulation or pharmaceutical composition of the present disclosure provides luteal phase support with a third dose. In some embodiments, the third dose is administered within about 8 to about 60 hours after administration of the second dose. In certain such embodiments, the third dose is administered within about 8 to about 12 hours after administration of the second dose. In some embodiments, the third dose is administered within about 8 to about 16 hours after administration of the second dose. In some embodiments, the third dose is administered within about 8 to about 24 hours after administration of the second dose. In some embodiments, the third dose is administered within about 8 to about 32 hours after administration of the second dose. In some embodiments, the third dose is administered within about 8 to about 40 hours after administration of the second dose. In some embodiments, the third dose is administered within about 8 to about 48 hours after administration of the second dose. In some embodiments, the third dose is administered within about 8 to about 54 hours after administration of the second dose. In some embodiments, the third dose is administered within about 12 to about 16 hours after administration of the second dose. In some embodiments, the third dose is administered within about 12 to about 24 hours after administration of the second dose. In some embodiments, the third dose is administered within about 12 to about 32 hours after administration of the second dose. In some embodiments, the third dose is administered within about 12 to about 40 hours after administration of the second dose. In some embodiments, the third dose is administered within about 12 to about 48 hours after administration of the second dose. In some embodiments, the third dose is administered within about 12 to about 54 hours after administration of the second dose. In some embodiments, the third dose is administered within about 24 to about 36 hours after administration of the second dose. In some embodiments, the third dose is administered within about 24 to about 48 hours after administration of the second dose. In some embodiments, the third dose is administered within about 24 to about 60 hours after administration of the second dose. In some embodiments, the third dose is administered within about 36 to about 48 hours after administration of the second dose. In some embodiments, the third dose is administered within about 36 to about 60 hours after administration of the second dose.In some embodiments, the third dose is administered within about 48 to about 60 hours after administration of the second dose.

[0188] In some embodiments, a formulation or pharmaceutical composition of the disclosure is administered a third dose followed by 1-5 additional doses. In some embodiments, a formulation or pharmaceutical composition of the disclosure administered a third dose followed by 1-5 additional doses provides luteal phase support. In some embodiments, a formulation or pharmaceutical composition of the disclosure administered a third dose provides luteal phase support. The formulation or pharmaceutical composition of the present disclosure is administered after collection of the oocytes in one to five additional doses. In some embodiments, the formulation or pharmaceutical composition of the present disclosure is administered after a third dose and then one to five additional doses are administered. In certain such embodiments, the one to five additional doses are administered within about 8 to about 12 hours after administration of the previous dose. In some embodiments, the one to five additional doses are administered within about 8 to about 16 hours after administration of the previous dose. In some embodiments, the one to five additional doses are administered within about 8 to about 24 hours after administration of the previous dose. In some embodiments, the one to five additional doses are administered within about 8 to about 32 hours after administration of the previous dose. In some embodiments, the one to five additional doses are administered within about 8 to about 40 hours after administration of the previous dose. In some embodiments, 1 to 5 additional doses are administered within about 8 to about 48 hours after administration of the previous dose. In some embodiments, 1 to 5 additional doses are administered within about 8 to about 54 hours after administration of the previous dose. In some embodiments, 1 to 5 additional doses are administered within about 12 to about 16 hours after administration of the previous dose. In some embodiments, 1 to 5 additional doses are administered within about 12 to about 24 hours after administration of the previous dose. In some embodiments, 1 to 5 additional doses are administered within about 12 to about 32 hours after administration of the previous dose. In some embodiments, 1 to 5 additional doses are administered within about 12 to about 40 hours after administration of the previous dose. In some embodiments, 1 to 5 additional doses are administered within about 12 to about 48 hours after administration of the previous dose. In some embodiments, 1 to 5 additional doses are administered within about 12 to about 54 hours after administration of the previous dose. In some embodiments, one to five additional doses are administered within about 24 to about 36 hours after administration of the previous dose. In some embodiments, one to five additional doses are administered within about 24 to about 48 hours after administration of the previous dose. In some embodiments, one to five additional doses are administered within about 24 to about 60 hours after administration of the previous dose.In some embodiments, one to five additional doses are administered within about 36 to about 48 hours after administration of the previous dose. In some embodiments, one to five additional doses are administered within about 36 to about 60 hours after administration of the previous dose. In some embodiments, one to five additional doses are administered within about 48 to about 60 hours after administration of the previous dose.

[0189] The following are examples of embodiments of the present disclosure and should not be construed as limiting. EXAMPLES

[0190] Throughout the figures and examples, the term "API-FB" is used to refer to the free form of Compound 1. The term "API-MA" is used to refer to the monoacetate salt form of Compound 1.

[0191] Additionally, throughout the figures and examples, the dosage amounts used refer to the amount of API-FB present in the formulation. It will be clear to one skilled in the art how to calculate the amount of API-FB, given the difference in molecular weight between API-FB and API-MA. For example, 10.0 mg of API-FB would be equivalent to 10.5 mg of API-MA.

[0192] The baseline levels referred to in the examples refer to the hormone levels in an individual prior to administration of one or more doses of a compound of the present disclosure.

[0193] In a series of pharmacological studies, the activity of API-MA was investigated in vitro and in vivo.

[0194] In vitro receptor binding studies demonstrated that API-MA has high affinity for human KISS1R, with an average IC 50 In the human GPR54-calcium mobilization assay, the agonistic concentration of API-MA was 50% effective concentration (EC 50 ) at a concentration of 266 pmol / L. 4) EC50 was 314 pmol / L.

[0195] Example 1: In vitro pharmacology Binding affinity of API-MA to KISS1R: The binding affinity of API-MA to the membrane fraction of recombinant cells expressing KISS1R was examined in a competitive binding assay. 125 I-Kisspeptin(45-54) was incubated with membrane fractions from rat, dog, monkey, and human KISS1R-expressing recombinant cells.

[0196] The results of the receptor binding assay showed that the binding affinity of API-MA to KISS1R varied depending on the species tested, with IC 50 The IC values ​​ranged from 230 to 870 pmol / L. In recombinant Chinese hamster ovary cells expressing human KISS1R (cell line h175-KB34), the IC 50 The IC value is for kisspeptin(45-54), a 10 amino acid residue peptide from the C-terminus of kisspeptin. 50 The IC value for kisspeptin(45-54) was approximately 2.5 times higher than that of 50 The IC value of API-MA was 93 pmol / L. 50 The value was 230 pmol / L.

[0197] Example 2: API-MA inhibits intracellular Ca in KISS1R-expressing Chinese hamster ovary cells 2+ Effect on levels By performing a fluorescence imaging plate reader assay, we confirmed that API-MA was able to detect intracellular Ca in KISS1R-expressing recombinant cells. 2+ API-MA was evaluated for its effect on intracellular Ca mobilization in rat, dog, monkey, or human KISS1R-expressing Chinese hamster ovary dihydrofolate reductase-negative cells. 2+ The EC 50The EC values ​​were 632 pmol / L in rat receptor expressing cells, 2010 pmol / L in dog receptor expressing cells, 74.0 pmol / L in monkey receptor expressing cells, and 266 pmol / L in human receptor expressing cells. 50 The EC values ​​for kisspeptin(45-54) were 310 pmol / L for the rat form, 1680 pmol / L for the dog form, 78.7 pmol / L for the monkey form, and 314 pmol / L for the human form. 50 API-MA EC for Value 50 The ratios of values ​​were 2.0 in cells expressing rat receptors, 1.2 in cells expressing dog receptors, 0.94 in cells expressing monkey receptors, and 0.85 in cells expressing human receptors. These results suggest that the agonistic activity of API-MA against KISS1R is as strong as that of kisspeptin(45-54).

[0198] Secondary Pharmacology: In a panel of 127 enzyme and radioligand binding assays, API-MA at 10 μmol / L did not produce any significant inhibitory effects in the indicated enzyme and receptor binding assays.

[0199] Example 3: Pharmacokinetics and Drug Metabolism in Animals The PK of API-MA was investigated in rats, dogs and monkeys. API-MA was rapidly absorbed after SC administration and the bioavailability of API-MA was good (>55%) in all species.

[0200] In vitro distribution and metabolism studies: 14The in vitro distribution ratios of [C]API-MA in rats were 7.8% at 0.01 μg / mL API-FB (free form), 8.0% at 0.1 μg / mL API-FB (free form), 7.1% at 1 μg / mL API-FB (free form), and 4.8% at 10 μg / mL API-FB (free form), and in dogs were 2.4% at 0.01 μg / mL API-FB (free form), 2.0% at 0.1 μg / mL API-FB (free form), 1.6% at 1 μg / mL API-FB (free form), and 10% at 10 μg / mL API-FB (free form). In humans, the distribution ratio of API-FB to blood cells was low and almost constant in the range of API-FB concentrations from 0.01 to 10 μg / mL. In rats, dogs, monkeys, and humans, the distribution ratio of API-FB to blood cells was low and almost constant in the range of API-FB concentrations from 0.01 to 10 μg / mL. 14 The in vitro plasma protein binding ratio of [C]API-FB was determined by ultracentrifugation. In addition, protein binding to human serum albumin (HSA), α1-acid glycoprotein (AGP) and HSA / AGP was investigated. The results from this study showed that the plasma protein binding of API-FB was moderate (range 55.3%-73.3%) in all species examined. In rats and dogs, rather low binding ratios were observed in the concentration range of 0.1-1.0 μg / mL API-FB. In monkeys and humans, binding was independent of drug concentration from 0.01-10 μg / mL API-FB. The binding ratio in HSA / AGP mixture was lower than that in human plasma, and unlike human plasma, the ratio tended to decrease in a concentration-dependent manner, suggesting that API-FB bound not only to albumin and α1-acid glycoprotein but also to other protein(s) in human plasma.

[0201] The inhibition of CYP by API-MA was evaluated in vitro using recombinant CYP. The data (IC 50 values ​​>10 μg / L) indicate that API-MA is unlikely to be an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4.

[0202] Pharmacokinetics in rats: The PK of API-MA was studied in rats after SC and IV administration. The PK profile of API-MA in rats is summarized in Table 1.

[0203] The maximum observed plasma concentrations (C max The increase in plasma concentration-time curve (AUC) of API-FB from 0 to 24 hours after SC administration of 10 mg / kg was less than dose-proportional (an increase of approximately 2.3 times). The mean values ​​were 381.3 ng / mL at 1 mg / kg and 284.6 ng / mL at 10 mg / kg. On the other hand, the area under the plasma concentration-time curve (AUC) of API-FB from 0 to 24 hours after SC administration of 10 mg / kg was (0-24) The increase in C in rats was 2.5-fold lower than that observed at 1 mg / kg. The mean value at the 10 mg / kg dose was 309 ng.hr / mL, and the mean value at the 1 mg / kg dose was 804 ng.hr / mL. max The reason why the AUC and AUC values ​​were not dose-proportional is unclear. However, the time to maximum observed plasma concentration (T max The terminal elimination half-life (T 1 / 2 ) was not sought.

[0204] After IV administration of API-MA at a dose of 1 mg / kg, the plasma concentration at 5 minutes (C 5min ) was 2672.3ng / mL. The concentration then decreased biphasically, and in the α phase, T 1 / 2 The T of the β phase was 0.5 h. Due to the limited number of data points, 1 / 2was not calculated. AUC (0-24) The value was 1457ng.hr / mL.

[0205] The bioavailability of API-MA was good (55.3%) when administered SC at 1 mg / kg in rats.

[0206] The PK linearity of API-MA was also investigated in rats after IV administration. 5min and AUC (0-24) The plasma C 5min The value is 0.0 The AUC (0-24) The values ​​were 14ng.hr / mL at the 0.01mg / kg dose, 140ng.hr / mL at the 0.1mg / kg dose, and 1390ng.hr / mL at the 1mg / kg dose. 1 / 2 The values ​​were 0.4 hours at 0.01 mg / kg and 0.1 mg / kg, and 0.5 hours at 1 mg / kg. These findings indicate that the PK of API-FB was linear in rats after a single IV dose over the dose range of 0.01 to 1 mg / kg. The increase in first-pass kinetics with SC administration beyond dose proportionality would indicate nonlinear PK in rats after SC administration. [Table 1]

[0207] [ 14Radioactivity concentrations were examined in tissues of male albino and pigmented rats after a single IV dose of [C]API-MA at 1.049 mg / kg (1 mg / kg API-FB). The results showed that API-MA-related compounds were widely distributed in tissues, and concentrations were lower in most tissues than in plasma, except for kidney and bladder. After IV administration of API-MA, radioactivity measured in albino rats was rapidly cleared from all tissues. API-MA-related compounds were also shown to have little affinity for melanin in vivo.

[0208] In two tests, 14 After a single SC or IV dose of 1.049 mg / kg [C]API-MA (1 mg / kg API-FB) was administered to male Sprague-Dawley rats, the excretion of the administered radioactivity in urine, feces, bile, and expired air was examined.

[0209] In the first study, urinary, fecal, and biliary excretion was evaluated. After SC or IV administration, API-MA was primarily excreted in urine (84.7% SC, 76.6% IV), followed by bile (15.5% SC, 20.7% IV) and feces (0.2% SC, 0.3% IV) at 24 hours post-dose.

[0210] In a second study, urinary, fecal and exhaled air excretion was investigated. After SC or IV administration, API-MA was primarily excreted in urine (78.1% SC vs. 70.0% IV) and feces (20.4% SC vs. 28.2% IV) at 48 hours post-dose. Exhaled air excretion was minimal. Results of this study indicate that [ 14 It has also been shown that after SC or IV administration of [C]API-MA to rats, excretion was nearly complete by 48 h post-administration.

[0211] Pharmacokinetics in Dogs: The PK of API-MA was studied in dogs following SC and IV administration. The PK profile of API-MA in dogs is summarized in Table 2 below.

[0212] After SC administration of API-MA to dogs, plasma C max and AUC (0-24) The plasma C values ​​increased dose-proportionally over the dose range of 0.1 to 10 mg / kg. max The values ​​were 86.6 ng / mL at the 0.1 mg / kg dose, 882.7 ng / mL at the 1 mg / kg dose, and 8842.5 ng / mL at the 10 mg / kg dose, and the plasma AUC (0-24) The values ​​were 252 ng.hr / mL at the 0.1 mg / kg dose, 2596 ng.hr / mL at the 1 mg / kg dose, and 28,626 ng.hr / mL at the 10 mg / kg dose. Plasma T max Values ​​were within 0.8-1.0 hours at the doses tested.

[0213] After bolus IV administration of API-MA at a dose of 1 mg / kg, plasma C 5min The value was 4254.4 ng / mL and the concentration decreased with a triphasic time course. 1 / 2 The value was 3.0 hours. AUC (0-24) The value was 3093ng.hr / mL.

[0214] Bioavailability of API-MA after SC administration was good, with estimates of 81.5% at the 0.1 mg / kg dose, 84.0% at the 1 mg / kg dose, and 92.7% at the 10 mg / kg dose.

[0215] Based on these results, API-MA administered SC undergoes slight first-pass kinetics prior to absorption, but API-MA is well absorbed in dogs and the PK of API-MA showed a dose-proportional increase over the dose range of 0.1-10 mg / kg. [Table 2]

[0216] Pharmacokinetics in Monkeys: The PK of API-MA was studied in monkeys after SC and IV administration. The PK profile of API-MA in monkeys is summarized in Table 3 below.

[0217] After SC administration to monkeys, C max and AUC (0-24) The plasma C values ​​increased dose-proportionally over the dose range of 0.1 to 10 mg / kg. max The values ​​were 122.6 ng / mL at a dose of 0.1 mg / kg, 1323.4 ng / mL at a dose of 1 mg / kg, and 12,089.6 ng / mL at a dose of 10 mg / kg, and the plasma AUC (0-24) The values ​​were 295ng.hr / mL at a dose of 0.1mg / kg and 2.0ng.hr / mL at a dose of 1mg / kg. 791ng.hr / mL at a dose of 10mg / kg and 31,576ng.hr / mL at a dose of 10mg / kg. max Values ​​were within 0.3-0.4 hours at the doses tested. max After IV administration, the concentration declined multi-exponentially, with a mean terminal elimination T 1 / 2 The time to distribution was approximately 2.6 hours, which was similar to that observed after IV administration. No rapid distribution phase was evident after SC administration, as it was partially masked by the slow absorption of API-MA from the SC injection site.

[0218] After bolus IV administration of API-MA at a dose of 1 mg / kg, plasma C 5min The value was 5027.0 ng / mL and the concentration decreased with a triphasic time course. 1 / 2 The value was 3.2 hours. AUC (0-24) The value was 3160ng.hr / mL.

[0219] The SC bioavailability of API-MA was good with values ​​of 94.9% at the 0.1 mg / kg dose, 90.1% at the 1.0 mg / kg dose, and 101.9% at the 10 mg / kg dose.

[0220] These results indicate that API-MA was well absorbed in monkeys and that when administered SC, API-MA underwent minimal or no first-pass effects prior to absorption.The PK of API-MA in monkeys showed a dose-proportional increase over the dose range of 0.1 to 10 mg / kg. [Table 3]

[0221] Pharmacokinetics and Product Metabolism: Where applicable, the following PK parameters are summarized for API-MA in plasma and urine following administration of API-MA. C max :Highest observed plasma concentration T max :C max arrival time C ss : Steady-state plasma concentration AUC (0-24) : Area under the plasma concentration-time curve (AUC) from 0 to 24 hours AUC (0-inf) : AUC from time 0 to infinity T 1 / 2 :Final elimination half-life CL / F: Apparent clearance (after subcutaneous [SC] administration) Fe: Percentage of dose excreted in urine

[0222] Example 4: Study Overview Single-dose PK-overview: Systemic exposure (C max and AUC (0-inf) The mean CL / F ranged from 13.7 to 19.8 L / h. The T of SC bolus-administered API-MA was in the range max The median values ​​ranged from 0.375 to 0.750 hours, suggesting that API-MA is rapidly taken up into the system from the SC administration site. Overall, the mean T 1 / 2The values ​​increased with increasing dose, indicating that the API-MA concentration was below the quantification limit of the assay, resulting in a T 1 / 2 This may be due to an underestimation of the apparent dose-dependence of this parameter. At the highest doses tested (0.25 mg and 0.5 mg), the mean T 1 / 2 The mean mean Fe ranged from 4.24% to 7.10% of the administered dose at doses of 0.004 to 0.5 mg.

[0223] Based on PK data from a Phase 1 study of API-MA in European men, AUC (0-inf) The CL / F values ​​ranged from 18.9 to 27.1 L / h after a single SC bolus of API-MA and after a 2-h infusion. max Median values ​​ranged from 0.5 to 0.750 hours, indicating that API-MA was rapidly taken up into the system from the SC administration site and were not dose-dependent across the range of SC doses evaluated in this study. At the highest doses tested (3 mg and 6 mg), mean T 1 / 2 The mean time to release was approximately 5.2 hours, and generally increased with increasing dose. In doses of 0.003 to 6 mg, Fe ranged from 3.09% to 5.40% of the administered dose.

[0224] Multiple-dose PK-Overview: In a Phase 1 study of chronic (13 consecutive days) SC infusion of API-MA, ss increased in an apparently dose-proportional manner, with mean CL / F values ​​ranging from 17.7 to 20.6 L / h over the dose range evaluated (0.01 to 1 mg). In a study of hormone-naive Japanese patients with prostate cancer, API-MA was administered as a 2-h SC infusion at doses of 0.5 or 1.0 mg / day for 14 days. Plasma concentrations of API-MA increased, reaching Cmax immediately after the end of the infusion, then declined, with mean T 1 / 2Values ​​were approximately 3-4 hours for both doses on both days 1 and 14. API-MA exposure increased approximately dose-proportionally with SC injection at doses of 0.5 mg / day and 1.0 mg / day. No accumulation of API-MA was observed after multiple SC administration for 14 days.

[0225] Summary of 1-Month Depot Injections: In another study, prostate cancer patients who were either undergoing GnRH agonist therapy or were potential candidates for future GnRH agonist therapy were administered a single 1-month depot injection of either 6 mg, 12 mg, or 24 mg (N=3 per treatment group). A high burst release of API-MA drug concentrations was observed within hours of administration of the depot injection. AUC (0-24) is the area under the plasma concentration-time curve (AUC (0-tlqc) ), indicating significant release of drug from the formulation during the burst phase. Very low levels of drug concentration were observed over the next few days, which then slowly increased, consistent with the presumption of delayed and sustained release from the formulation. In all cases, API-MA was no longer detectable by 8 weeks after administration.

[0226] Pharmacokinetics of single doses of API-MA: This study was conducted as a randomized, double-blind, placebo-controlled, parallel-group, ascending-dose study in Japan to evaluate the safety, plasma and urinary PK, and endocrine PD effects of API-MA following a single SC bolus (0.001-0.5 mg) or 2-h SC infusion (0.25-0.5 mg), which is believed to stimulate testosterone levels. Thirty-seven healthy Japanese male subjects aged 50-74 years were enrolled in nine cohorts. Subjects enrolled in the first seven cohorts received either 0.001 mg, 0.004 mg, 0.01 mg, 0.04 mg, 0.1 mg, 0.25 mg, or 0.5 mg of API-MA. In the 0.001 mg cohort, three subjects received API-MA and two received placebo. In the remaining cohorts, three subjects received API-MA and one received placebo. Subjects enrolled in cohorts 8 and 9 received 0.25 mg or 0.5 mg API-MA or placebo via a single 2-h SC infusion. In both cohorts, three subjects received API-MA and one received placebo. The plasma PK analysis set consisted of 31 subjects (bolus cohort: 25, infusion cohort: 6) and the urinary PK analysis set consisted of 35 subjects (bolus cohort: 27, infusion cohort: 8).

[0227] To measure plasma concentrations of API-MA in subjects in the SC bolus cohort, blood samples were collected at nominal times pre-dose, 0.083 h post-dose, 0.25 h post-dose, 0.5 h post-dose, 0.75 h post-dose, 1 h post-dose, 2 h post-dose, 3 h post-dose, 4 h post-dose, 6 h post-dose, 8 h post-dose, 12 h post-dose, 16 h post-dose, 24 h post-dose, 36 h post-dose, 48 h post-dose, and 72 h post-dose. To measure urinary excretion of API-MA, urine samples were collected at nominal times pre-dose, 0-4 h post-dose, 4-8 h post-dose, 8-12 h post-dose, 12-24 h post-dose, 24-36 h post-dose, 36-48 h post-dose, and 48-72 h post-dose.

[0228] To measure plasma concentrations of API-MA in subjects in the SC infusion cohort, blood samples were collected at the following nominal times: pre-dose, 0.25 hours after start of infusion, 0.5 hours after start of infusion, 1 hour after start of infusion, 2 hours after start of infusion, 2.25 hours after start of infusion, 2.5 hours after start of infusion, 2.75 hours after start of infusion, 3 hours after start of infusion, 4 hours after start of infusion, 5 hours after start of infusion, 6 hours after start of infusion, 8 hours after start of infusion, 10 hours after start of infusion, 14 hours after start of infusion, 24 hours after start of infusion, 36 hours after start of infusion, 48 hours after start of infusion, and 72 hours after start of infusion. To measure urinary excretion of API-MA, urine specimens were collected at the following nominal times: pre-dose, 0-4 hours after start of infusion, 4-8 hours after start of infusion, 8-12 hours after start of infusion, 12-24 hours after start of infusion, 24-36 hours after start of infusion, 36-48 hours after start of infusion, and 48-72 hours after start of infusion.

[0229] The mean plasma and urinary PK parameter values ​​for a single dose of API-MA administered by SC bolus and a single dose of API-MA administered by 2-hour SC infusion are listed in Table 4 below. [Table 4]

[0230] Systemic exposure to API-MA (C max and AUC (0-inf) (measured as α, β-glucose ... max 1.023 (95% confidence interval [CI]: 0.970-1.076), AUC (0-inf) The C value was 1.027 (95%CI: 0.979-1.075) after 2-hour SC injection of 0.5 mg API-MA. max and AUC (0-inf) The mean values ​​of were similar to those after the SC bolus (C maxwas 8230pg / mL compared to 9050pg / mL, and AUC (0-inf) (29970 hr·pg / mL vs 34650 hr·pg / mL). Note that there was only one subject in the 0.25 mg infusion cohort. After a single bolus dose of API-MA and a 2-hour SC infusion, the mean CL / F ranged from 13.7 to 19.8 L / hour.

[0231] SC bolus administration of API-MA max The median times ranged from 0.375 to 0.750 hours, suggesting that API-MA was rapidly taken up into the system from the SC administration site. The rapid uptake of API-MA did not appear to be dose-dependent.

[0232] Generally speaking, the average T 1 / 2 The T values ​​were prolonged with increasing dose, as a result of API-MA concentrations being below the quantification limit of the assay, after administration of low doses of API-MA. 1 / 2 This may be due to an underestimation of the apparent dose-dependence of this parameter. At the highest doses tested (0.25 mg and 0.5 mg), the mean T 1 / 2 was 3.77 to 4.27 hours.

[0233] No API-MA was detected in the urine after a single SC bolus of 0.001 mg API-MA. Across the higher dose bolus and infusion cohorts (0.004-0.5 mg), mean single dose Fe ranged from 4.24% to 7.10% of the administered dose of API-MA. Plots of cumulative urinary excretion of API-MA indicated that excretion was essentially complete by 24 hours.

[0234] Example 5: Pharmacokinetic Effects of API-MA Administered as a SC Bolus Another study was a phase 1, randomized, double-blind, placebo-controlled, parallel-group, ascending-dose study of the safety, tolerability, plasma and urinary PK, and endocrine pharmacodynamic effects of API-MA (potential to stimulate testosterone levels) administered as a SC bolus (0.001-0.3 mg) or a 2-h SC infusion (1-6 mg). This study was conducted in France.

[0235] Eighty-two healthy European male subjects aged 50-76 years were enrolled in nine cohorts. Eighty-one of the 82 subjects (98.8%) were white and one of the 82 subjects (1.2%) was black / African American. Subjects enrolled in the first six cohorts received 0.001 mg, 0.003 mg, 0.01 mg, 0.03 mg, 0.1 mg, or 0.3 mg of API-MA or placebo by single SC bolus. In the 0.3 mg cohort, six subjects received API-MA and two received placebo. In the remaining cohorts, seven subjects received API-MA and three received placebo. Subjects enrolled in the seventh, eighth, and ninth cohorts received 1 mg, 3 mg, or 6 mg of API-MA or placebo by single 2-h SC infusion. In these cohorts, six subjects received API-MA and two received placebo.

[0236] To measure plasma concentrations of API-MA in subjects in the SC bolus cohort, blood samples were collected at nominal times pre-dose, 0.083 h post-dose, 0.25 h post-dose, 0.5 h post-dose, 0.75 h post-dose, 1 h post-dose, 2 h post-dose, 3 h post-dose, 4 h post-dose, 6 h post-dose, 8 h post-dose, 12 h post-dose, 16 h post-dose, 24 h post-dose, 36 h post-dose, 48 h post-dose, and 72 h post-dose. To measure urinary excretion of API-MA, urine samples were collected at nominal times pre-dose until dosing, 0-6 h post-dose, 6-12 h post-dose, 12-24 h post-dose, 24-48 h post-dose, and 48-72 h post-dose.

[0237] To measure plasma concentrations of API-MA in subjects in the SC infusion cohort, blood samples were collected at the following nominal times: pre-dose, 0.5 h after initiation of infusion, 1 h after initiation of infusion, 1.5 h after initiation of infusion, 2 h after initiation of infusion, 2.25 h after initiation of infusion, 2.5 h after initiation of infusion, 3 h after initiation of infusion, 4 h after initiation of infusion, 6 h after initiation of infusion, 8 h after initiation of infusion, 10 h after initiation of infusion, 14 h after initiation of infusion, 18 h after initiation of infusion, 26 h after initiation of infusion, 50 h after initiation of infusion, and 74 h after initiation of infusion. To measure urinary excretion of API-MA, urine samples were collected at the following nominal times: pre-dose until initiation of infusion, 0-6 h after initiation of infusion, 6-12 h after initiation of infusion, 12-24 h after initiation of infusion, 24-48 h after initiation of infusion, and 48-72 h after initiation of infusion.

[0238] The mean plasma API-MA concentration-time curves following single SC administration of API-MA at doses ranging from 0.001 to 6 mg are shown in Figure 2. The mean coefficients of variation (%CV) of plasma and urinary PK parameter values ​​for single doses of API-MA administered by SC bolus and by 2-hour SC infusion are listed in Tables 5-8 below. [Table 5] [Table 6] [Table 7] [Table 8]

[0239] Following administration of a single SC bolus dose ranging from 0.001 to 0.3 mg, API-MA (C max ) increased in a dose-proportional manner. Systemic exposure (AUC (0-inf)The estimated exponent of the power equation is C max 1.003 (95%CI:0.956-1.050), AUC (0-inf) The CL / F values ​​after a single SC bolus and a 2-h infusion of API-MA ranged from 18.9 to 27.1 L / h.

[0240] SC bolus administration of API-MA max Median times ranged from 0.5 to 0.750 hours, indicating that API-MA was rapidly taken up into the system from the SC administration site. The rapid SC uptake of API-MA was not dose-dependent across the SC dose range evaluated in this study.

[0241] Generally speaking, the average T 1 / 2 The values ​​increased with increasing dose. 1 / 2 Possible reasons for the long T 1 / 2 It has been suggested that this may be due to the inclusion of measurable API-MA concentrations at the tails of the curve when estimating T. Thus, the observed dose-dependence of this parameter does not represent the nonlinear pharmacokinetics of API-MA. At the highest doses tested (3 mg and 6 mg), the mean T 1 / 2 was approximately 5.2 hours.

[0242] Following a single SC bolus of 0.001 mg API-MA, only small amounts of API-MA were detected in the urine. The mean (CV%) Fe in this cohort was 3.466%. In other dose bolus and infusion cohorts (0.003-6 mg), the mean single dose Fe ranged from 2.997% to 5.380% of the administered dose of API-MA.

[0243] Example 6: Multiple dose pharmacokinetics of API-MA Another study was a Phase 1 clinical trial of multiple dose administration of API-MA. This study was conducted in France. This was a randomized, double-blind, placebo-controlled, parallel-group, ascending-dose study of the safety, tolerability, plasma PK, and endocrine pharmacodynamic effects of API-MA (which appears to suppress testosterone) administered as a SC bolus (0.1 mg) on ​​day 1 followed by continuous SC infusion (i.e., 24 h / day) on days 2-14 (0.01 mg, 0.1 mg, 0.3 mg, or 1.0 mg / day). Thirty healthy European male subjects aged 50-78 years were enrolled in four cohorts; 29 of the 30 subjects (96.7%) were white and one subject (3.3%) was black.

[0244] After SC bolus administration, plasma concentrations of API-MA were measured at pre-dose, 0.083 hours, 0.25 hours, 0.5 hours, 0.75 hours, 1 hour, 2 hours, 4 hours, 6 hours, and 12 hours after administration. Blood samples were collected at the nominal times of 6 hours after start of infusion, 12 hours after start of infusion, 24 hours after start of infusion, 54 hours after start of infusion, 60 hours after start of infusion, 72 hours after start of infusion, 150 hours after start of infusion, 156 hours after start of infusion, 168 hours after start of infusion, 222 hours after start of infusion, 228 hours after start of infusion, 240 hours after start of infusion, 294 hours after start of infusion, 300 hours after start of infusion, and 312 hours after start of infusion.

[0245] For comparison, mean plasma PK parameter values ​​of a single dose of API-MA administered by SC bolus are listed in Table 9 by dose group, along with values ​​after 13 consecutive days of SC infusion on days 2-14, as shown in Table 7. Because single-dose PK of API-MA could only be assessed for 24 hours before the start of API-MA infusion, the only PK parameters that could be estimated were C max , T max and AUC (0-24) The inter-individual variability of PK parameters was generally small, with %CVs below 58%. [Table 9]

[0246] The mean plasma PK parameter values ​​of API-MA administered by SC infusion on days 2 through 14 for 13 consecutive days are listed in Table 7. ss There was a clear dose-proportional increase over the dose range examined (0.01-1.0 mg). Across the cohort, CL / F ranged from 17.7 to 20.6 L / h. Interindividual variability in PK parameters was low, with CV% below 40%. [Table 10]

[0247] Another study was a multiple-dose Phase 1 clinical trial of API-MA. This was an open-label, ascending-dose study of API-MA (potential to suppress testosterone in hormone-naive Japanese patients with prostate cancer) administered once daily for 14 days by 2-hour SC infusion. Six patients received API-MA at doses of 0.5 mg (3 patients) and 1.0 mg (3 patients) daily for 14 days.

[0248] To measure plasma concentrations of API-MA, blood samples were collected on day 1 (pre-dose, 2 h post-dose, 4 h post-dose, 6 h post-dose, 10 h post-dose), days 2, 4, 6, 8, 10, and 12 (pre-dose), day 14 (pre-dose, 2 h post-dose, 4 h post-dose, 6 h post-dose, 10 h post-dose, 24 h post-dose, 48 h post-dose), days 21, and 28. To measure urinary excretion of API-MA, urine samples were collected on day 1 (pre-dose, 0-4 h post-dose, 4-8 h post-dose, 8-12 h post-dose, 12-24 h post-dose) and day 14 (0-4 h post-dose, 4-8 h post-dose, 8-12 h post-dose, 12-24 h post-dose).

[0249] The mean [±SD] API-FB concentration in plasma-time profiles of multiple SC doses of API-MA at 0.5 mg / day and 1.0 mg / day for 14 days are shown in Figure 3. A summary of PK parameters on days 1 and 14 for the two doses is shown in Table 11 below. Cmax and AUC were similar on days 1 and 14, indicating no accumulation of the peptide. Cmax and AUC were dose proportional. [Table 11]

[0250] After SC administration of API-MA at 0.5 mg / day and 1.0 mg / day for 14 days, on days 1 and 14, immediately after the end of the 2-hour infusion, max was observed, then decreased, and the average T 1 / 2 Values ​​were approximately 3-4 hours at both doses on both days 1 and 14. At 0.5 mg / day, mean CL / F values ​​were 13.4 L / h on day 1 and 12.6 L / h on day 14, and at 1.0 mg / day, 13.6 L / h on day 1 and 13.4 L / h on day 14, indicating that the apparent clearance of API-FB was similar at both doses. The Vz / F of API-FB was also similar at both dose levels. AUC after multiple dose administration (0-tau) / AUC after single dose administration (0-inf) The estimated accumulation index (AI) calculated using the ratio of (0-tau) / AUC after single dose administration (0-tau) Calculated as a ratio of All Rs obtained were approximately 1, indicating that the PK of API-FB was time independent and that there was minimal or no drug accumulation following daily 2-h SC infusions for 14 days at doses of 0.5 mg and 1 mg.

[0251] After SC administration of API-MA at 0.5 mg / day or 1.0 mg / day for 14 days, urinary excretion of API-FB was nearly complete by 8 hours post-dose on days 1 and 14. The mean cumulative excretion percentages at 24 hours post-dose were 6.50% on day 1 and 8.99% on day 14 for the 0.5 mg / day dose, and 8.86% on day 1 and 9.41% on day 14 for the 1.0 mg / day dose. These findings suggest that renal excretion does not contribute significantly to the clearance of API-FB.

[0252] Example 7: Pharmacokinetics of 1-Month Depot Administration of API-MA Prostate cancer patients who had completed primary treatment for prostate cancer at least 6 months prior to screening and who were receiving GnRH therapy or were potential candidates for future GnRH therapy were enrolled in a separate study. Nine patients were enrolled, three in each dose group (6 mg, 12 mg, and 24 mg). All were Caucasian males. Patients received API-MA as a single monthly depot SC injection into the abdomen (intended to initiate both a high burst release of API-MA and rapid stimulation of the hypothalamic-pituitary-gonadal axis, likely to suppress testosterone). Overall, four of the nine patients were concomitantly treated with GnRH therapy. To measure plasma concentrations of API-MA, blood samples were collected pre-dose and after 1 month of depot injection at nominal times: 0.25 h, 0.5 h, 0.75 h, 1 h, 2 h, 4 h, 6 h, 12 h, days 2, 3, 5, 8, 15, 22 and 29), month 2 (days 8, 15, 22 and 29) and month 3.

[0253] Figures 4 and 5 show the mean plasma concentration-time curves for day 1 (up to 12 hours) and the complete profile (up to 3 months) for each dose group. A high burst release of API-MA drug concentrations was observed within hours of administration of the depot injection. AUC (0-24) is the observed AUC (0-tlqc)In both cases, API-MA constituted more than 60% of the total API-MA, indicating significant release of drug from the formulation during the burst phase. Drug concentrations were very low over the next few days and then increased slowly, suggesting delayed and sustained release from the formulation after successive doses of API-MA, as well as the onset of desensitization. In both cases, API-MA was no longer detectable by 8 weeks after dosing.

[0254] Table 12 shows the results for each treatment group. max , T max , AUC (0-24) , the area under the plasma concentration-time curve (AUC (0-29d) ), AUC (0-tlqc) Descriptive statistics are presented, including the PK parameters of time to last quantifiable concentration (Tlqc) and time to last quantifiable concentration (Tlqc). Mean values ​​representing drug exposure generally increased at slightly less than dose-proportional levels. [Table 12]

[0255] Overall, the low plasma concentrations of API-MA, the delayed release profile over the first month after administration, and the high interpatient variability of the one-month depot formulation were deemed unacceptable for further clinical development in prostate cancer patients. Furthermore, these results are not applicable to the dosing strategy that would be used in patients with hypothalamic function, since it would be desirable to stimulate the hypothalamic-pituitary-gonadal axis without causing testosterone suppression.

[0256] Pharmacokinetics: Single-dose Pharmacokinetics Summary: Following administration of a single dose of API-MA to 37 Japanese men, serum LH and FSH concentrations increased. LH and FSH concentrations peaked at 12-24 hours and returned to baseline by 72 hours. The magnitude of the increase in hormone concentrations was similar across the dose range (0.001-0.5 mg). In a single-dose Phase 1 study of API-MA in 82 European men, administration of API-MA increased serum LH and FSH concentrations, which peaked at 6-12 hours and returned to baseline by 72 hours. The magnitude and duration of the increase in hormone concentrations were similar across the dose range (0.001-6 mg).

[0257] Summary of Multiple-Dose Pharmacokinetics: In the two multiple-dose studies, LH levels were ultimately suppressed at all doses used, as expected. In Study C18001, 30 healthy European men received a single 0.1 mg SC injection followed by chronic (13 consecutive days) SC infusions of API-MA at doses of 0.01 mg / day, 0.1 mg / day, 0.3 mg / day, and 1.0 mg / day. Gonadotropin concentrations peaked 24 hours after the 0.1 mg bolus injection on day 1, consistent with other single-dose Phase 1 studies. During chronic infusion of API-MA, serum LH and FSH concentrations declined to values ​​below baseline and returned to baseline values ​​within 7 days of dosing. In the majority of subjects, serum LH concentrations declined to low values. LH concentrations in all subjects in the 0.1 mg / day and 0.3 mg / day cohorts remained below the lower limit of normal for a significant portion of the time during the SC infusion. Serum LH and FSH levels were transiently elevated and then decreased by API-MA, and this inhibition was maintained throughout the treatment period.Serum PSA levels were decreased after administration of API-MA, and this decrease was more pronounced in patients receiving API-MA at 1.0 mg / day.

[0258] Pharmacokinetics of single doses of API-MA: In the Phase 1 clinical trial of API-MA, subjects enrolled in the first seven cohorts received a single SC bolus of 0.001 mg, 0.004 mg, 0.01 mg, 0.04 mg, 0.1 mg, 0.25 mg, or 0.5 mg of API-MA or placebo. Subjects enrolled in the eighth and ninth cohorts received a single SC infusion of 0.25 mg or 0.5 mg of API-MA or placebo. The pharmacokinetics of the hormones LH, FSH, dihydroepiandrosterone sulfate (DHEA-S), growth hormone (GH), prolactin (PRL), thyroid stimulating hormone (TSH), and adrenocorticotropic hormone (ACTH) were evaluated. The pharmacokinetic analysis set consisted of 37 subjects (bolus cohort: 29, infusion cohort: 8). To measure serum concentrations of hormones in subjects in both the bolus and infusion cohorts, blood samples were collected at the nominal times of pre-dose, 2 h post-dose, 4 h post-dose, 6 h post-dose, 8 h post-dose, 12 h post-dose, 24 h post-dose, 48 h post-dose, 72 h post-dose, and 312 h post-dose. In addition, blood samples were collected the day before administration of API-MA for measurements of LH and FSH. The time course of mean serum LH concentrations after single SC bolus administration of API-MA at doses ranging from 0.001 mg to 0.5 mg is shown in Figure 6. LH concentrations peaked at 12-24 hours and generally returned to baseline by 72 hours post-dose. The magnitude and duration of rise in LH concentrations were similar across the dose range (0.001-0.5 mg). The time course of LH was similar after a single 2-hour SC infusion of API-MA (data not shown).

[0259] As shown in Figure 7, after a single SC bolus administration of API-MA, serum FSH concentrations were increased more than placebo. The increase in FSH peaked within 24 hours and generally returned to pre-dose levels by 72 hours after injection. The magnitude and duration of increase in LH and FSH concentrations were similar across the dose range (0.001-0.5 mg). After a single 2-hour SC infusion of API-MA, the time courses of LH and FSH were similar (data not shown).

[0260] Another study was a single-dose Phase 1 clinical trial of API-MA in healthy men aged 50-76 years. Subjects enrolled in the first seven cohorts received 0.001 mg, 0.003 mg, 0.01 mg, 0.03 mg, 0.1 mg, or 0.3 mg of API-MA or placebo by single SC bolus. Subjects enrolled in the seventh, eighth, and ninth cohorts received 1 mg, 3 mg, or 6 mg of API-MA or placebo by single 2-h SC infusion. The pharmacokinetics of each hormone, LH and FSH, was evaluated. PRL, TSH, cortisol, sex hormone-binding globulin (SHBG), and plasma ACTH (also known as corticotropin) concentrations were measured on the day before dosing and on the fourth day (final visit). In the bolus cohort, blood samples were collected at the nominal times of the day before dosing, pre-dose, 0.083 hours after dosing, 0.25 hours after dosing, 0.75 hours after dosing, 1 hour after dosing, 2 hours after dosing, 3 hours after dosing, 4 hours after dosing, 6 hours after dosing, 8 hours after dosing, 12 hours after dosing, 16 hours after dosing, 24 hours after dosing, 36 hours after dosing, 48 hours after dosing, and 72 hours after dosing to measure serum concentrations of LH and FSH. In the infusion cohort, blood samples were collected at the following nominal times: the day before dosing, before dosing or initiation of infusion, 0.5 hours after initiation of infusion, 1 hour after initiation of infusion, 1.5 hours after initiation of infusion, 2 hours after initiation of infusion (end of infusion), 2.25 hours after initiation of infusion, 2.5 hours after initiation of infusion, 3 hours after initiation of infusion, 4 hours after initiation of infusion, 6 hours after initiation of infusion, 8 hours after initiation of infusion, 10 hours after initiation of infusion, 14 hours after initiation of infusion, 18 hours after initiation of infusion, 26 hours after initiation of infusion, 50 hours after initiation of infusion, and 74 hours after initiation of infusion. Serum LH concentrations over time are shown in Figure 8. Serum LH concentrations increased after a single SC bolus of API-MA and after a single 2-hour SC infusion of API-MA. Concentrations peaked at 6-12 hours and returned to baseline by 72 hours. The magnitude and duration of increase in LH concentrations were similar across the dose range (0.001-6 mg).

[0261] As shown in Figure 9, administration of API-MA generally resulted in a modest initial increase in mean FSH mid-levels at all dose levels, followed by a decline towards baseline levels by 72 hours. These increases were not dose-dependent. Peak values ​​were generally reached at approximately 12 hours at all dose levels. No relevant changes in serum concentrations of SHBG, prolactin, TSH, corticotropin or cortisol were observed following administration of API-MA at any dose level.

[0262] Example 8: Pharmacokinetic Effects of Multiple Doses of API-MA This was a phase 1 study of multiday continuous SC infusion of API-MA in 30 healthy European men aged >50 years. Subjects were enrolled in four cohorts and received a single SC bolus of 0.1 mg API-MA or placebo (day 1) followed by continuous SC infusion of 0.01 mg / day, 0.1 mg / day, 0.3 mg / day, or 1.0 mg / day API-MA or placebo for 13 days (days 2–14). In each dose level cohort, 5–6 men received active API-MA and 1–2 men received placebo. Pharmacodynamics of the hormones LH and FSH were evaluated.

[0263] To measure serum concentrations of LH and FSH, blood samples were collected at the following nominal times: the day before administration of API-MA, -24 h (24 h), -16 h (16 h), and -12 h (12 h) after the SC bolus, just before the SC bolus, 6 h after the bolus, 12 h after the bolus, 24 h after the bolus, 30 h after the bolus, 36 h after the bolus, 48 ​​h after the bolus, 78 h after the bolus, 84 h after the bolus, 96 h after the bolus, 174 h after the bolus, 180 h after the bolus, 192 h after the bolus, 246 h after the bolus, 252 h after the bolus, 264 h after the bolus, 318 h after the bolus, 324 h after the bolus, and 336 h after the bolus. SC infusion was initiated 24 hours after the bolus injection, and all samples taken after the 24 hour time point were taken during the SC infusion. Blood samples were also taken on days 16, 17, 21, 28, and 44 to monitor the return of hormone concentrations to baseline values.

[0264] As shown in Figures 10 and 11, in all active treatment groups, mean serum concentrations of LH and FSH increased after SC bolus administration of 0.1 mg API-MA on day 1. During the 13-day SC infusion of API-MA, mean serum LH and FSH concentrations decreased to values ​​below baseline and returned to near baseline values ​​within 7 days of administration. In most subjects, serum LH concentrations decreased to low values. All subjects in the 0.1 mg / day and 0.3 mg / day cohorts had LH concentrations below the lower limit of normal for the majority of the SC infusion treatment period. In contrast, in placebo-treated subjects, mean serum concentrations of LH and FSH remained within the normal range throughout the study.

[0265] This was a phase 1 study in hormone-naive Japanese patients with prostate cancer. Six patients received API-MA at doses of 0.5 mg (3 patients) and 1.0 mg (3 patients) via 2-h SC infusion once daily for 14 days. Summary statistics for serum concentrations of LH, FSH, GH, PRL, and TSH, plasma concentrations of ACTH, and serum concentrations of prostate-specific antigen (PSA) (concentrations at baseline, at each assessment point, and change from baseline) were calculated for each dose, and the data (individual values ​​and mean ± standard deviation) were plotted against time for each dose. For the API-MA 0.5 mg / day group, serum LH profiles are shown in Figure 12. Serum LH levels rose sharply on day 2 and returned to baseline levels by day 4. These levels were completely suppressed by days 6 through 16, and returned to baseline levels by 1 week after the last dose. The changes in serum LH were similar in the 0.5 and 1.0 mg doses of API-MA (data for the 1.0 mg / day API-MA group not shown).

[0266] Serum FSH profiles are shown in Figure 13 for the API-MA 0.5 mg / day group. Serum FSH levels also rose sharply on day 2, returning to baseline levels by day 4. These levels were completely suppressed from day 6 to day 16, returning to baseline levels by one week after the last dose. Changes in serum FSH were similar for 0.5 mg and 1.0 mg API-MA (data for the API-MA 1.0 mg / day group not shown).

[0267] Serum PSA levels decreased after administration of API-MA, and low PSA levels were maintained in all subjects up to 1 week after the last dose. Serum PSA levels decreased by approximately 40% compared to baseline levels in patients receiving 0.5 mg API-MA and, more significantly, by approximately 50%-60% in patients receiving 1.0 mg API-MA.

[0268] Example 9: Effect of one-month depot administration of API-MA Nine patients with prostate cancer were enrolled in a separate study, with three in each dose group (6 mg, 12 mg, and 24 mg). Patients received API-MA as a single monthly depot injection, which was designed to initiate both a high burst release of API-MA and rapid stimulation of the hypothalamic-pituitary-gonadal axis. Overall, four of the nine patients received concomitant GnRH therapy. Pharmacokinetic assessments included LH and serum PSA concentrations. Results were grouped based on patients who received concomitant GnRH therapy and those who did not.

[0269] In GnRH-naive patients, a corresponding decrease in LH was observed in testosterone changes. Postscreening serum LH concentrations ranged from 0.1 to 0.5 mIU / mL in the 6 mg group, 0.1 to <7.9 mIU / mL in the 12 mg group, and 0.3 to 9.8 mIU / mL in the 24 mg group, with individual variation among patients throughout the follow-up period. Two of nine patients (one in the 6 mg group and one in the 12 mg group) who were treated with concomitant GnRH analog therapy had PSA concentrations <0.01 ng / mL, and there was no detectable percent change from baseline in any value except one measurement throughout the study. In the remaining seven patients, the maximum percent change from baseline in PSA was seen on day 29 in month 1 (8% and 19% in the 6 mg group, 25% and 62% in the 12 mg group, and 74%, 79%, and 88% in the 24 mg group). Further declines in percent change from baseline were seen on day 29 in month 2 in three patients (one in the 6 mg group, one in the 12 mg group, and one in the 24 mg group), with the greatest decline in PSA (91%) observed in the 24 mg group.

[0270] Example 10: Use of Compound 1 and Relugolix in ART In an effort to improve both the safety and efficacy of ART, such as the IVF and / or ET process, important modifications to some of the key steps of the process are described in the present invention, which involve the use of compound 1 and relugolix.

[0271] Traditional IVF protocols begin with an initial phase known as COS, in which FSH is administered on the second or third day of the patient's menstrual cycle to stimulate the growth and development of follicular follicles and continues until ovulation occurs (approximately day 14). Approximately three to five days after FSH is started, either a GnRH agonist or a GnRH antagonist (now more commonly used) is added to the regimen to prevent premature ovulation (the release of an immature follicle by the LH surge), and the same FSH is continued until ovulation occurs. The common GnRH antagonist currently used in the protocol is injectable Cetrorelix, but this particular advanced embodiment uses the oral GnRH antagonist Rerugolix, which may reduce the number of frequent injections and allow for finer adjustment of GnRH antagonist activity than injectables in ART such as IVF and / or ET processes. The increased residual GnRH antagonist activity may improve the LH response to the trigger (compound 1 below), which may ultimately increase implantation rates. Rerugolix can suppress and prevent premature ovulation, allowing eggs to mature and then be retrieved from the ovaries (rather than the fallopian tubes). Rerugolix can also prevent high-order multiple pregnancies that may result from eggs being exposed to sperm in the fallopian tubes when intercourse occurs. Together, this stimulation process by FSH and the GnRH antagonist Rerugolix is ​​called COS.

[0272] Once the follicles have progressed to the desired state (dominant follicles measuring >14mm), a so-called "trigger" agent is used to stimulate final maturation, release, and collection of the eggs from the ovaries in preparation for IVF and ET to the uterus. Compound 1 (2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a pharma- ceutically acceptable salt and pharma-ceutically acceptable excipient) is used as the trigger agent. Compound 1 is used as the trigger to stimulate oocyte maturation and induce ovulation in preparation for subsequent egg retrieval, fertilization (in vitro), and ET. Other agents (e.g., estradiol and progestins) are also used to support the uterus (endometrium) in preparation for transfer (so-called luteal phase support).

[0273] One of the major risks associated with ART, including IVF and / or ET processes, is the development of OHSS. Some patients are at increased risk for developing OHSS, but the use of hCG-based triggering agents (i.e., hCG alone or hCG with GnRH agonists) is known to increase the risk of OHSS. Compound 1 appears to significantly reduce the risk of OHSS.

[0274] The use of Compound 1 as a trigger agent is expected to achieve similar or improved pregnancy rates compared to hCG-based or GnRH agonist trigger agents. Compound 1 promotes the maturation, release (ovulation) and collection of fresh mature oocytes (eggs) from the ovaries, thereby improving pregnancy rates while significantly reducing the risk of serious side effects such as OHSS.

[0275] The use of hCG-based triggering agents is known to increase the need for fractionated freezing protocols that delay embryo transfer. Compound 1's MOA results in less adverse effects on the endometrium than current treatments. Thus, the endometrium is ready for transfer (high endometrial receptivity) immediately after egg retrieval, reducing the need for fractionation (need to freeze eggs or embryos between egg retrieval and transfer). After egg retrieval, eggs are fertilized with sperm, fresh embryos are transferred to the endometrium, and pregnancy occurs. Compound 1 reduces the need for fractionated freezing protocols, reducing the number of IVF cycles and the time to pregnancy, while maintaining acceptable pregnancy rates and significantly reducing OHSS rates.

[0276] Example 11: Investigation of the physiological effects of Compound 1 in women Part 1: Identifying the dose range of Compound 1 Kisspeptin-54 has previously been shown to be clinically effective as a trigger for oocyte maturation in IVF studies. In this study, doses of Compound 1 administered during the early follicular phase of the menstrual cycle were analyzed to allow identification of doses capable of stimulating an LH response and to compare similarities and differences in LH responsiveness to kisspeptin-54.

[0277] BMI between 18 and 30 kg / m 2 The study population included healthy women aged 18-35 years, with no medical problems, not taking any medications, and not using hormonal contraception. Three healthy female subjects were selected and randomized to receive a single dose of each of the three study regimens listed below (one regimen per study period). All women were scheduled for three study day 1 visits (during each follicular phase of the menstrual cycle). Each subject received a single dose of one of the three study regimens listed below at the study day 1 visit for each study period (three study periods in total), so that at the end of this study part, each subject had received all three study regimens listed below (one per study period). Kisspeptin-54 (KP54), 9.6 nmol / kg ·Compound 1, 0.003nmol / kg* or 0.00368 mcg / kg ·Compound 1, 0.03nmol / kg * or 0.0368 mcg / kg *For example, a 60 kg woman receiving Compound 1 at a dose of 0.003 nmol / kg would receive 0.18 nmol or 0.221 mcg. The order in which subjects received one of the three study regimens was determined by a randomization matrix.

[0278] Vials of Compound 1 were stored at 4° C. and consisted of 200 mcg (0.2 mg) in 2000 mcl (2 mL) (i.e., 0.1 mcg / mcl (0.1 mg / mL)). Lyophilized kisspeptin-54 (600 nmol per vial) was reconstituted with 0.5-1 mL of saline for subcutaneous injection (Table 13). [Table 13]

[0279] The study included a screening visit to collect participants' complete medical history and perform general physical examinations and blood tests. Each of the three study periods consisted of three scheduled study visits per study period (excluding screening and follow-up). The study day 1 (SD1) visit for each study period occurred during the follicular phase of the menstrual cycle (days 1-4), the SD2 visit occurred 24 hours after dosing, and the SD3 visit occurred 48 hours after dosing (Figure 14). Follow-up phone calls were conducted 7-10 days after dosing in each study period.

[0280] On study day 1, after a negative urine pregnancy test, mice were administered a single dose (subcutaneous injection into the abdomen) of either Compound 1 (0.003 nmol / kg or 0.03 nmol / kg) or kisspeptin-54 (9.6 nmol / kg) at time 0.

[0281] Immediately after dosing, serum LH, FSH, E2 (estradiol), P (progesterone) and SHBG levels were assessed at 30 minute intervals for up to 14 hours (Figures 15A-15C, 16A-16C, 17, 18, 19, 20A and 20B). These PD variables were also assessed 24 hours (study day 2) and 48 hours (study day 3) after dosing. Changes in SHBG were less rapid and blood volume decreased when measured every 3 hours.

[0282] A maximum blood volume of 3 mL was required for the measurement of serum reproductive hormone levels (LH, FSH, E2, and P). Blood samples for serum analysis were collected in plain evacuated blood collection tubes (Beckto Serum was collected at 4 °C for 1 h at RT (N. Dickson, Franklin Lakes, NJ, USA), allowed to clot (approximately 1 h at room temperature), and spun at 3000 rpm for 10 min. Serum was then stored at -20 °C in a locked freezer until assay for serum reproductive hormone levels.

[0283] Plasma levels of Compound 1 and kisspeptin-54 were assessed for the first 6 hours to minimize withdrawal of excess blood volume.

[0284] As shown in Figures 15A and 16A, subjects receiving kisspeptin-54 experienced an increase in LH levels that peaked 4-6 hours after administration of kisspeptin-54, with the LH surge lasting approximately 14 hours. Subjects receiving 0.003 nmol / kg Compound 1 (Figures 15C and 16B) and 0.03 nmol / kg Compound 1 (Figures 15B and 16C) also experienced an increase in LH following administration of Compound 1, but the peak LH levels were reached much later than observed following kisspeptin-54 administration, and the LH surge lasted much longer than observed following kisspeptin-54 administration (Figures 17-19). Following administration of 0.003 nmol / kg Compound 1, peak serum LH levels were observed 14-36 hours after administration, with the LH surge lasting approximately 48 hours. After an initial drop in LH levels, peak serum LH levels were observed 18-20 hours after administration of Compound 1 at a dose of 0.03 nmol / kg, and the LH surge lasted for approximately 14 hours and ended 28 hours after administration. In IVF, a longer LH surge is preferable to promote oocyte maturation. Furthermore, it was unexpected to observe a prolonged LH surge during the early follicular phase, especially since the LH surge with kisspeptin-54 lasted only 14 hours, whereas a surge of approximately 48 hours was observed with Compound 1 at a dose of 0.003 nmol / kg.

[0285] A small increase in E2 was observed after administration of Compound 1, similar to that observed with kisspeptin-54 and supporting a similar mechanism of action in stimulating the release of gonadotropins and sex hormones (Figure 20B). Surprisingly, the FSH response was much smaller than the LH response, which is in stark contrast to what was observed in men, where robust responses to both LH and FSH were evident (Figure 20A and Example 7, Figures 8 and 9). In addition, there was some potential desensitization of the FSH response at 24 and 48 hours, which was again less evident in men (Figures 9 and 20A).

[0286] Compound 1 at a dose of 0.003 nmol / kg yielded results for only two subjects, as the third subject presented on what was believed to be cycle day 4 after light menstrual bleeding (FIG. 16B). Her actual cycle occurred several days later, and serum progesterone levels confirmed that she was, in fact, in the luteal phase (day 36) of her previous cycle at the time of the study visit.

[0287] Part 2: A randomized, open-label, crossover study to investigate the effects of Compound 1 in healthy women The objective of this study part is to identify a dose of Compound 1 (administered during the follicular phase of the menstrual cycle) that provides optimal safety, tolerability and PD profile (i.e., LH responsiveness) in healthy women. Low, medium and high doses of Compound 1 spanning the dose range of Compound 1 identified in Part 1 will be compared to kisspeptin-54 (9.6 nmol / kg) at a dose previously shown to be effective in triggering oocyte maturation during IVF treatment, again with the goal of increasing peak LH response by approximately 10-20% compared to kisspeptin-54. This study will allow rapid identification of a dose of Compound 1 that can later be used as a triggering agent in IVF therapy. Compound 1 will also be compared to a subcutaneous dose of a GnRH agonist (triptorelin 0.2 mg) currently used to trigger oocyte maturation in IVF therapy. It will be compared.

[0288] As mentioned above, in part 1 of this study, Compound 1 was administered during the follicular phase of the menstrual cycle, whereas in this phase, Compound 1 is administered in a COS setting as part of pre-IVF ART, and therefore the amplitude of the LH surge is likely to differ from that observed when Compound 1 was administered during the follicular phase.

[0289] The study population included those with a BMI between 18 and 30 kg / m 2The study will include eight healthy women aged 18-35 years who have no medical problems and are not taking any medications or hormonal contraception. The screening visit for this study will collect the same information as detailed in Part 1.

[0290] This study part will consist of six study periods. During each study period, a follow-up visit will occur within 7-10 days of dosing. Eight subjects will be randomized to receive a single dose of each of the six study regimens (one regimen per study period). All women will have six Study Day 1 visits (during each follicular phase of the menstrual cycle). Each subject will receive a single dose of one of the six study regimens listed below at the Study Day 1 visit per study period, such that at the end of this study part, each subject will have received all six study regimens listed below (one per study period). Saline (0.9%), 100 μL Compound 1, low dose, e.g., 0.003 nmol / kg * or 0.00368 mcg / kg (or an alternative lower dose identified after Part 1). Compound 1, medium dose, e.g., 0.01 nmol / kg * or 0.0123 mcg / kg (or an alternative intermediate dose identified after Part 1). Compound 1, high dose, e.g., 0.03 nmol / kg * or 0.0368 mcg / kg (or an alternative higher dose identified after Part 1). Kisspeptin-54, 9.6 nmol / kg GnRH agonist (triptorelin, 0.2 mg, SC) *For example, a 60 kg woman receiving Compound 1 at a dose of 0.003 nmol / kg will receive 0.18 nmol or 0.221 mcg. The order in which individual women receive one of the six study regimens will be determined by a randomization matrix.

[0291] On study day 1, after a negative urine pregnancy test, at time 0, animals will be administered a single dose (subcutaneous injection into the abdomen) of either Compound 1 (low dose, e.g., 0.003 nmol / kg, medium dose, e.g., 0.01 nmol / kg, or high dose, e.g., 0.03 nmol / kg), kisspeptin-54 (9.6 nmol / kg), GnRH agonist (triptorelin 0.2 mg) or saline (0.9%, 100 μl).

[0292] Blood collection, testing, drug storage and dose preparation will be performed as in Part 1.

[0293] Part 3: A randomized, open-label, crossover study to evaluate the effects of Compound 1 in women with anovulatory PCOS The objective of this study part is to compare the PK / PD profile (specifically LH and FSH responses) of compound 1 at the optimal dose (identified in part 2 in healthy women) with the PK / PD profile seen in women with anovulatory PCOS. Women will be diagnosed with anovulatory PCOS if they have oligomenorrhea (menstrual cycle length >35 days), elevated serum AMH (>35 pmol / L) or ultrasound antral follicle counts >23, and / or clinical or hormonal evidence of hyperandrogenism. Based on previous studies with kisspeptin-54, LH response was significantly increased in women with PCOS. is expected to be similar to, but slightly higher than, healthy women. Responses to a single dose of Compound 1 will also be compared to that of a GnRH agonist (triptorelin 0.2 mg), a commonly used therapy to trigger oocyte maturation in women with PCOS. This will allow a comparison of Compound 1 at an optimal dose (preliminarily identified in part 2) with the current standard of care.

[0294] The study population will be women aged 18-35 years with anovulatory PCOS.

[0295] The screening visit in this study will collect the same information detailed in Part 1, with the addition of two additions: 1) women will be induced with Provera prior to SD1 (10 mg BID for 1 week immediately prior to SD1) and 2) following Provera induction, women will begin each study period as they did in Parts 1 and 2 (beginning on days 1-4 of the menstrual cycle (follicular phase) with Provera induction).

[0296] According to the randomization matrix, eight subjects will be randomized to receive a single dose of each of the four study drug regimens (one regimen per study period). All women will have four Study Day 1 visits (in consecutive months, during the follicular phase of the menstrual cycle). Each subject will receive a single dose of one of the four study regimens listed below at the Study Day 1 visit per study period, such that at the end of this study part, each subject will have received all four study regimens listed below (one per study period). Saline (0.9%), 100 μL ·Compound 1 * KP54, 9.6 nmol / kg, SC GnRH agonist (triptorelin 0.2 mg, SC) *The dose of Compound 1 will be confirmed in Part 2 of this study (healthy volunteers) and the blood collection periods for PD analysis after each study regimen will be confirmed after Part 1 of this study, e.g., blood collection periods after Compound 1 may be shortened from 14 hours to 8-12 hours, after kisspeptin-54 to 8-10 hours, and after saline to 6-8 hours.

[0297] On study day 1, after a negative urine pregnancy test, at time 0, animals will be administered a single dose (subcutaneous injection into the abdomen) of the optimal dose of Compound 1 (to be determined in Part 2 of this study), kisspeptin-54 (9.6 nmol / kg), GnRH agonist (0.2 mg triptorelin) or saline (0.9%, 100 μl).

[0298] Blood sampling, testing, drug storage and drug preparation will be carried out as in Parts 1 and 2.

[0299] Enumeration of embodiments Some embodiments of the present disclosure relate to embodiment I below.

[0300] Embodiment I-1. A method for promoting oocyte maturation and inducing ovulation in assisted reproductive technology (ART) such as IVF or embryo transfer (ET) processes, comprising administering to a female human subject a therapeutically effective amount of about 0.001 mg to about 600 mg of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide, or a corresponding amount of a pharma- ceutically acceptable salt thereof.

[0301] Embodiment I-2. The pharma- ceutically acceptable salt thereof is 2-(N-acetyl-D-tyrosyl) The method according to embodiment I-1, wherein the hydroxyl group is N-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide monoacetate.

[0302] The method according to embodiment I-1, wherein a therapeutically effective amount of about 0.001 mg to about 600 mg of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide, or a corresponding amount of a pharma- ceutically acceptable salt thereof, is administered by injection.

[0303] The method according to embodiment I-1, wherein a therapeutically effective amount of about 0.001 mg to about 600 mg of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide, or a corresponding amount of a pharma- ceutically acceptable salt thereof, is administered in the form of a delayed release single dose.

[0304] Embodiment I-5. The method of embodiment I-1, wherein the 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide is represented by the formula: [ka]

[0305] Embodiment I-6. The method of embodiment I-2, wherein the 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide monoacetate is represented by the formula: [ka]

[0306] The method of embodiment I-1, wherein administration of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a pharma- ceutically acceptable salt thereof triggers ovulation in a human female subject (i) without increasing VEGF levels, or (ii) with an increase in VEGF levels for less than 24 hours.

[0307] Embodiment I-8. A method for promoting oocyte maturation in ART such as IVF or ET processes, comprising administering to a female human subject by injection a therapeutically effective amount of about 0.001 mg to about 5 mg of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide, or a corresponding amount of a pharma- ceutically acceptable salt thereof.

[0308] Embodiment I-9. The method according to embodiment I-8, wherein the pharma- ceutically acceptable salt is 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide monoacetate.

[0309] Embodiment I-10. The method of embodiment I-8, wherein the administration is subcutaneous administration.

[0310] Embodiment I-11. The method of embodiment I-8, wherein the administration is intramuscular administration.

[0311] Embodiment I-12. The method of embodiment I-8, wherein the administration is intravenous administration.

[0312] The method of embodiment I-8, wherein the 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide is represented by the formula: [ka]

[0313] The method of embodiment I-8, wherein 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide monoacetate is represented by the formula: [ka]

[0314] Embodiment I-15. A method for promoting oocyte maturation in ART such as IVF or ET processes, comprising administering to a female human subject by intranasal route a therapeutically effective amount of about 0.001 mg to about 5 mg of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide, or a corresponding amount of a pharma- ceutically acceptable salt thereof.

[0315] Embodiment I-16. The method according to embodiment I-15, wherein the pharma- ceutically acceptable salt is 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide monoacetate.

[0316] The method of embodiment I-15, wherein the 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide is represented by the formula: [ka]

[0317] The method of embodiment I-15, wherein 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide monoacetate is represented by the formula: [ka]

[0318] Embodiment I-19. A method for inducing ovulation in an IVF or ART such as an ET process, comprising administering to a human female subject one or more human gonadotropins together with a GnRH agonist or GnRH antagonist (after about 2-3 days) to promote an early COS phase and prevent premature ovulation, and administering 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a pharma- ceutically acceptable salt thereof after the early COS phase to effectively stimulate oocyte maturation and induce ovulation without (i) increasing the total blood concentration level of VEGF or (ii) increasing the total level of VEGF for less than 24 hours.

[0319] Embodiment I-20. The method of embodiment I-19, wherein the pharma- ceutically acceptable salt is 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide monoacetate.

[0320] The method of embodiment I-21, wherein 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide is administered in an amount of about 0.001 mg to about 600 mg, or a corresponding amount of a pharma- ceutically acceptable salt thereof.

[0321] The method of embodiment I-22, wherein 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide is administered by injection in an amount of about 0.001 mg to about 5 mg, or a corresponding amount of a pharma- ceutically acceptable salt thereof.

[0322] The method of embodiment I-23, wherein 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide is administered intranasally in an amount of about 0.001 mg to about 5 mg, or a corresponding amount of a pharma- ceutically acceptable salt thereof.

[0323] Embodiment I-24. The method of embodiment I-19, wherein the one or more human gonadotropins are administered orally or by injection, and the one or more human gonadotropins consist of follicle stimulating hormone, luteinizing hormone, or a combination thereof.

[0324] In the same protocol as 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or its pharma- ceutical acceptable salt (as a trigger agent), a GnRH agonist is used in the COS phase, the GnRH agonist being in combination with leuprorelin acetate and 2-(N-acetyl-D-tyrosyl-trans The method described in embodiment I-19, wherein when a GnRH antagonist is used in the COS phase in the same protocol as N-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a pharma- ceutically acceptable salt thereof (as the trigger agent), the GnRH antagonist is selected from the group consisting of ganirelix, cetrorelix, relugolix, and a pharma- ceutically acceptable salt of any of the foregoing.

[0325] Embodiment I-26. The method of embodiment I-19, wherein the GnRH agonist is selected from the group consisting of leuprorelin acetate, gonadorelin, buserelin, triptorelin, goserelin, nafarelin, histrelin, deslorelin, meterelin, recirelin, and pharma- ceutically acceptable salts of any of the foregoing.

[0326] Embodiment I-27. The method of embodiment I-19, wherein the GnRH antagonist is relugolix or a pharma- ceutically acceptable salt thereof.

[0327] Embodiment I-28. The method of embodiment I-19, wherein the GnRH antagonist is selected from the group consisting of cetrorelix, ganirelix, abarelix, Nal-Blu, antide, azaline B, degarelix, D63153, relugolix, teverelix, and pharma- ceutically acceptable salts of any of the foregoing.

[0328] In an ART such as an IVF or ET process, hCG-based 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a pharma- ceutically acceptable salt thereof is used as the triggering agent for reducing the rate of OHSS compared to the triggering agent described above.

[0329] Embodiment I-30. A method for achieving pregnancy rates in ART such as IVF or ET processes that are comparable to or superior to GnRH agonist or hCG-based trigger agents, using 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a pharma- ceutically acceptable salt thereof as the trigger agent.

[0330] Embodiment I-31. A method for shortening the time to pregnancy in ART such as IVF or ET processes compared to hCG-based triggering agents, comprising using 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a pharma- ceutically acceptable salt thereof as the triggering agent.

[0331] Embodiment I-32. A method of inducing ovulation in an anovulatory human female subject suffering from secondary ovarian insufficiency, comprising the steps of: (1) pretreating the subject with one or more human gonadotropins; and (2) administering to the subject a therapeutically effective amount of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide, or a pharma-ceutically acceptable salt thereof.

[0332] Embodiment I-33. A method for preventing premature ovulation during the COS phase of ART, such as the IVF and / or ET process, using relugolix or a pharma- ceutically acceptable salt thereof, as opposed to using a GnRH agonist during the COS phase.

[0333] Some embodiments of the present disclosure relate to embodiment II below.

[0334] Embodiment II-1. A method of increasing endogenous LH levels in a female in need thereof, comprising administering to the female an initial dose of about 0.00003 mg to about 0.030 mg of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide, or a corresponding amount of a pharma- ceutically acceptable salt thereof, wherein the female is receiving ART and is at risk for OHSS, and after administration of the initial dose, the female's blood endogenous LH level is increased above the female's blood endogenous LH level prior to administration of the initial dose.

[0335] Embodiment II-2. A method of increasing endogenous LH levels in a woman undergoing ART in need of increasing endogenous LH levels, comprising administering to the woman an initial dose of about 0.00003 mg to about 0.00004 mg of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide. 030 mg, or a corresponding amount of a pharmacologic agent or a pharmacologic agent thereof, wherein the woman is receiving ART and, at least 36 hours after administration of the first dose, the level of endogenous LH in the woman's blood is increased above the level of endogenous LH in the woman's blood before administration of the first dose.

[0336] Embodiment II-3. A method of increasing endogenous LH levels in a woman undergoing ART in need of such an increase, comprising administering to the woman an initial dose of about 0.00003 mg to about 0.030 mg of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide, or a corresponding amount of a pharmaceutically acceptable salt thereof; The woman is receiving ART and has peak endogenous LH levels in the blood at least about 12 hours after administration of the first dose.

[0337] Embodiment II-4. The method of embodiment II-3, wherein the peak endogenous LH blood level occurs about 12 hours to about 48 hours after administration of the first dose.

[0338] Embodiment II-5. A method of increasing endogenous LH levels in a female undergoing ART and in need of luteal phase support, comprising administering to said female a trigger dose of an oocyte maturation agent as part of her ART regimen, followed by administering to said female an initial dose of about 0.00003 mg to about 0.030 mg of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide, or a corresponding amount of a pharma- ceutically acceptable salt thereof.

[0339] Embodiment II-6. The method of any one of the preceding embodiments, wherein the woman's blood endogenous LH level is increased from about 12 hours to about 96 hours after administration of the first dose above the woman's blood endogenous LH level prior to administration of the first dose.

[0340] Embodiment II-7. The method of any one of the preceding embodiments, wherein the level of end...

Claims

1. 1. A composition for use in a method of increasing endogenous luteinizing hormone (LH) levels in a female in need thereof comprising 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a pharma- ceutically acceptable salt thereof, said method comprising: administering to said female an initial dose of 0.0003 mg to 0.015 mg of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide, or the corresponding amount of a pharma- ceutically acceptable salt thereof, wherein peak blood endogenous LH levels occur 12 to 48 hours after administration of said initial dose. composition.

2. 2. The composition of claim 1, which achieves peak endogenous LH levels in the blood at least about 12 hours after administration of the first dose.

3. 3. The composition of claim 1 or 2, wherein the endogenous LH level in the woman's blood is elevated above the endogenous LH level in the woman's blood prior to administration of the first dose for at least 48 hours after administration of a corresponding amount of a first dose of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a pharma- ceutically acceptable salt thereof.

4. 3. The composition of claim 1 or 2, wherein the endogenous LH level in the woman's blood is increased from about 14 hours to about 84 hours after administration of a corresponding amount of an initial dose of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide, or a pharma- ceutically acceptable salt thereof, above the endogenous LH level in the woman's blood prior to administration of the initial dose.

5. 5. The composition of any one of claims 1 to 4, wherein the woman is infertile; anovulatory; late childbearing; or suffers from anovulatory infertility not due to secondary ovarian insufficiency, oligomenorrhea, amenorrhea, endometriosis, polycystic ovarian syndrome (PCOS), or premature ovarian failure, or any combination thereof.

6. The composition of any one of claims 1 to 5, wherein the female is infertile; anovulatory; or has advanced maternal age; or any combination thereof.

Citation Information

Patent Citations

  • Methods for Programmed Ovarian Stimulation Protocols

    JP2002541122A

  • Gonadal function improving agent

    JP2005097237A

  • Use of gpcr54 ligands for the treatment of infertility

    JP2007533748A

  • Metastine derivatives and their uses

    JP2009520682A

  • Compositions for regulated ovarian stimulation

    JP2014522871A